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Abstract 
 
Human African trypanosomiasis and leishmaniasis are caused by parasites 
belonging to the genera Trypanosoma and Leishmania, respectively. Significant 
numbers of people are affected by these diseases worldwide, which are fatal if 
untreated. Animals can also be infected, posing agricultural and economic 
hindrances, especially in poor countries. Although chemotherapy can be used for 
treatment, many problems are associated with it, including drug toxicity, 
resistance, lack of guaranteed supply, and high treatment cost. Therefore, there 
is an urgent need for new treatment approaches. Here, we aim to examine the 
in vitro efficacy of curcumin and phosphonium compounds against these 
parasites, assay their toxicity to human kidney cells in vitro, and investigate the 
mechanism of antiparasite activity of curcumin.  
The Alamar blue assay was used to test 158 curcumin analogues against 
Leishmania major promastigotes and Leishmania mexicana promastigotes and 
axenic amastigotes to obtain in vitro EC50 values. Many curcumin compounds 
such as AS-HK122 and AS-HK126 exhibited anti-leishmanial activities similar to or 
better than the current clinical drug pentamidine. Similarly, EC50 values of 83 
phosphonium compounds against Trypanosoma brucei brucei bloodstream forms 
were determined. More than 20% of the tested compounds were found to be 
more active than the standard veterinary drug diminazene aceturate. Multi-drug 
resistant strains were used to determine that there is no cross-resistance 
between the tested compounds and the diamidine or melaminophenyl arsenical 
classes of trypanocides.  
Structure activity relationship (SAR) analysis revealed that mono-O-
demethylated curcumin compounds showed 10-fold higher activity against the 
parasites than curcumin. The addition of one or two pentyl pyridinium (C10H15N) 
groups on specific positions of the aromatic ring also increased the activity of 
these compounds. Furthermore, curcumin compounds with an isoxazole ring 
instead of the diketo motif showed higher activity and the lowest EC50 values. 
Similarly, pentyl bromide (OC5H10Br) substitutions on the phenyl rings improved 
the antiparasitic activity. Curcuminoids with trienone linkers showed increased 
antiparasitic activity against all parasites tested.  
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Eighty-three phosphonium analogues were tested against T. brucei brucei. SAR 
analysis indicated that the bulky substituents surrounding the bisphosphonium 
cations led to strong antiparasitic activity while the nature of the linker had less 
effect on the activity. Some monophosphonium analogues registered the lowest 
EC50 values of all the phosphonium compounds.  
The toxicity of the curcumin and phosphonium analogues to HEK cells was 
analysed in vitro. All curcumin and phosphonium compounds demonstrated lower 
toxicity to HEK cells than to the parasites. Of the 83 phosphonium compounds, 
60 displayed >200-fold in vitro selectivity index (SI). 
We also investigated the mode of antiparasitic activity of curcumin compounds. 
Preliminary toxicity tests had revealed that AS-HK014 caused rapid depletion of 
glutathione content in rat hepatocytes. Therefore, we tested AS-HK014 activity 
in the presence of different concentrations of L-glutathione, and AS-HK014 
activity was found to decrease with increased L-glutathione concentrations, 
strongly suggesting that glutathione reacted with the active compound. Indeed, 
a chemical adduct was observed between the two compounds and identified 
through mass spectrometry. 
A trypanosome cell line (TA014) adapted to AS-HK014 was produced. TA014 and 
wild-type T. brucei brucei were treated with AS-HK014 and compared with each 
other and with untreated controls. The glutathione and trypanothione levels 
were lower in the treated WT cells than in the untreated cells. However, there 
was no change in the glutamate, ornithine, or spermidine levels, providing no 
evidence for the inhibition of trypanothione synthesis, suggesting that the effect 
is probably not metabolic but chemical.  
AS-HK014 did not significantly affect thiol levels in TA014; this might reflect a 
higher level of trypanothione synthesis through increased glutathione synthetase 
(GS) and/or γ-glutamylcysteine synthetase (γ-GCS) expression. Therefore, we 
analysed the protein levels using western blotting, and sequenced the encoding 
genes in both WT and TA014 to identify any mutations in the open reading 
frames (ORFs). However, we found no changes in the GS and γ-GCS protein 
levels in resistant trypanosomes and no mutations were found in the GS and γ-
GCS ORFs. It is clear that the resistance is to the reactive enone motif of AS-
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HK014 rather than to curcumin and curcuminoids in general, since TA014 only 
displayed resistance to AS-HK014 analogues bearing the enone motif while 
sensitivity to curcumin remained unchanged, confirming that this motif is 
responsible for the higher activity of AS-HK014 compared to curcumin.  
The effects of bisphosphonium analogues on T. brucei brucei bloodstream forms 
were investigated to identify the target. All tested analogues rapidly reduced 
the T. brucei brucei mitochondrial membrane potential Ψm and decreased the 
intracellular ATP level after one hour of incubation, suggesting that the 
compounds may be targeting the mitochondria. The intracellular Ca2+ levels 
increased gradually after eight hours, suggesting that the damaged mitochondria 
are unable to retain the stored Ca2+ as their membrane potential dissipates.  
We also studied the trypanosome cell cycle after incubating the parasites with 
bisphosphonium compounds. The cell cycle defects became apparent after eight 
hours of incubation: DNA synthesis could not be initiated, leading to a dramatic 
reduction of cells in the S phase. This result was also confirmed by fluorescence 
microscopic assessment of DNA configuration. After eight hours of incubation 
with the bisphosphonium compound CD38, the number of 2K1N cells significantly 
decreased as compared with the control. There may be a causal relationship 
between mitochondrial damage and cell cycle defects. Transmission electron 
microscopy images of the cells obtained after 12 h of exposure to CD38 also 
revealed the presence of mitochondrial damage. 
We tested whether bisphosphonium compounds can induce programmed cell 
death in trypanosomes. A TUNEL assay was used to detecting DNA 
fragmentation; the results showed increased DNA fragmentation after 24-h 
treatment with two different bisphosphonium compounds, CD38 and EFpI7. This 
result indicates is consistent with apoptosis occurring in treated cells but there 
was no evidence suggesting that bisphosophonium-induced cell death in 
trypanosomes is dependent on new protein synthesis. 
In conclusion, curcumin and phosphonium analogues exhibit promising 
antiparasitic activity, and some analogues could be optimised for in vivo 
evaluation. Further investigations on the site of action of phosphonium 
compounds in the mitochondrion are in progress.             
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People all over the world suffer from innumerable types of diseases, with many 
different causes. One frequent cause of disease is infection with microscopic 
organisms; namely, viruses, fungi, bacteria and protozoa. Protozoa come in a 
variety of forms; among them are Trypanosoma and Leishmania, both of which 
are transmitted by insect bites and affect many people in large geographical 
areas.  
Sleeping sickness (Human African trypanosomiasis; HAT) and leishmaniasis are 
caused by species of protozoa called Trypanosoma and Leishmania, respectively, 
and are among the major tropical and subtropical diseases (Newton, 1974). 
These parasites both belong to the Trypanosomatidae family, which is 
responsible for a large number of diseases in both humans and animals. They 
share the same organelle, known as a kinetoplast; consequently, they fall into 
the Kinetoplastida order, a subdivision of the Zoomastigophora class. 
1.1 Human African Trypanosomiasis (HAT) 
1.1.1 Disease 
Human African trypanosomiasis (HAT); or sleeping sickness, is one of the world‘s 
most neglected infectious diseases. It is caused by the protozoan parasite 
Trypanosoma brucei, which has three subspecies, T. b. gambiense, T. b. 
rhodesiense, and T. b. brucei. Each subspecies causes a distinct pathology 
(Barrett, 1999). The tsetse flies that transmit T. b. gambiense parasites are 
found in West and Central Africa, whereas T. b. rhodesiense is spread in East 
Africa. T. b. brucei is present throughout sub-Saharan Africa where tsetse flies 
are prevalent. T. b. gambiense causes the chronic form of sleeping sickness in 
humans, but is not thought to infect many animal species. T. b. rhodesiense 
leads to acute sleeping sickness in humans, developing very rapidly. This species 
is  zoonotic, with a significant animal reservoir. T. b. brucei infects domestic 
and wild animals and is unable to infect to human due to Trypanosome Lytic 
Factor (TLF), which is found in human serum (Molina Portela et al., 2000). There 
are two TLF, haptoglobin-related protein (HRP) and apolipoprotein L1 (ApoL1) 
(Drain et al., 2001). By contrast, T. b. gambiense and T. b. rhodesiense are 
resistant to TLF and, as a result are infectious to humans (Molina Portela et al., 
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2000).It is well known that certain species of tsetse flies (Glossina) act as 
intermediaries in the transfer of trypanosomiasis. The species responsible for T. 
b. rhodesiense is Glossina morsitans, whereas Glossina palpalis is the main 
carrier of T. b. gambiense (Garcia, 2007). 
There are 36 countries in sub-Saharan African at risk from human African 
trypanosomiasis, and it is thus a threat to about 60 million people in these 
countries (Garcia, 2007). According to Barrett et al (Barrett et al., 2003), the 
number of people infected with human African trypanosomiasis is around 
500,000, resulting in 50,000 deaths per year. There were roughly 10,000 new 
cases of African trypanosomiasis in 2009 (Simarro et al., 2011). 
 
Figure 1.1. Distribution of human African trypanosomiasis (Brun et al., 2010)  
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1.1.2 Morphology 
Trypanosomes are eukaryotic cells, which belong to the order Kinetoplastida 
because they contain kinetoplasts. These cells have all the usual eukaryotic 
organelles, i.e. the nucleus, mitochondrion, endoplasmic reticulum, Golgi 
apparatus, lysosomes, and cell membrane. The trypanosome cell has is 
asymmetric, with clearly different anterior and posterior ends. Trypanosomes 
pass through five distinct forms during their life cycles in mammals and tsetse 
flies (Matthews, 2005). The origin of the flagellum is close to the posterior end 
of the cell, near the basal body, and passes along the cell, holding together a 
thin layer known as the undulating membrane, which connects the cell body and 
much of the flagellum. The kinetoplast is connected to the basal body. 
Trypanosomes have a fixed and flexible form and this contributes to the 
structure of the pellicle (Vickerman, 1974). The cell membrane consists of 
phospholipids, proteins, cholesterol, and glycolipids. In the bloodstream, a 
dense coat of variable surface glycoproteins (VSG) covers the trypanosome 
surface to protect it from the mammalian immune response (Garcia, 2007). The 
morphology of the two human-infective African trypanosomes is very similar and 
it can be difficult to differentiate between them on this basis alone. According 
to Hide and Tilley (Hide & Tilley, 2001) the different species of trypanosomes 
can best be distinguished from their DNA sequences. 
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Figure 1.2. The structure of Trypanosoma brucei  
Reproduced from (Vickerman et al., 1993) 
  
 
1.1.3 Life Cycle 
The life cycle of a trypanosome has two stages, their time in a vertebrate host 
(human or animal) and that in an invertebrate vector (tsetse fly). Morphological 
transformations and biochemical changes are seen as the life cycle progresses. 
These changes affect the morphology of the parasite, including the position of 
the kinetoplast in relation to the nucleus. The life cycle begins when the 
metacyclic trypomastigote is ingested by the tsetse fly when feeding on host 
blood. The metacyclic trypomastigote has a long, slender cell body (14-30 µm 
long and 1.5 – 3.5 µm wide) alongside the flagellum. The basal body and 
kinetoplast are near the posterior end (Garcia, 2007;Matthews, 2005). The cell, 
in this form, is divided by binary fission in the blood and lymph nodes. After 
many divisions, its long slender form is transformed into a stumpy form that is 
shorter and thicker. At this stage, the stumpy form can infect the vector. Thus, 
when the tsetse fly takes a blood meal, the stumpy trypomastigote passes into 
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its digestive canal and reaches the mid-gut. In the mid-gut, the stumpy 
trypomastigote again undergoes morphological changes and some organellar 
changes as the binary fission transforms it into its procyclic trypomastigote form. 
These changes include a loss of the Variable Surface Glycoproteins (VSG) surface 
coat, and a much more developed mitochondrion (Matthews, 2005). After 
approximately two weeks, the procyclic form migrates to the salivary glands via 
the hypo pharynx. In the salivary glands, the procyclic trypomastigote transforms 
to its epimastigote form, which has the nucleus at the posterior end, while the 
kinetoplast and the basal body are at the anterior end. In addition, it develops a 
long flagellum, which is attached along the length of the cell body. After two to 
five days of growth by binary fission, the epimastigote form develops into the 
metacyclic trypomastigote form; at which point, it is ready to infect the 
vertebrate host. The tsetse fly that has trypanosomes in metacyclic form 
remains infected for the rest of its life (Garcia, 2007). The life cycle of the 
tsetse fly lasts about three weeks, while the life cycle of the trypanosome from 
its entry into a vertebrate host to its re-entry takes 18-34 days (Garcia, 
2007;Jeffrey & Leach, 1966).  
 
Figure 1.3. Life cycle of Trypanosomiasis. 
http://www.dpd.cdc.gov/dpdx/html/trypanosomiasisafrican.htm 
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1.1.4 Clinical manifestations of the disease 
The clinical progression of sleeping sickness depends on the type of trypanosome 
infection. There are two kinds of disease known as: the acute disease that 
results from T. b. rhodesiense and leads to Rhodesian sleeping sickness, and the 
chronic disease caused by T. b. gambiense and leads to Gambian sleeping 
sickness. The incubation period for Rhodesian sleeping sickness is two to three 
weeks, and death generally occurs within a year; Gambian sleeping sickness has 
an incubation period of several days to some weeks (Markell et al., 1999). The 
duration of infection for Rhodesian sleeping sickness is about six months, 
whereas it is about two years in Gambian sleeping sickness (Welburn et al., 
2001). In general, there are two stages of sleeping sickness, which are classified 
according to the presence of parasites in the central nervous system (CNS) 
(Barrett et al., 2003;Garcia, 2007). In the first stage of the disease, the 
parasites multiply under the skin, leading to a nodule or ulcer. After several 
weeks, the parasites begin to spread through the body and attack lymph nodes; 
they then enter the bloodstream. At this point, common symptoms begin to 
appear, such as headache, fever with night sweats, malaise, and weakness. 
Lymphadenopathy is the main indication of Gambian sleeping sickness, because 
the lymph nodes will swell along the back of the neck. This swelling is known as 
Winterbottom‘s sign (Barrett et al., 2003;Markell et al., 1999). However, in 
Rhodesian sleeping sickness, this swelling may not be present. The second stage 
of the disease begins when parasites penetrate the Central Nervous System 
(CNS). In T. b. rhodesiense, this occurs a few weeks after infection, while it can 
be several months to a year with T. b. gambiense. At this stage, headaches 
become harsh and the sleep disorder becomes noticeable. There are personality 
changes and apathy and, finally, the patient falls into coma and, if not treated, 
will then die (Barrett et al., 2003;Garcia, 2007;Markell et al., 1999). 
1.1.5 Diagnosis 
The diagnosis of trypanosomiasis initially depends on noticing the symptoms of 
disease, such as irregular fever and swelling of lymph nodes (Winterbottom‘s 
sign). Thereafter, a number of methods can be used to accurately diagnose 
trypanosomiasis in humans. In the past, enlargement of the lymph nodes in the 
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back of the neck was the main method used to identify the disease in slaves in 
the late 18th century (Barrett et al., 2003). An examination of fluid taken from 
the lymph node, using stains to discover the metacyclic trypomastigote can now 
verify this diagnosis. The blood sample is the easiest technique although it has 
some problems. The blood is placed on slides and stained, after which 
metacyclic trypomastigotes can be detected in the blood using a microscope. 
However, the parasites can be difficult to detect during the afebrile phase 
because, in this period, there are few parasites in the blood (Garcia, 
2007;Markell et al., 1999). In addition, cerebrospinal Fluid (CSF) can also be 
collected for diagnosis of trypomastigote, primarily in the second stage of 
disease. The CSF must be centrifuged and stained in order to find 
trypomastigotes. Another method, Antigen Detection, an enzyme-linked 
immunosorbent assay (ELISA) method is used to detect antigens in the CSF and 
serum. Briefly: a special card, called the card indirect agglutination 
trypanosomiasis test (CIATT) is used to detect circulating antigens in a person 
who has African trypanosomiasis. Moreover, Antibody Detection, the card 
agglutination trypanosomiasis test (CATT) can be applied to blood, serum or 
plasma, and CSF to discover antibodies against T. brucei. Increased levels of IgG 
are a clear sign of the disease (Garcia, 2007;Markell et al., 1999). Furthermore, 
as differentiation among species of trypanosomiasis is very difficult, DNA 
diagnosis can be important in deciding the species of trypanosomiasis, as 
treatment differs for the two species. However, the geographical location is 
usually a sufficient indicator of species.  
 
1.1.6 The control of HAT  
The control of the disease can be achieved two ways: the control of disease by 
minimising transmission of the parasites by their vector, or by using medicinal 
treatments to kill parasites within the mammalian host. The development of an 
effective vaccine against any African trypanosome remains unlikely in the 
foreseeable future, mainly due to the antigenic variation in their surface coat 
(Stuart et al., 2008). 
Trypanosomes parasites are transmission by the tsetse fly, which is distributed in 
sub-Sahara Africa in the size of areas more than 8.5 million km2. Controlling the 
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flies is an important choice for reducing the disease burden. During the early 
20th century, animals were killed and massive areas of forests destroyed to 
deprive flies of habitat and food; however this method is unacceptable because 
of the massive environmental damage (Allsopp, 2001). It is true that insecticides 
such as DDT can be used to eliminate the flies, however this method also has 
disadvantages. For instance, the flies become resistant to insecticides and the 
chemicals led to pollution of the environment and food chain (Aksoy, 2003). 
Another method that has been used is a bait technique that depends on 
attracting tsetse into fabric traps. This method is effective (and not harmful to 
the environment), particularly where these traps are placed near cattle pens, 
where the tsetse takes its meal (Allsopp, 2001). Recently, sterile insect 
technique (SIT) has been used to decrease the population of flies which could 
help to decrease the disease level in long-term. Using sterile male insects is a 
successful method and is environmentally friendly, but it is criticized for its high 
cost  (Aksoy et al., 2001).   
1.1.7 Treatment of HAT 
According to Jordan (Jordan, 1986), using drugs to treat sleeping sickness is an 
easier and cheaper means of overcoming trypanosomiasis than killing all tsetse 
flies. There are five drugs available for the treatment of sleeping sickness. 
Pentamidine and suramin are used in first stage of disease, while melarsoprol, 
eflornithine, and nifurtimox treat the second stage. 
1.1.7.1   Pentamidine   
Pentamidine is a drug known for its medical significance and its structure, which 
contains two benzamidine groups (figure 1.4). It is used in the treatment of T. b. 
gambiense infections because of its therapeutic efficacy, and also exhibits 
prophylactic activity (Bacchi, 1993). At the molecular level, this drug interacts 
with minor grooves of DNA where the concentrations of adenine and thymine are 
high and this features allow the multifactorial impact of the drug on cellular 
processes (Moreno et al., 2010). The ionic form of each of the amidine moieties 
at physiological pH is a single positive charge and pentamidine is therefore a di-
cation. This renders the drug incapable of crossing the blood brain barrier (BBB) 
and other bio-membranes and it is found to be physiologically effective only 
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during the initial stages of sleeping sickness (Denise & Barrett, 2001). The 
concentration of Pentamidine achieved within parasites residing inside the host 
cell is believed to reach millimolar levels, due to the involvement of several 
transport proteins in the trypanosome‘s plasma membrane (de Koning, 2008). 
The P2 aminopurine transporter contributes approximately 50% of Pentamidine 
uptake by T. b. brucei (depending on concentration); the drug is further 
transported by the High Affinity Pentamidine Transporter (HAPT1) and the Low 
Affinity Pentamidine Transporter (LAPT1)  (de Koning, 2001b). The action of 
pentamidine is likely to be multi factorial. One contributing mechanisms is its 
binding to the minor groove of DNA (Moreno et al., 2010). Destruction of the 
kinetoplast by Pentamidine was also observed as the drug has the ability to 
interact with the small circular DNA that comprise kinetoplast also known as 
kDNA (Tevis et al., 2009). The mitochondria membrane potential is rapidly 
affected by pentamidine which may means that the mitochondria are a target of 
the pentamidine (Lanteri et al., 2008)  Dosage is 4 mg/kg per day by 
intramuscular injection for 7-10 days (Legros et al., 2002;Markell et al., 1999). 
Side effects, however, consist of nausea, vomiting, and hypotension (Garcia, 
2007;Markell et al., 1999).  
1.1.7.2   Suramin 
Suramin is a derivative of naphthalene and has a polysulphonated structure 
(figure 1.4). It is used for the treatment of the surra disease in camels, which is 
caused by T. evansi (Zhou et al., 2004). It was discovered in 1916 by two 
scientists working for Bayer, Richard Kothe and Oskar Dressel (Haberkorn et al., 
2001). In humans it is used in the treatment regime of the initial stages of 
infections caused by T. b. rhodesiense but almost never for T. b. gambiense 
(WHO, 1995). Its side-effects have been found to be stronger more severe than 
with pentamidine, when used for infections of T. b. gambiense (Pepin & Milord, 
1994). At physiological pH it exhibits 6 negative charges and this highly charged 
molecule is therefore unable to cross membranes by diffusion (Delespaux & de 
Koning, 2007). Suramin binds firmly to low density lipoproteins (LDLs); these are 
plasma proteins in the mammalian bloodstream and are considered as the sole 
source of sterols in trypanosomes. T. b. brucei plasma membranes  contain 
receptors that are responsible for endocytosis of LDL, and this overall process 
facilitates the uptake of Suramin into the cell (Bacchi, 2009;Barrett et al., 
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2007). In a very recent study Alsford and colleagues have introduced a new a 
versatile tool termed RNA interference target sequencing (RIT-seq) for the 
purpose of functional analyses at molecular level to identify drug target (Alsford 
et al., 2012). However, this study showed that adifferent protein, ISG75, may be 
involved in the endocytosis of suramin. this study further succeeded in 
identifying good candidates for the pentamidine transporters, and confirmed the 
role of the trypanothione pathway in susceptibility to arsenical drugs. 
A test dose is recommended, followed by five injections of 20 mg/kg per day 
over 5-7 days (Jannin & Cattand, 2004). Side effects that have been noted 
include anaphylactic shock, nausea, vomiting, loss of consciousness, pruritus, 
oedema, and renal failure (Garcia, 2007;Legros et al., 2002). 
1.1.7.3 Melarsoprol 
One of the members of the melaminophenyl family named Melarsoprol (structure 
shown in figure 1.4) is a drug that exhibits a therapeutic effect against second 
stage infection with T. b. gambiense or T. b. rhodesiense. Clinical trials results 
showed that 5% of patients who received treatment regime of Melarsoprol died 
from its high toxicity (Blum et al., 2001), yet the drug has also been used to 
treat leukaemia patients (Soignet et al., 1999). One explanation for the poor 
outcome is the formation of reactive arsenical encephalopathy. The toxic impact 
of Melarsoprol on trypanosomes is still not clear but studies suggest that it forms 
stable adducts with thiols, most probably with dihydrotrypanothione to form 
MelT (Fairlamb et al., 1989). However, this is likely to be a defence mechanism 
of the cell rather than its mode of action.  
Melarsoprol as a treatment against infections caused by T. b. gambiense has 
recently become less efficacious, with a high failure rate especially in areas with 
high epidemic profile such as the Democratic Republic of Congo, Southern 
Sudan, Uganda and Angola. It seems highly likely that this increase in failure rate 
is the result of drug resistance in the parasites (Delespaux & de Koning, 2007). 
The recommended dose is 2.2 mg/kg per day for ten days. Possible side effects 
include nausea, vomiting, and encephalopathy (Garcia, 2007;Jannin & Cattand, 
2004;Legros et al., 2002). 
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1.1.7.4 Eflornithine (DFMO) 
α-Difluoromethylornithine, also known as Eflornithine (structure in figure 1.4), is 
used in the treatment of Melarsoprol-refractory gambiense sleeping sickness in 
humans; it is not effective against T. b. rhodesiense infections (Delespaux & de 
Koning, 2007). There are fewer adverse side effects of this drug because it is 
generally less toxic compared to Melarsoprol.  Once it was licensed for human 
subjects, it was used for the first time in treatment of HAT (1990) caused by T. 
b. gambiense and it was found to be physiologically active in last stage of 
infection. DFMO acts as an inhibitor of the enzyme Ornithine Decarboxylase 
(ODC), a key enzyme in the synthesis of the polyamines spermidine, spermine, 
and putrescine that are essential for cell proliferation (Burri & Brun, 2003). 
Studies have shown that DFMO efficiency inhibits ODC in both trypanosomes and 
humans. However, the selectivity of effect for this drug is the result of 
differences in human and trypanosome ODC. The human cells are able to replace 
their ODC enzyme much more rapidly than the trypanosome (Iten et al., 
1997;Tabor & Tabor, 1984).  
Oral administration of the Eflornithine is impractical because of bio-availability, 
and administration by intravenous infusion is generally recommended, although 
efforts to develop an oral formulation are ongoing (Manson-Bahr, 1974). Until 
recently it was believed that DFMO might enter trypanosomes by passive 
diffusion (de Koning, 2001a;Denise & Barrett, 2001). However, it was recently 
found independently by several groups that DFMO uptake in fact requires the 
expression of the amino acid transporter TbAAT6 (Baker et al., 2011;Schumann 
et al., 2011;Vincent et al., 2010). Recent reports show that resistance against 
DFMO can be developed easily in trypanosomes. Results of one study show that a 
high level of resistance against DFMO in T. b. brucei strain 427 bloodstream 
forms was developed within 60 days. This study employed the approach of 
culturing sensitive cells in higher concentrations of the drug and linked 
resistance to the loss of the AAT6 gene (Vincent et al., 2010).  
The protocol for treatment is 100 mg/kg every six hours for two weeks via slow 
intravenous infusion. Side effects can include pancytopenia, diarrhoea, and 
anaemia (Garcia, 2007;Jannin & Cattand, 2004;Legros et al., 2002;Markell et al., 
1999). 
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1.1.7.5 Nifurtimox     
This drug is a member of the 5-nitrofuran family (for structure see figure 1.4)and 
it is well known for its anti-protozoal action. It has been used for this purpose 
since the 1960s. It is used to treat the acute form of protozoal infections 
including Chagas disease in South America and was recently introduced for the 
treatment of late-stage infection caused by T. b.  gambiense in a combination 
formulation with eflornithine. The benefits of using this drug are that its oral 
administrable forms are available and not expensive. It also doesn‘t display cross 
resistance when administered with other drugs. However, it is ineffective as 
monotherapy, with the dosage and duration of treatment being restricted by 
unacceptable levels of toxicity. To avoid such instances of toxicity in patients, 
lower drug dosages of drug are recommended for a short duration, which is 
possible when combined with Eflornithine (Delespaux & de Koning, 2007;Lutje et 
al., 2010;Yun et al., 2010), as the drugs appear to act synergistically. Currently, 
a combination therapy of Eflornithine and nifurtimox is replacing the mono-
therapy of Eflornithine (Opigo & Woodrow, 2009;Priotto et al., 2009).  
The recommended dose of nifurtimox is 15 mg/kg per day in three doses over 
two weeks for children and 20 mg/kg per day in 3 doses for two weeks for 
adults. Side effects may include confusion, weight loss, tremors, and vertigo 
(Garcia, 2007;Legros et al., 2002). 
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1.1.8 Drug Resistance 
Of the several problems that surround the chemotherapy of Human African 
Trypanosomiasis, drug resistance is one of the primary reasons for treatment 
failure and has led to difficulty in the control of this disease. Although there has 
been long-term use of different kinds of drugs for treating trypanosomiasis, the 
mechanism of resistance is unclear (Ross et al., 1997). Delespaux and De Koning 
(Delespaux & de Koning, 2007) reported that one of the most important reasons 
for drug resistance is due to the shortage of drug accumulation into the 
trypanosome. Furthermore, decreasing uptake of the drug by the trypanosome is 
frequently connected with drug resistance (de Koning, 2001b). In particular, De 
Koning (de Koning, 2001a) mentioned that loss of the purine transporter 
TbAT1/P2 leads to resistance. However, when two drugs share in the same mode 
of uptake through the P2 transporter, this leads to cross-resistance (de Koning et 
al., 2004). There are many examples of resistance to trypanosomiasis drugs. 
Resistance to melarsoprol has been reported (Legros et al., 1999). In Uganda, 
resistance of T. b. rhodesiense to DFMO has been reported (Iten et al., 1995). 
Pentamidine
e 
Suramin 
Melarsoprol 
Eflornithine 
Nifurtimox 
Figure 1.4. Chemical Structurs of drugs used against Trypanosomiasis. 
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1.2 Leishmaniasis 
Leishmania spp. are protozoa of the Trypanosomatidae family and are 
transmitted to mammalian hosts by sand flies. Two subgenera divide the genus 
Leishmania, and this divide centres on the site of the parasite‘s development in 
the sand fly‘s body. In the subgenus Leishmania, the parasite grows in the 
frontal portion of the alimentary area, whereas in the subgenus Viannia, it 
develops in the mid-gut and hindgut (Garcia, 2007). There are more than 30 
species of Leishmania distributed across the world, which are found in two main 
regions: the Old World and the New World. Endemic areas of the Old World 
include Africa, Southern Europe, Asia, the Middle East, and India, while the New 
World endemic regions consist of Central and South America. According to WHO 
(2010), there are many of Leishmania species are responsible for most of the 
parasitic disease burden (Table 1.1). 
Species Region Disease 
L. donovani Old World Visceral Leishmaniasis (VL) & Cutaneous 
Leishmaniasis (CL) & PKDL 
L. major Old World Cutaneous Leishmaniasis (CL) & Visceral 
Leishmaniasis (VL) & Mucocutaneous Cutaneous 
Leishmaniasis (MCL) 
L. tropica Old World Cutaneous Leishmaniasis (CL) & Mucocutaneous 
Cutaneous Leishmaniasis (MCL) 
L. aethiopica Old World Cutaneous Leishmaniasis (CL) & Mucocutaneous 
Cutaneous Leishmaniasis (MCL) 
L. mexicana New World Diffuse Cutaneous Leishmaniasis (DCL) 
L. brasiliensis New World Cutaneous Leishmaniasis (CL) & Mucocutaneous 
Cutaneous Leishmaniasis (MCL)   
L. amazonensis New World Cutaneous Leishmaniasis (CL) & Mucocutaneous 
Cutaneous Leishmaniasis (MCL) & Diffuse 
Cutaneous Leishmaniasis (DCL)   
L. infantum New World Visceral Leishmaniasis (VL) & Cutaneous 
Leishmaniasis (CL) 
Table 1.1.  Major species and location of Leishmania which cause different types of the 
disease 
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1.2.1 Disease 
There are four types of leishmaniasis: visceral leishmaniasis (VL) (also known as 
kala azar or dumdum fever), cutaneous leishmaniasis (CL), diffuse cutaneous 
leishmaniasis (DCL), and mucocutaneous leishmaniasis (MCL) (Table 1). 
According to the World Health Organization (WHO, 2007), more than 12 million 
people are currently infected and there are two million new cases every year, 
with around 350 million people at risk. This disease affects the poorest 
populations in 88 countries, the majority of which are developing countries in 
Asia and South America (Garcia, 2007;Matlashewski, 2001;WHO, 2007). VL is 
found in 70 countries, with an estimated 500,000 new cases per year, whereas 
CL is present in 82 countries with annual estimates of 1.5 million cases per year 
(Desjeux, 2004;Garcia, 2007;WHO, 2007). Around 90% of CL cases are 
concentrated in seven countries: Afghanistan, Algeria, Brazil, Iran, Peru, Saudi 
Arabia, and Syria; while, about 60% of VL cases occur in three countries: 
Bangladesh, India and Nepal (TDR, 2009). Leishmaniasis is transmitted by female 
sandflies. There are 30 known species of sand fly. Of these, the Phlebotomus 
genus is found only in the Old World and the Lutzomyia genus is found only in 
the New World. Leishmania species could be transferred via leishmaniasis-
contaminated blood (Markell et al., 1999), potentially spreading species to new 
areas. 
 
Figure 1.5. Leishmaniasis is endemic in tropical, Asian and southern European countries. 
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1.2.2 Morphology 
Leishmania are protozoan parasites belonging to the Kinetoplastida order 
because they contain a kinetoplast in all cells. There are two main forms of 
Leishmania: amastigotes and promastigotes. Amastigote forms live in 
macrophages in blood hosts, whereas promastigote forms live in sandflies.  Both 
forms have all the major cell organisms, i.e. nucleus, kinetoplast, 
mitochondrion, Golgi apparatus, flagellar pocket, endoplasmic reticulum, and 
glycosome (Besteiro et al., 2007). The amastigotes are small and circular (3-5 
µm in diameter), while the promastigotes are extended (1.5-3.5 by 15-20 µm) 
with one flagellum of 15-28 µm (Besteiro et al., 2007;Garcia, 2007). 
 
Figure 1.6. The main intracellular organelles Leishmania Promastigote (left) and amastigote 
(right) (Besteiro et al., 2007) 
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1.2.3 Life cycle 
Leishmaniasis is transmitted by the bite of sand flies that are at the infectious 
stage and so transmit metacyclic promastigotes. When sandflies feed on the 
blood of a host, the metacyclic promastigotes are passed to the host. The 
promastigotes are taken up by the macrophage where they quickly transform 
into their amastigote form in the phagolysosome and lose their flagella. The 
amastigotes multiply within the macrophages via binary fission until the cells are 
damaged, causing the amastigotes to be released for invasion of other 
macrophages (Chappuis et al., 2007). What follows at this point depends on the 
species of leishmaniasis, In CL, the amastigotes appear in the skin and causes 
chronic infection in parts of the body such as the hands, face, feet, arms, and 
legs. In VL, they pass to deeper organs, for instance, the spleen, liver, and bone 
marrow. When new sandflies feed on the blood of mammals that have 
amastigotes in the macrophages of their blood, the macrophages are ingested 
and amastigotes are released in the sandfly‘s mid-gut. They then transform into 
promastigotes and multiply by longitudinal fission in metacyclic promastigote 
form. The metacyclic promastigotes are highly mobile and migrate to the 
hypostome of the fly. Metacyclic promastigotes are then found in the 
mouthparts, where they are ready to infect vertebrate hosts during the fly‘s 
next blood meal. The life cycle of the sand fly depends on the species, but 
ranges between four and eighteen days (Garcia, 2007). 
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Figure 1.7. Life cycle of Leishmaniasis. 
 Reproduced from http://dpd.cdc.gov/dpdx/html/Leishmaniasis.htm 
 
1.2.4 Clinical Disease 
There are four types of leishmaniasis disease are different for different species 
that causes the disease. 
1.2.4.1 Cutaneous Leishmaniasis (CL) 
The incubation period of CL is two to eight weeks and may extend to a couple of 
years (Garcia, 2007;Markell et al., 1999). The first symptoms of cutaneous 
disease are lesions at the point of entry where the bite of the sandfly occurred. 
This point is initially painless but soon becomes itchy. These lesions normally 
appear on parts of the body that are more frequently uncovered, such as the 
face, arms, and legs. The disease can go on to create a great number of lesions. 
These can further develop into ulcers covered by a scab and containing 
exudates. Other symptoms depend on species. For example, in L. major the 
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lesions have inflammation and crusting and are necrotic and exudative. In L. 
tropica, the lesions are less necrotic but exhibit greater swelling and a thicker 
crust (Garcia, 2007;WHO, 2007). 
1.2.4.2 Mucocutaneous Leishmaniasis (MCL)  
The disease usually begins after an early cutaneous infection. Cutaneous lesions 
develop and can become very large. MCL causes infection of mucosal surfaces 
with lesions that can lead to destruction of one side or all of the mucous 
membranes of the mouth and nose. Others symptoms include fever, anaemia, 
and weight loss. Failure to treat this disease is likely to lead to the loss of all of 
the soft parts of the nose, palate, and lips. In the Old World, MCL are related to 
L. tropica and L. major, whereas in the New World they are linked to L. 
braziliensis and L. guyanesis (Desjeux, 2004;Markell et al., 1999). 
1.2.4.3 Diffuse Cutaneous Leishmaniasis (DCL) 
Diffuse cutaneous leishmaniasis (DCL) is an uncommon manifestation of 
cutaneous leishmaniasis. According to Desjeux (Desjeux, 2004), ―This occurs in 
individuals with defective cell-mediated immune response. Its severity is due to 
disseminated lesions that resemble those of lepromatous leprosy‖. These lesions 
are usually scaly with numerous nodules and can occur over the whole of body 
(Garcia, 2007). Several Leishmania species cause diffuse cutaneous 
leishmaniasis. In the Old World, L. aethiopica, and, in the New World, L. 
pifanoi, L. amazonensis, and L. mexicana cause DCL (Garcia, 2007). 
1.2.4.4 Visceral Leishmaniasis (VL) 
The incubation period of VL is usually between two and six months (Chappuis et 
al., 2007;Garcia, 2007). This is the most dangerous of the leishmaniasis diseases 
and leads to death if not treated (Matlashewski, 2001). The main symptom of VL 
patients is fever, which is accompanied by weight loss, chills, weakness, 
anaemia, swelling of the spleen and liver, diarrhoea, and enlarged lymph nodes. 
In addition, VL patients can sometimes develop another disease after the VL has 
been treated, known as post-kala azar dermal leishmaniasis (PKDL). In India, 
more than 20% of patients treated for VL develop PKDL, and this figure rises to 
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50% in Sudanese VL patients. PKDL is a cutaneous disease but quite different 
from CL, and much more diffuse. In the beginning, macules form near the 
mouth. These then spread to the face and continue to the arms, the trunk, and 
the legs (Garcia, 2007). VL is caused by L. donovani and L. infantum, in the Old 
World and L. chagasi and L. amazonensis in the New World (Garcia, 2007;Markell 
et al., 1999). 
1.2.5 Diagnosis 
Diagnosis of leishmaniasis can usually be undertaken by general practitioners, 
but this depends on the symptoms, and on how common the disease is in a given 
area. However, in parts of the world where leishmaniasis disease is rare, 
diagnosis depends on the appearance of amastigotes or promastigotes in samples 
(Garcia, 2007). Parasitology and serology are very important to the diagnosis of 
leishmaniasis (Manson-Bahr, 1987). Parasitological diagnosis relies on detection 
of the parasites in the blood, skin, lymph nodes, experimental animals, spleen, 
liver, and bone marrow using blood films, needle biopsies, and biopsies (Garcia, 
2007;Kreier, 1987;Manson-Bahr, 1987). Serological diagnosis on the other hand, 
is usually based on the presence of Leishmania antibodies in the blood (Jhingran 
et al., 2008). Many serological methods are used to detect leishmaniasis, 
including direct agglutination tests (DAT), immunofluorescence tests (IFAT), and 
enzyme-linked immunosorbent assays (ELISA) (Garcia, 2007;Jhingran et al., 
2008;Manson-Bahr, 1987). 
1.2.6 The control of Leishmaniasis 
It could be said that control of leishmaniasis depends on three strategies: vector 
control, treatment and vaccines. Vector control to minimize or interrupt disease 
transmission takes many forms. For example, using insecticides like DDT 
although it has disadvantages is a good choice. In India, The use of DDT is part of 
the plan to eliminate Visceral Leishmaniasis by 2015 (Killick-Kendrick, 2010). 
There are several types of insecticides that can be used such as malathion, 
propoxur and deltamethrin (WHO, 2010). In addition, bed nets and wearing 
clothing to cover arms are effective for reducing the disease by decrease 
exposure to the bites of flies. 
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Using vaccines is not yet a means for the prevention of leishmaniasis. To date, in 
spite of efforts to design vaccines, no vaccine can be used because the problem 
is limited by the necessary attempt to translate the successful use of vaccines in 
experimental animals to humans, and to translate those results into practical 
field applications, rather than just laboratory tests (Kedzierski, 2010).          
1.2.7 Treatment of leishmaniasis 
As with many protozoan diseases, there are many problems associated with the 
therapy of leishmaniasis. Despite the fact that humans recover from CL without 
assistance, over a period of a few months to several years (Garcia, 2007), the 
use of drugs for rapid treatment is still much preferable due to the disfiguring 
nature of the lesions and the potential for secondary infections. There are five 
main drugs used in the chemotherapy of leishmaniasis: pentavalent antimonials, 
amphotericin B, miltefosine, paromomycin, and pentamidine. The most effective 
treatment of leishmaniasis depends on the species and the clinical manifestation 
(Peters & Killick-Kendrick, 1987). 
1.2.7.1 Pentavalent antimonial 
Since 1947 the treatment of leishmaniasis includes the use of antimonial drugs 
for the reduction of visceral and cutaneous leishmaniasis. There are two such 
drug preparations that are available for antimonial therapy, i.e. Pentostam and 
Glucantime. Figure 1.8 shows the Pentostam structure as sodium stibogluconate; 
Glucantime is known as Meglumine antimoniate. Some of the clinical symptoms 
that arise from pentavalent antimonial toxicity are malaise, vomiting and 
anorexia (Chang et al., 1985;Kreier, 1987). Cases of visceral leishmaniasis were 
found to be responded by antimony therapy. Relapse  may occur over the 
patient‘s life time and its treatment often involves the second line therapy of 
amphotericin B or Pentamidine (Olliaro et al., 2002). Unfortunately, half of the 
patients who received this treatment regime were found to have VL disease 
(Ganguly, 2002). Initially WHO approved 20 mg of antimonial per kg per day for 
treating Leishmaniasis and later its recommended up to 850 mg / per kg of body 
for 28 days (Balana-Fouce et al., 1998).  
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Intracellular ATP level is decreased due to the metabolic action of this drug as it 
interferes with glycolysis and with β-oxidation of fatty acids in amastigotes of 
many species of Leishmania (Van Voorhis, 1990). Oral administration of 
pentavalent antimonial is reported to be possible, and the drug can be 
developed (Frezard et al., 2008) from a complex of meglumine antimoniate 
(MA), β-cyclodextrin (β-CD), and pentavalent antimonial (Sb) (NMG-Sb- β-CD-Sb-
NMG). This drug enters through the gastrointestinal epithelium by simple 
diffusion. Clinical manifestations upon high drug dosages include myalgia, 
hepatotoxicity, and malaise (Hepburn et al., 1993), headache, anorexia, nausea, 
cardiotoxicity and phlebitis (Navin et al., 1992). The few other symptoms that 
appear with high dosages are fever, skin rash, gastrointestinal irritation, and 
cough (Warren & Mahmoud, 1984) and pancreatitis (Gasser, Jr. et al., 1994). 
However, in some cases treatment is ineffective due to the resistance by 
parasites against the administered antimonial; approximately 10 to 25 % of the 
cases who received the treatment are reported to have frequent relapse in the 
former disease condition (Opperdoes & Michels, 2008). This treatment is 
considered as the first line drug against Leishmaniasis while the second line 
treatment regime includes Pentamidine, Amphotericin B alone and the 
formulation of amphotericin B encapsulated in liposomes (AmBisome) (WHO, 
2007).  
1.2.7.2 Amphotericin B 
This drug is also employed as second line treatment of different types of 
Leishmaniasis and studies have shown that this drug has a positive physiological 
impact in patients who have VL relapses (Olliaro & Bryceson, 1993) but some 
disadvantages of using this drug are its high toxicity and cost. However, some 
lipid formulations of this drug have been prepared to overcome such issues, 
including cholesterol sulphate amphotericin B liposomes (Amphocil), 
disteroylphosphotidyl amphotericin B complex (AmpBisome) and abeleet. These 
lipids formulations offer less toxicity and are more efficient in bringing about VL 
and ML remission (Yardley & Croft, 2000). In studies employing VL and CL 
experimental models, amphotericin B and its liposomic form were observed to 
be active in abating the infection intensity (Croft et al., 2005). Amphotericin B 
(AmpB) is reported to prevent binding of L. donovani with macrophages, thus 
limiting macrophage infection. AmpB is thought to interact with cholesterol of 
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the host macrophages and ergosterol of the parasite (Paila et al., 2010). 
Countries like India and Nepal recommend this drug in Leishmaniasis infection 
and its dosage period is extended if the infection process has spread to splenic 
smears and marrow. 
Dose range of this drug varies from 0.5 to 1 mg/Kg of body weight. High drug 
doses are prohibited because of its toxic metabolic impact at this concentration. 
Side effects at high doses include hepatotoxicity, hypomagnesaemia, fever, 
hypokalemia, renal dysfunction, myocditis, sudden death and bone marrow 
suppression (Balana-Fouce et al., 1998;Sundar, 2001).  
In Leishmania and fungi, the mode of action of amphotericin B involves sterol 
metabolism as it acts on a sterol called 24-ergosterol, the main sterol in their 
plasma membranes. Amphotericin B binding to ergosterol causes parasite death 
because of increased membrane permeability (Balana-Fouce et al., 1998;Singh 
et al., 2006).  
1.2.7.3 Miltefosine 
The best feature of this drug is that its oral administrable form is available in 
the market, which has a high impact on remitting VL (Fischer et al., 2001;TDR, 
2002). It is also active in reducing CL infections (Croft et al., 2005). This drug 
was proven to be therapeutically effective against VL in studies conducted in 
Bihar, India with 94% potential of disease treatment (Singh et al., 2006). Besides 
this, researches conducted in Africa and Columbia showed similar results against 
CL (Opperdoes & Michels, 2008). Acting at a cellular level, Miltefosine induces 
the production of inducible nitric oxide synthase 2 (iNOS2), thus catalysing the 
production of nitric oxide within macrophages and killing parasites (Wadhone et 
al., 2009). Range of optimum dosages for Miltefosine is recommended to be 2.5 
mg/kg of body weight in a day for a period of four weeks (Jha et al., 
1999;Sundar et al., 2002). Side effect associated with Miltefosine include only 
minor symptoms such as gastrointestinal disturbances including vomiting (40% 
cases) and 20% of the patients complained about diarrhoea (Singh et al., 2006). 
Some other concerns raised in using this treatment regime are its long half-life 
which makes the drug available for enough time to have resistance developing 
against it (Singh et al., 2006). In order to decrease the potential for resistance 
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several combinations with other drugs have been investigated (Seifert & Croft, 
2006); specifically combinations miltefosine with Paromomycin, Sitamaquine, 
Pentostam or amphotericin B were tested. Among all these combinations, the 
most effective combination therapies were the ones employing amphotericin B 
and Paromomycin.  
1.2.7.4 Paromomycin 
The structure of this drug is presented in figure 1.8. It is widely employed in the 
treatment of bacterial and intestinal parasitic infections e.g. VL. Cases with 
reported antimonial resistance are recommended to take this therapy and its 
added benefits are low cost, high efficiency and authorization (Olliaro et al., 
2002;Sundar, 2001). This treatment is declared to be safe and it has replaced 
amphotericin B in VL, as that drug is costly and toxic. Formulations for oral  
administration and topical use have been prepared and they are effective 
against enteric protozoa and old world CL (Flanigan et al., 1996). However, 
topical paromomycin formulations are still undergoing clinical trial and have yet 
to be approved. Optimum dosage for this drug ranges from 14 to 16 mg/kg thrice 
a week and the maximum amount of this drug given can reach 1 g. Side effects 
associated with this drug include nephrotoxicity (Sundar, 2001). In central 
Tunisia, topical Paromomycin prescriptions are given because it is active against 
Leishmania major which causes zoonotic CL in that country.  Observations of this 
study showed that it is ineffective in this type of Leishmaniasis (Ben et al., 
1995). Paromomycin led to inhibition of protein synthesis in the promastigote 
stage of L. mexicana and reduced proliferation but had little effect on 
mammalian cells. This drug strongly interacts with parasites, whereas it does not 
bind to mammalian cells (Fernandez et al., 2011). Studies have been conducted 
to determine the therapeutic effect of combination of Paromomycin and 
antimonial in old and new type of Leishmaniasis (Jha et al., 1999;Thakur et al., 
2000). 
1.2.7.5 Pentamidine 
Diagram 1.8 shows the structure of Pentamidine. This drug is employed as a 
second line treatment regime of antimony-relapsed visceral leishmaniasis. It 
displays relatively high toxicity and cost, but is reportedly a quite effective 
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antileismanial agent. In general, pentamidine is not considered a major drug for 
treating leishmaniasis. In some cases—mostly after treatment failure with 
pentavalent antimonials—pentamidine is used as a second line drug. However, in 
a few countries such as Suriname, pentamidine is used as a first line drug for CL 
(Van Der Meide et al., 2009). Its route of administration is intramuscular and the 
injections contain drug dosage in range of 2-4 mg/kg body weight. The drug is 
administered thrice a week for a period of 3-4 weeks (Balana-Fouce et al., 
1998).30 to 50% of the patients who received this therapy were reported to have 
side effects including hyperglycemia, hypoglycemia, sterile injection abscess 
(Sundar, 2001) and sudden shock, anemia, nephrotoxicity, hepatic enzymes 
induction, and skin rashes (Balana-Fouce et al., 1998;Sundar, 2001) while 10% of 
the cases developed diabetes mellitus manifestations (Ganguly, 2002).  
The drug enters the cell via active transportation, possibly using the arginine 
and polyamine transport system (Basselin et al., 1996). The exact metabolic 
mechanism through which it drugs kill parasite is still unknown but it is 
suggested that it affects mitochondrial membrane potential and this rendering it 
non-functional (Basselin et al., 1996;Mukherjee et al., 2006). 
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 Figure 1.8. Chemical structures of drugs used against Leishmaniasis. 
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1.2.8 Drug Resistance 
Recently, resistance to drugs has emerged as a major problem in the control of 
Leishmania parasites, which has serious impact on community health in endemic 
areas. According to Croft and Coombs (Croft & Coombs, 2003), many  Leishmania 
species, including L. donovani and L. tropica, are zoonotic and consequently 
increases in drug resistance are less probable unless these is also substantial 
human to human transmission. The reduced benefit of pentavalent antimony for 
treating of VL is due to drug resistance (Sundar et al., 2008), which has added 
another dimension to this matter. Moreover, in India, the use of pentamidine for 
some parasites has been stopped due to resistance (Sundar, 2001). Despite the 
fact that mechanisms of resistance are not well understood, some explanations 
have been put forward regarding this issue. For example, underdosing may lead 
to resistance (Polonio & Efferth, 2008). On the other hand, Brochu et al (Brochu 
et al., 2003) have suggested that reduced accumulation of a drug can lead to 
resistance.  
1.3 Transporters in kinetoplastids and their importance in 
drugs development   
Kinetoplastids are obligatory parasites that are completely dependent on the 
host environment to obtain the necessary materials for their cellular functions. 
Cell membranes of all cells have many roles, and one of these is to control the 
movement of materials into and out of the cell. Membrane transporters are 
responsible for the movement of necessary nutrients, the regulation of 
physiological concentrations, cellular communication, and elimination of waste 
products. Controlling the molecular traffic across the cell membrane is 
performed through five methods: simple diffusion, facilitated diffusion, active 
transport, endocytosis, and exocytosis (Mohammed, 2000). Drug therapy is one 
of the ways by which parasites are controlled and their numbers reduced, and as 
most drug targets are intracellular, drugs must pass through the parasite 
membranes. Thus, transport processes play key roles in not only maintaining the 
life of cells but also in the action of anti-infective agents.  
Abdulsalam Alkhaldi, 2012                                                                                        Chapter 1       28 
Among many other necessary materials for the life of the parasite, nucleosides 
and nucleobases, which are essential for nucleic acid synthesis, must pass 
through the membrane. Purines and pyrimidines are necessary for synthesis of 
nucleic acids in all cells. All protozoan parasites are incapable of de novo purine 
biosynthesis, and they depend on their hosts to obtain purines (de Koning et al., 
2005). In contrast, de novo synthesis of pyrimidine rings occurs in all protozoan 
parasites, except for Giardia lamblia, Tritrichomonas foetus and Tritrichomonas 
vaginalis (Hassan & Coombs, 1988).  
Many proteins are associated with the cell surface and assist in the passage of 
materials across the cell membrane. In eukaryotes, there are two known families 
of mammalian transport proteins that help to move free nucleosides and 
nucleobases through the cell membrane. These are non-homologous and 
classified based on mechanism of translocation of substrate. The first family is 
the Equilibrative Nucleoside Transporter (ENT) family that enables the 
movement of these molecules down concentration gradients into or out of cells 
(facilitated diffusion) (Baldwin et al., 2004). However, some protozoan 
transporters of the ENT family have been shown to be energy dependent, using 
the proton gradient across the plasma membrane to efficiently transport 
substrate (de Koning et al., 2005).  The second family is the Concentrative 
Nucleoside Transporter (CNT) family that uses a co-transport mechanism for 
sodium ions (Gray et al., 2004). The CNT family consists of three subtypes of 
sodium-dependent transporters: CNT1 or (SLC28A1) which transports pyrimidine 
nucleosides, CNT2 or (SLC28A2) which is responsible for purine nucleoside 
transport, and CNT3 (also referred to as SLC28A3) which transports both 
pyrimidine and purine nucleosides (Gray et al., 2004). However, no members of 
this transporter family have been detected in protozoa, although ENT 
transporters do not account for all known nucleobase transport activities, 
especially those mediating pyrimidine uptake (de Koning, 2007). 
Apart from selective uptake through unique protozoan transporters, antiparasitic 
drugs rely for their selective action on unique targets not present, or sufficiently 
different, in the human host. Therefore, new drug development programmes 
commonly seek to target pathways or enzymes that do not exist in host cells. 
One example is trypanothione, which is essential to trypanosomatids and found 
only in kinetoplastid parasites. Another example is ornithine decarboxylase 
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(ODC), which although essential in both humans and T. b. gambiense, is 
sufficiently different between the two species to be a good drug target 
(Delespaux & de Koning, 2007). 
1.4 Trypanosome metabolism  
Many studies have been conducted on trypanosome metabolic processes, 
particularly with emphasis on glycolysis (Albert et al., 2005;Haanstra et al., 
2008;Visser & Opperdoes, 1980) and trypanothione synthesis (Fairlamb et al., 
1987;Xiao et al., 2009). The biochemical pathways were investigated using 
HPLC, NMR and classical techniques of biochemistry and enzymology. 
Quantification of phosphorylated compounds in the bloodstream and procyclic of 
T. brucei was performed via NMR (Moreno et al., 2000) and also for performing 
analysis in enzyme inhibition process in the same organism (Coustou et al., 
2005). However, the in-depth analysis of some pathways such as glycolysis and 
mitochondrial functions have left other aspects of kinetoplastid biochemistry 
relatively under-explored. The application of systems biology and metabolomics 
to this problem is starting to address some of the gaps, however. For instance, 
analysis of alterations in procyclic trypanosome metabolism after change of 
carbon source from glucose to proline was performed through Hydrophylic 
Interaction Chromatography (HILIC)-Orbitrap mass spectrometry (Kamleh et al., 
2008). In the case of this energy metabolism shift, this highlights a number of 
other metabolite changes, e.g. glutamate, 5-carboxypyrroline and glutathione in 
cells cultured in proline rich media (Kamleh et al., 2008), in turn identifying 
biochemical pathways being activated or inhibited by the change in medium. 
1.4.1 Thiol metabolism 
Mammalian cells contain high concentrations of glutathione and at physiological 
pH it serves as a sulfhydryl buffer. Besides this, it is involved in many cellular 
metabolic processes including DNA & protein synthesis, amino acids importation 
and detoxification of oxidative species (Hayes & McLellan, 1999;Meister, 1981). 
The molecular structure of glutathione consists of a tri-peptide thiol. Clarity in 
the host and parasite metabolic processes and the variation between them is 
essential for the development of effective treatment regimes against 
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trypanosome infections (Wang, 1995). Glutathione metabolism is different in 
trypanosome and mammals because the former involves the contribution of the 
glutathione and spermidine conjugate named trypanothione that is responsible 
for thiol pool availability for further metabolic processes (Fairlamb et al., 1997). 
The biosynthesis of trypanothione (and glutathione) starts with the synthesis of 
glutamylcyteine from glutamic acid and cysteine by the catalytic action of γ-
glutamylcysteine synthetase (γ-GCS) (Griffith & Mulcahy, 1999). This enzyme is 
rate limiting in mammalian species (Griffith, 1999) whereas the homologous 
enzyme catalyzes trypanothione in the  trypanosomatid Leishmania tarentolae 
(Grondin et al., 1997). The synthesis of glutathione is completed by the addition 
of the third amino acid, glycine, by glutathione synthase (GS). Two glutathione 
residues are then coupled to spermidine to yield one molecule of trypanothione, 
in a reaction mediated by trypanothione synthetase (TrypSyn).  
There are several different mechanisms through which trypanothione 
metabolism can be targeted. The first one involves the inhibition of 
trypanothione reductase (TryR) by specific inhibitors such as those of the 
pyrimidinobenzothiazepine and thiaisoalloxazine scaffolds (Galarreta et al., 
2008). Secondly, inhibition of trypanothione synthetase itself is possible and a 
recent report from the Fairlamb group describes a series of potent quinol 
inhibitors for this enzyme (König et al., 2011). In addition, drugs like DFMO are 
found to be effective in inhibiting trypanothione synthesis by inhibiting 
putrescine and spermidine production (Vincent et al., 2012). 
1.4.2 The role of mitochondria in bloodstream form T. b. brucei 
One of the major organelles present in a trypanosome is the mitochondrion, 
which is singular and it requires the cell division cycle to duplicate. 10-20% of 
the total DNA of the T. brucei is present in the mitochondrion of the cell, which 
contains its own genome, which is not uniform in shape because the shape of the 
genome is dependent on the stage of the cell cycle. The mitochondrion does not 
fully mature in the bloodstream form (BSF) and contains singular canal without 
of inner membrane folding. The mitochondrion of bloodstream forms lacks both 
Krebs cycle and the classical respiratory chain, whereas both the respiratory 
chain and Krebs cycle are present in the procyclic forms (PCF). The 
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mitochondrion is present in the form of a network with inner membrane folding 
(van Weelden et al., 2003;Vickerman, 1985). 
Both morphological and functional changes to the mitochondria take place 
during the process of differentiation of T. brucei between the distinct life-cycle 
stages, as the source of the energy of the parasite changes from amino acid to 
glucose oxidation (Vickerman, 1985). Via the glycolytic pathway the BSF cells 
make use of the sugar-rich environment of the mammalian bloodstream for their 
energy metabolism (Bienen et al., 1993). There is no cytochrome-mediated 
respiratory chain in the BSF cells; rather they contain the glycerol-3-phosphate 
dehydrogenase and the salicylic hydroxamic acid (SHAM)-sensitive alternative 
oxidase which is a significant electron transport chain present in the 
mitochondria, also known as the trypanosome alternative oxidase (TAO) 
(Chaudhuri et al., 2006). A mitochondrial membrane potential is preserved 
regardless of the absence of complete cytochrome-containing complexes III and 
IV in BSF trypanosomes, driven by ATP hydrolysis of the FoF1-ATP synthase 
complex, which exports portions from the mitochondrial matrix (Schnaufer et 
al., 2005). 
1.5 Trypanosome signalling pathways 
There are several types of signals that regulate cellular processes including gene 
expression patterns in response to extracellular triggers. These signals are called 
second messengers and include cAMP and calcium ions (Ca2+), which in turn 
activate effecter proteins such as Protein Kinase A and other protein kinases, 
Calmodulin, ion channels and other pathways in many cell types. 
1.5.1 cAMP 
In this case the role of second messenger is played by cyclic adenosine 
monophosphate (cAMP), which is involved in many biological processes. The 
discovery of the Adenylyl cyclase (AC) activity in trypanosomes took place in 
1974 in Trypanosoma gambiense (Walter et al., 1974), which led to estimating 
cAMP levels in different life-cycle stages of Trypanosoma lewisi, and it was 
discovered that in the non-reproducing state, the cAMP concentration was 
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around twice that of the reproducing form (Strickler & Patton, 1975). As the 
parasitaemia in rats increased so did the cAMP concentration in the parasites 
suggesting a role in quorum sensing and possibly in differentiation to short-
stumpy forms or exchanges of the VSG coat; similar alterations were seen in the 
strains that caused a relapsing parasitaemia (Mancini & Patton, 1981). Interest in 
the cAMP-dependent pathways has recently peaked with reports showing that 
cAMP phosphodiesterases TbPDEB1/B2 and some adenylyl cyclases are essential 
and potential drug targets (de Koning et al., 2012;Salmon et al., 2012). 
1.5.2 Calcium Ions 
Calcium ions (Ca2+) plays a crucial role as omnipresent messengers in the cell, 
and facilitate many cellular responses such as proliferation, contraction, 
secretion, differentiation and cell division. In parasites, Ca2+ plays a vital role in 
their interaction with host cells. There are two intracellular Ca2+ transport 
systems in Trypanosoma brucei, one of them in mitochondria and the other in 
the endoplasmic reticulum (Moreno et al., 1992). For Trypanosoma cruzi, there 
is also a relationship with increased virulence of parasites as well as their 
penetration into the host cell (Docampo & Moreno, 1996).  
Intracellular Ca2+ can be released to the cytosol from numerous organelles, 
including endoplasmic reticulum, mitochondria and acidocalcisomes. Apart from 
its physiological role as a regulator, extracellular Ca2+ plays an important role in 
the action of several trypanocidal drugs, for instance potentiating the effect of 
melarsoprol (Clarkson Jr & Amole, 1982). 
Until now there has been no evidence of the existence of voltage-dependent 
Ca2+ channels in parasitic protozoa (Moreno & Docampo, 2003). However, Ca2+ 
entry into Trypanosoma brucei can be stimulated by Phospholipase A2 activity, 
which releases arachidonic acid and is itself Ca2+-regulated (Eintracht et al., 
1998). 
The concentration of intracellular Ca2+ and its homeostasis in the cell is very 
important. Any changes might lead to a failure in metabolism and cell death. 
Importantly, mitochondrial calcium release has also been implicated in 
programmed cell death (Fidalgo & Gille, 2011). Therefore, studying intracellular 
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Ca2+ in trypanosomes and the effect of different drugs on intracellular Ca2+ could 
help to understand the mode of action for some of the lead compounds that are 
under development against trypanosomiasis. 
1.6 Mode of Action Studies 
The process of drug development is very expensive and early investigation of a 
potential lead compound‘s mode of action (MoA) can either help advancing the 
project through target-based optimisation and improved assays, or help dismiss 
the scaffold early if it is found that the MoA is inappropriate. Possibly the most 
powerful tool for lead compound optimisation is medicinal chemistry based on 
analysis of a proper structure-activity relationship (SAR) of structural analogues 
interacting with a single protein target. This allows for the rational optimisation 
of the lead compound structure towards desirable qualities such as higher 
affinity, higher specificity, metabolic stability, oral absorption etc. For this to 
be possible MoA studies are required in order to identify the target of 
antiparasitic agents with promising activity and selectivity discovered through 
screening in whole-cell assays. 
Initially, the active compound led to drug discovery with information regarding 
mode of action coming much later, now, attempts are being made to discover if 
it can be drawn from the discovery of a good metabolic target. To examine a 
drug‘s effect on the tiny metabolites present within a cell population, a new 
method called Metabolomics is considered very beneficial because it eases up 
the process of licensing and cost of drug discovery. 
There are two pathways of metabolomics-based mode of action, initially, the 
alterations after drug induction are observed using metabolic fingerprint, and 
then the metabolome is compared with drugs that have known modes of action 
using multivariate statistical analysis (Yi et al., 2007). However, there are few 
trypanocides with known mode of action, although examples exist, such as 
Eflornithine and the new N-myristoyltransferase (NMT) inhibitors. But is unlikely 
that a novel compound of unknown trypanocidal mode of action would exactly 
mimic the actions of ether eflornithine or NMT inhibitors, thus unbiased 
approach to mode of action discovery is necessary. The second pathway is more 
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consistent because it focuses more on the separate metabolite abundance 
changes which take place after adding the drug (Le Roch et al., 2008) and this 
permits the discovery of new modes of action and also prediction of off-target 
effects. 
1.7 New drugs for protozoa 
Currently, chemotherapy is still important for the control of most parasitic 
diseases, such as trypanosomiasis and leishmaniasis. However, problems 
associated with treatment of these diseases include drug toxicity, resistance, a 
lack of guaranteed supply, and high cost. In addition, at present, with the rapid 
development of the world in all fields, the numbers of people who have parasitic 
diseases are extreme. For example, more than 12 million people are presently 
infected by leishmaniasis and 50,000 new cases per year of African 
trypanosomiasis are reported. Obviously these numbers do not include the large 
numbers of people in remote areas that are never formally diagnosed with the 
disease. Furthermore, a large number of antiparasitic drugs have been only 
experimentally tested in animal models, so little is known about their efficacy 
on parasitic hosts (el Kouni, 2003).  
According to DNDi in 2012 (http://dndi.org/press-releases/1207-astellas-and-
dndi.html) the newest drugs used for the treatment of HAT and VL are 
nifurtimox-eflornithine combination therapy (NECT) and sodium stibogluconate 
and paromomycin (SSG&PM) combination therapy, respectively. 
Currently, there are several compounds under consideration for the treatment of 
HAT and Leishmaniasis. In addition, Fexinidazole is one new drug that is being 
developed against HAT; it shows ability to kill the parasites of both species that 
caused HAT in vitro and in vivo (Kaiser et al., 2011). Another very promising new 
class of compounds is the oxaboroles (Maser et al., 2012), which is being 
developed by DNDi and Scynexis. The lead oxaborole SCYX-7158 is active in both 
acute and cerebral mouse models of trypanosomiasis, and has now started Phase 
I clinical trials (Nare et al., 2010). 
Despite the improved pipeline for antiparasitic drug development it is essential 
that efforts countinue to identify new, unrelated lead compounds, as experience 
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shows that many preclinical candidates will not in the end be approved for 
human use. Consequently, this study will focus on several promising lead 
compounds to study their effects on pathogenic parasites. 
 
1.8 Treatment of protozoan infections by natural 
products and their derivatives 
Only a very restricted number of drugs are licensed and used as antiparasitic 
agents due to the development of drug resistance, which causes most of the 
drugs to become dormant or less active against the parasites. This has led to the 
discontinuation of the use of many compounds that were once highly efficacious, 
like chloroquine for malaria. In the disease endemic countries, issues such as 
toxicity, price and accessibility are also major factors affecting the use of 
antiparasitic drugs. One possible approach to improve this situation is to screen 
for antiprotozoal activities in natural resources, such as plants, microorganisms 
(bacteria, fungi), marine organisms, sponges and invertebrates. These provide 
an enormous diversity of potent bio-active compounds that may be amenable for 
clinical application (Kayser et al., 2003).  
More than 20,000 species of plants are being used to produce traditional medical 
treatments for a plethora of diseases and ailments (Phillipson, 1994). It has been 
estimated that around 6.1 billion people in the world (66%) trust traditional 
medicines more than pharmaceutical drugs, despite limited knowledge about 
their toxicity and efficacy, due to issues such as restriction in accessibility, 
and/or the increased costs of pharmaceutical drugs (Tagboto & Townson, 2001). 
Consequently, the use of these traditional medicines has contributed to many 
deaths, despite the great value in some of natural and herbal medicines. 
Foxglove, ephedra, and morphine are the first three natural sources derived 
from plants for use in traditional medicines. These drugs can be used in the 
treatment of heart disease, respiratory disorders, and produces an effective 
analgesic effect, respectively (Tagboto & Townson, 2001). For the production of 
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new anti-infective agents with reduced toxicity and higher efficacy natural 
products are often used as starting point.  
Further detail regarding many natural antiparasitics is being given below. For 
the treatment of malaria, quinine and artimisinin are used and to confront 
several parasitic and non-parasitic diseases, curcumin is used. Antibiotics are 
widely used against many infectious agents, prominently including infections of 
bacterial origin but in specific cases also protozoan disease. 
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1.8.1 Quinolines in malaria 
Quinine is a natural white crystalline alkaloid compound (see below), which is 
derived from the bark of Cinchona trees. It was initially discovered in South 
America for the treatment of tropical fevers. Nowadays, it is being used to treat 
malaria caused by P. falciparum and also as an analgesic and anti-inflammatory 
agent. 
 
 
 
The quinine base is found in 5 states, namely: quinine dihydrochloride, quinine 
hydrochloride, quinine sulfate and quinine gluconate. All these quinine bases can 
be administered in doses of 8 mg/kg of quinine base three times a day either 
orally or by intravenous injection. Furthermore, it can also be administered 
rectally or intramuscularly every 12 hours in doses of 20 mg per kg or 12.5 mg/kg 
of quinine base, as mentioned by Barennes and colleagues (Barennes et al., 
2006).  
Even though the mode of action of quinine against malaria parasites is still under 
examination,  it is believed to be similar to chloroquine; causing cytotoxicity by 
inhibiting the polymerisation of haem into haemozoin, resulting in free haem 
which is toxic for the parasite (Yakuob et al., 1995). Quinine and its chemical 
quinoline analogues accumulate in the parasite‘s food vacuole into which they 
freely diffuse prior to being trapped by protonation. It is this accumulation that 
that leads to a sufficiently high local concentration to interfere with haem 
polymerisation. 
Cinchonism, heart attack, stroke, cardiac arrhythmias, hearing loss, 
cardiovascular problems, nausea, headach and visual loss are some of the side 
effects observed after Quinine administration (Bodenhamer & Smilkstein, 
1993;Boland et al., 1985;Jung et al., 1993;Smilkstein et al., 1987;Wolf et al., 
1992). Despite various studies on the use of quinine, very few studies have 
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studied the effect of this compound on trypanosomes in vitro. Merschjohann and 
co-workers did one of these studies, which measured the efficacy of this drug 
together with 33 other alkaloids on two species of Trypanosoma: T. b. brucei 
and T. congolense (Merschjohann et al., 2001). As a result, the IC50 value of 
quinine on T. b. brucei was determined about 5 µM. 
1.8.2 Antibiotics 
Antibiotics are of course known as antibacterials, and are used for treatment of 
infection caused by bacteria, but ‗antibiotics‘ are an extremely diverse category 
of compounds and are used to treat many diseases that are caused by different 
organisms such as fungi and protozoa. 
One of the famous antibiotics used for treatment malaria is tetracycline 
(IMBODEN, Jr. et al., 1950), Ruiz-Sanchez et al (RUIZ et al., 1952) effectively 
used tetracycline to treat malaria which is caused by P. falciparum and P. vivax, 
although its effect as an antimalarial is slow (Dahl et al., 2006). This antibiotic 
acts on the ribosome of bacterial origin that is located within the Plasmodium 
plastid and thus inhibits protein biosynthesis within this organelle (Connell et 
al., 2003) 
There are many efforts to discover new antibiotics against trypanosomes. For 
instance, Ishiyama and his colleges (Ishiyama et al., 2008) have found two 
antibiotics that have a strong antitrypanosomal effect in vitro and in vivo: KS-
505a and Alazopeptin display in vitro IC50 values in the range 1.6 to 0.5 µg/ml 
against T. b. brucei and T. b. rhodesiense, which is almost the same IC50 as for 
registered HAT drugs suramin and eﬂornithine. In addition, nine antimicrobial 
peptides were tested on African trypanosomes bloodstream and Procyclic forms 
and the results shows that the antibiotic BMAP-27 inhibited 100% of growth at 
low concentrations (2 µM and 9 µM for bloodstream and procyclic respectively). 
Five of the nine antimicrobial peptides inhibited the growth of both lifecycle 
stages, highlighting the possibility of development of those antibiotics as 
chemotherapy for trypanosomes (Haines et al., 2003). 
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Antibiotics are also used to treat Leishmaniasis, and this includes one of the 
most important antileishmanial dugs, Amphotericin B. More details about this 
antibiotic have already been given in (section 1.2.7.2).       
1.8.3 Curcumin 
Curcumin (structure see below) is a phenolic compound, and a natural yellow 
dye, which is derived from the roots and rhizomes of different species of 
Curcuma plants, called Zingiberaceae (Perez-Arriaga et al., 2006). Another plant 
of this species is the Curcuma longa Linn (turmeric) which is considered a 
significant medicinal plant which can also be used to give colour, spice and 
flavour to foods (Iqbal et al., 2003;Pan et al., 1999a;Sharma et al., 2005a). 
There are three man components of Curcuma spp, the first is essential oils e.g. 
zingiberene, turmerones and atlantones, second is turmerin (a water soluble 
peptide) and the third is curcuminoids e.g. curcumin and its immediate 
derivatives (Sharma et al., 2005a). 
 
Aside from water, Curcumin has the ability to dissolves in acetone, ethanol and 
dimethylsulphoxide (Sharma et al., 2005a). It was also suggested by Wang et al. 
(Wang et al., 1997) that curcumin is not stable in the neutral and basic pH 
because it disintegrates into feruloyl-methane and ferulic acid. There is 
evidence to suggest that the main curcumin metabolites are the oxidation 
products dihydrocurcumin and tetrahydrocurcumim, which are further 
metabolised to monoglucuronide conjugates (Maheshwari et al., 2006;Pan et al., 
1999b). Holder and his co-workers also suggested that the main metabolites of 
curcumin are glucuronide conjugates of tetrahydrocurcumim (THC) and 
hexahydrocurcumin (Holder et al., 1978). 
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1.8.3.1 Curcumin use in medicine  
Curcumin has been used to treat many medical problems and it has long been 
used as a traditional medicine in India (Sharma et al., 2005b). Curcumin has 
been reported as having anti-microbial, anti-inflammatory, anti-mutagenic, and 
anti-oxidant activities, as well as wound-healing abilities (Maheshwari et al., 
2006;Sharma et al., 2005b). In addition, curcumin has been reported to have 
anti-cancer properties (Sharma et al, 2005; Iqbal et al, 2003; Koide et al, 2002). 
Inflammation plays an important role in chronic diseases such as asthma, and 
curcumin, as mentioned before, is an effective anti-inflammatory agent. For 
example, curcumin downregulates the expression of the enzyme COX-2 that is 
correlated with many types of inflammation (Lee et al., 2005). Curcumin also 
inhibits the action of TNF, which is one of the most pro-inflammatory cytokines 
(Gulcubuk et al., 2006). Furthermore, curcumin has been shown to guard against 
several inflammatory diseases such as colitis (Sugimoto et al., 2002), arthritis 
(Joe et al., 1997), pancreatitis (Gulcubuk et al., 2006;Masamune et al., 2006) 
and allergies . 
Oxidative stress also plays an important role in the pathogenesis of many 
diseases such as cerebral ischemia-reperfusion injury, myocardial ischemia, 
cancer and hypoxia (Maheshwari et al., 2006). Curcumin has been reported to 
aid in the defence of different cells from oxidative stress (Atsumi et al., 2005). 
Curcumin has been shown potent against many types of cancer such as skin 
(Kuttan et al., 1987), liver (Notarbartolo et al., 2005), prostate (Imaida et al., 
2001), breast (Choudhuri et al., 2002), colon (Chen et al., 1999) and lung cancer 
(Radhakrishna Pillai et al., 2004). Many studies have demonstrated that 
curcumin inhibits chemical carcinogenesis in animal models.  
In addition, curcumin has been shown to have anti-parasitic effects with 
parasites such as Trypanosoma (Nose et al., 1998), Leishmania species (Gomes 
et al., 2002;Koide et al., 2002;Saleheen et al., 2002) and P. falciparum (Mishra 
et al., 2008). Recently, curcumin was also shown to be effective against 
Trypanosoma cruzi; it caused reduced parasitemia in infected mice and killed 
the parasites in vitro (Nagajyothi et al., 2012).     
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1.8.4 Artemisinin 
The herb Artemisia annua produces a compound called Artemisinin (structure 
see below)(Ferreira & Janick, 1996). This compound was identified in the 1960s 
by Chinese biologist Tu Youyou who named it Qinghaosu in Chinese. This 
compound is made from natural herbs which are used to cure various conditions 
such as skin diseases, malaria, parasitic infections such as Schistosoma mansoni, 
S. japonicum and Clonorchis sinensis (Hien & White, 1993), leukaemia and colon 
cancer (Efferth et al., 2001). Other than this, it is also used for the cure and 
prevention of breast cancer (Rowen, 2002) because it regulates hormones. In the 
1970s, the compound was also given the title of a multi-drug resistance drug for 
the treatment of P. falciparum malaria (Arnold et al., 1990). 
 
 
 
Artemether, artesunate, arteether and artelinate are a few chemical derivatives 
of artemisinin and these compounds have the ability transform into an active 
plasma metabolite state called, dihydroartemisinin, and this is the actual state 
which has the anti-malarial activity (Wilairatana et al., 1998). The safe dose of 
artemisinin that can be administered for treatment of the disease is 3 g for 
around 3-5 days (about 50 mg per kg bodyweight), but it is advised to use this 
with other antimalarial drugs having a longer half life because the derivative 
compounds have a short half-life (White, 2004). 
Despite limited knowledge regarding the specific mechanism of action of 
artemisinin, a study was conducted in 2005 using a yeast model and it was seen 
that this drug initially acts on the electron transport chain and releases local 
reactive oxygen species which in turn results in depolarization of the 
mitochondrial membrane (Li et al., 2005). One study suggested that the one of 
the mode of action of artemisinin is dose alkylation of heme to form adduct from 
reaction between artemisinin and heme (O'Neill et al., 2010). 
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Artemsinin did not harm the human body despite a high dosage in a 70 mg/kg 
body weight per day (Rowen, 2002). But there was a case study which showed 
that in a subject receiving a high dose (120 mg/kg) of artimisinin over 3 days 
(Hien & White, 1993), the concentrations of serum aspartate aminotransferase 
(AST) were increased and this could be indicative of acute or mild hepato-
toxicity. 
 
1.9 Aims 
This thesis will aim to investigate these points: 
1. To identify new curcumin analogues with activity against Leishmania spp 
and African trypanosomes in vitro. 
2. To identify new phosphonium salts with activity against African 
trypanosomes in vitro. 
3. To analyse the structure activity relationship (SAR) for curcumin 
compounds on Leishmania spp and phosphonium compounds on African 
trypanosomes. 
4. To study the mode of action of the most promising curcumin compound. 
5. To identify the target of phosphonium analogues. 
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2 Chapter two: Material and Methods 
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2.1  Cell culture 
2.1.1 Trypanosoma brucei blood stream forms (BSF) in-vitro: 
Three strains of bloodstream form (BSF) of Trypanosoma brucei were used in this 
study: (A) Trypanosoma brucei brucei wild type strain (s427-WT), (B) TbAT1 
knock out (KO) is derived from the s427-WT strain by the deletion of both alleles 
coding for the TbAT1/P2 transporter. This leads to resistance to diminazene 
aceturate and low levels of resistance to several other drugs including 
pentamidine and melarsen oxide (Matovu et al., 2003); (C) TbAT1-B48 is derived 
from TbAT1-KO by increasing their exposure to pentamidine, which causes a high 
resistance to diminazene, pentamidine and melaminophenyl arsenicals. 
Consequently, these cells do not have the TbAT1/P2 transporter or the high 
affinity pentamidine transporter (HAPT) (Bridges et al., 2007). The standard 
culture medium that has been used for three strains is HMI-9 medium (Hirumi & 
Hirumi, 1989) with 10% heat-inactivated Fetal Calf Serum (FCS) and 14 µl of β-
mercaptoethanol (Sigma) per litre of medium, with pH adjustment with HCl or 
NaOH to 7.4. The medium was sterilized inside a flow cabinet by filtration 
through 0.22 µm Millipore Express PLUS membranes (PES) filters. The parasites 
were cultured and incubated at 37 ºC under 5% CO2 atmosphere and were 
passaged three times per week in vented flasks. 
 
2.1.2  Leishmania mexicana & Leishmania major Promastigotes: 
Leishmania mexicana (MNYC/BZ/62/M379 strain) and Leishmania major (Friedlin 
strain) were grown in HOMEM medium (pH 7.4) with 10% heat-inactivated Fetal 
Calf Serum (FCS) in plastic flasks at 25ºC. Cultures were passaged into fresh 
medium three times per week. 
   
2.1.3 Leishmania mexicana amastigotes: 
Axenic Leishmania mexicana amastigotes cultures were maintained in 80% 
Schneider’s Drosophila Medium, complemented with 20% heat-inactivated FCS 
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with 0.3% Gentamycin (G 1272) for each ml of medium, and 10 µl of 1.0 M HCl 
for every 1 ml of medium to adjust to pH 5.5. The medium was sterilized inside 
a flow cabinet by filtration through 0.22 µm Millipore Express PLUS membranes 
(PES) filters, then stored at 4ºC. The parasites were cultured and incubated at 
32 ºC under 5% CO2 and were passaged twice a week in vented flasks by adding 1 
ml from the original culture to 10 ml fresh medium with the observation that the 
cells of L. mexicana amastigotes grow in the form of colonies. As a result, cells 
were withdrawn using a syringe with the needle against the side of the flask, to 
ensure that all of the cells were separated before passage.  
 
2.1.4 Human embryonic kidney (HEK) cells (strain 293T): 
Human Embryonic Kidney Cells were grown in a standard culture that included 
500 ml Dulbecco’s Modified Eagle’s Medium-DMEM (Sigma), 50 ml newborn Calf 
Serum (NBCS) (Gibco), 5 ml Penicillin/Streptomycin (Gibco) and 5 ml L-Glutamax 
(200 mM, Gibco). All constituents were mixed under sterile conditions in a 500 
ml bottle of DMEM, then kept medium at 4ºC.  
The cells were cultured and incubated at 37ºC + 5% CO2 and were passaged three 
times per week when they reached 80-85% confluence in passage ratio in vented 
flasks. Flasks are incubated on their sides (horizontally) to expose a larger 
surface in order to allow cells adherence, which is essential for the cell growth 
as a monolayer.  
 
2.1.5  Bacterial strains: 
XL1 strain of Escherichia coli was used for routine cloning of T. b. brucei 
genomic sequences. E. coli cells were kept as glycerol stabilates at -80 ºC. Cells 
were moved and grown in LB broth (sigma) that was supplemented with 100 
µg/ml of ampiciline (sigma) at 37 ºC under vigorous shaking (250 rpm) overnight.  
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2.2 Preparation of stabilates  
Stabilates were manufactured from the different strains that we used on a daily 
basis. A cell suspension of to 2 × 106 cells/ml in HMI-9 (10% FCS) was diluted 1:1 
with HMI-9 containing 30% of glycerol. Immediately after the preparation of 
dilutions, samples kept in vials were transferred to a -80oC freezer and stored 
for 24 h prior to transfer to liquid nitrogen for permanent storage. 
Stabilates were taken out from liquid nitrogen and brought to room temperature 
by simply thawing. Harvesting of cells was performed by centrifugation at a 
speed of 3000 × g for 10 minutes at 21 °C and the cells were resuspended in 
normal HMI-9/FCS. 
 
2.3 Drug sensitivity using Alamar blue 
Alamar Blue is used as an indicator of metabolic cell function. The dye 
(Resazurin sodium salt) is added to a cell culture containing a test drug solution 
to determine the in vitro drug sensitivity of African trypanosomes (Raz et al., 
1997) and Leishmania spp (Fumarola et al., 2004) to the drug.. Alamar blue is 
used to measure cell proliferation or cell viability depending on the metabolic 
activity of cells. Live cells will metabolise resazurin (blue and nonfluorescent) to 
resorufin (pink and highly fluorescent), whereas metabolic activity stops with 
cell death and the resazurin does not change. By using special software, the EC50 
can be determined for different concentrations of the drug.  
 An Alamar Blue solution was prepared by dissolving 12.5 mg Resazurin sodium 
salt (Sigma) in 100 ml of Phosphate Buffered Saline (PBS) and adjusting the pH to 
7.4. The solution was sterilized inside a flow cabinet by filtration through a 0.22 
µm Millipore Express PLUS membrane (PES) filter. This dye solution can be stored 
at 4 ºC away from the light for several weeks or frozen for longer storage (Raz et 
al., 1997). 
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All drugs dilutions are freshly prepared in the individual medium on the same 
day of the assay, ensuring that the final concentration of solvent (usually DMSO) 
does not surpass 1%, as higher levels will affect trypanosome growth.  
 
2.3.1  Drug sensitivity using Alamar Blue assay in bloodstream 
forms of T. b. brucei 
Stock solutions of drugs were typically prepared at 20 mM or 40 mM in DMSO and 
diluted to 200 µM with HMI-9 medium + 10% FCS; 200 µl of this was added to the 
first well of rows (A), (C), (E) and (G) of a 96-well plate, setting up for doubling 
dilutions of 4 different drugs, each over two rows of a 96-well plate (Figure 1). 
Diminazene or/and Pentamidine are used as positive controls for each 
experiment. 100 µl of HMI-9 medium is pipetted into all remaining wells. 100 µl 
of a drug preparation are taken by a multichannel pipettor from the first column 
in rows (A), (C), (E) and (G) and mixed gently with the medium in the wells of 
the second column, then another 100 µl from second column wells are added to 
third column wells and so on, creating a doubling dilution. The last column of 
the plate (which is the first column in rows B, D, F and H) does not receive any 
drug solution, because this is the drug free control.  
Cell counts were performed (haemocytometer) and cells density adjusted to the 
desired concentration of 2 × 105 cells/ml of which 100 µl was added to all of the 
wells in the plate, resulting in 1×105 cells/ml for all wells. The plates were 
incubated at 37ºC + 5% CO2 for 48 hours after which 20 µl sterile Alamar Blue 
solution was added to every well, followed by a further incubation of 24 h. The 
fluorescence of the wells was read by a FLUOstar OPTIMA Fluorimeter (BMG 
Labtech) at wavelengths 530 nm for excitation and 590 nm for emission. The 
fluorescence values were analysed via GraphPad Prism5 software, plotting the 
data to an equation for a sigmoid curve and to determine the EC50 values. 
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Figure 2.1. explains the way drugs are doubly diluted down two rows across the plate.       
Indicates the drug free wells  
 
2.3.2 Drug sensitivity using Alamar Blue assay in Leishmania 
mexicana amastigotes 
The Alamar Blue assay for Leishmania mexicana amastigotes is similar to that for 
Trypanosoma brucei brucei, with the following exceptions, A- 80% Schneider‘s 
Drosophila Medium (SDM), with 20% FCS and 0.3% Gentamycin was used. B- The 
final density of cells in all wells was 1×106 cells/ml. C- When the cells were 
counted, the cells were first separated using a syringe as described above.   
The plates were incubated at 32 ºC + 5% CO2 for 72 hours after which 20 µl 
Alamar Blue solution was added to all wells, and the plate was incubated for an 
additional 48 h, after which fluorescence was determined in a fluorimeter. 
 
2.3.3 Drug sensitivity using Alamar Blue assay in L. mexicana 
and L. major promastigotes 
The Alamar Blue assay for L. mexicana and L. major promastigotes is also the 
same way as in Trypanosoma brucei brucei except: A- Using HOMEM medium (pH 
7.4) with 10% heat-inactivated Fetal Calf Serum (FCS). B-The final density of 
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cells in each well was 1×106 cells/ml. C- The plate is incubated at 25ºC + 5% CO2 
for 72 hours after which 20 µl Alamar Blue solution is added to every well and 
the plate incubated for a further 48 hours.  
  
2.3.4 Alamar Blue assay in Human Embryonic Kidney (HEK) Cells 
Passaging the cells is done through several steps, which are summarised as 
follows: The medium is removed from vented culture flask by withdraw it and 2 
ml of pre-warmed 37 ºC 0.25% Trypsin-EDTA solution (Sigma) are added to the 
flask and left for 5 minutes after which 8 ml of medium (pre-warmed to 37 ºC) is 
added, and the suspension is mixed and transferred to a sterile 15 ml centrifuge 
tube, and the cells are spun down at 1200 rpm for 5 min at room temperature. 
The supernatant is decanted and the cells re-suspended in 10 ml of medium. 1 
ml of cell suspension is added to a vented flask with 10 ml of medium and the 
flask is incubated at 37 ºC + 5% CO2. 
Cell counts are performed by pipetting 10 µl of cell suspension (after mixing) 
into the haemocytometer counting chamber. Cell suspensions could be used for 
the Alamar Blue assay as well. Cells are counted and adjusted to a density of the 
desired concentration (3 × 105 cells/ml). 100 µl of this suspension is added to 
each well of a 96-well plate, so every well contains 3×104 cells. The plate is 
incubated at 37 ºC + 5% CO2 for 3 hours to allow the cells to adhere to the 
bottom of the plate. Drug stocks are prepared at 800 µM (two times 
concentration) by diluting them in DMEM medium. Phenyl arsine oxide (PAO) is 
prepared at 200 µM as a positive control. Using a separate 96-well plate, 260 µl 
of the drug stock is pipetted into the first column in rows (A), (C), (E) and (G) of 
96-wells plates (figure 1), so that two rows are used for every drug. 130 µl of 
DMEM medium is pipetted into all remaining wells. 130 µl of drug is taken by 
multichannel from the first column in rows (A), (C), (E) and (G) and mixed gently 
with the medium in the wells of second column, then another 100 µl from the 
second column wells are added to third column wells and so on, the last column 
of the plate (which is the first column in rows B, D, F and H) does not receive 
any drug solution, because this is the drug free control. After of incubating the 
plate that has HEK cells for 3 hours, 100 µl/well of the plate that contains the 
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drug dilution series is transferred to the opposite well on the plate that contains 
the HEK cells, using a multichannel pipette. The result is a final concentration of 
drug in the first wells of 400 µM (for PAO this is 100 µM). The plate is then 
incubated at 37 ºC + 5% CO2 for 16 hours followed by the addition of 20 µl of 
Alamar Blue solution to every well and incubation at 37 ºC + 5% CO2 for a further 
24 hours. The fluorescence of the plate is read on a Fluorimeter at wavelengths 
530 nm for excitation and 590 nm for emission. The data are then analysed using 
GraphPad Prism4 software to draw the graph and determine the EC50 values. 
 
2.4 Drug sensitivity using Cell count 
A set of compounds with different concentrations was tested on trypanosomes 
for monitoring in vitro cell growth using cell count. The parasites were taken 
from cultures at the late logarithmic phase of growth and cell density was 
determined using a haemocytometer. Cell density was adjusted to the desired 
concentration and diluted with fresh HMI-9/FCS medium. The cell count was 
taken in triplicate at four time points (0, 4, 8 and 12h) on each day for each 
concentration of the compounds, for 72 h. 
 
2.5  Drug sensitivity using Propidium Iodide assay 
This procedure is used in order to monitor the speed of action of test compounds 
on trypanosomes in real time. Cells become fluorescent as PI enters the cell and 
binds to nucleic acids. This occurs only upon breach of the plasma membrane, 
i.e. loss of cellular integrity. In this method, 100 µl of HMI-9/FCS was added to 
each well of a 96-well plate and 200 µl from different compounds of the 
appropriate concentration, also in HMI-9, was added to the first column, 
whereas the last wells of each column received only media and served as drug 
free controls. 100 µl of the drug solution was taken by a multichannel pipettor 
from the first column and mixed gently with the medium in the wells of the 
second column, then another 100 µl from second column wells are added to third 
column wells, and so on, to make a doubling drug dilution. Cell density was 
adjusted to a suspension of 1×107 ml-1 in the presence of 18 µM of PI. In addition, 
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18 µM of PI without cells was prepared for the negative control, which is the 
same doubling drug dilution series in the absence of cells. The plates were then 
incubated in a FLUOstar OPTIMA fluorimeter (BMG Labtech) at 37 ºC with 5% CO2, 
and the fluorescence was observed at 544 nm excitation and 620 nm emission for 
up to 8 hours, with absorbance values analysed using GraphPad Prism 5 software 
to plot the data. 
 
2.6 Determination of the mitochondrial membrane 
potential by flow cytometry 
The mitochondrial membrane potential of treated and untreated cells was 
assessed by using Tetramethylrhodamine ethyl ester (TMRE) (Denninger et al., 
2007;Figarella et al., 2006). The cell density was adjusted to 1×106 cells/ml with 
and without test compounds for the start of the experiment. 1 ml of sample was 
transferred at each time point into a microfuge tube and centrifuged at 2500 
rpm for 10 min at 4 C, and was then resuspended in 1 ml PBS containing 25 nM 
of TMRE, and cells were incubated at 37 C for 30 minutes. In addition, 100 nM 
of valinomycin and 10 µM of troglitazone were used as controls, as they are 
known to induce mitochondrial membrane depolarisation and hyperpolarisation, 
respectively (Denninger et al., 2007). All samples were analysed by flow 
cytometry using a FL2-heigth detector and CellQuest software. 
 
 
2.7 Cell cycle using flow cytometry 
Flow cytometry was used as described by (Hammarton et al., 2003) to study the 
effects of test compounds on DNA content in Trypanosoma brucei brucei. The 
cell density was adjusted to 1×106 cells/ml with and without test compounds for 
the duration of the experiment. 1 ml of sample was transferred at each time 
point into microfuge tubes and centrifuged at 2500 rpm for 10 min at 4C, then 
resuspended and fixed in 1 ml of 70% methanol and 30% PBS and left at 4 C 
overnight. After storage, the samples were washed twice with 1 ml of PBS and 
subsequently resuspended in 1 ml PBS containing propidium iodide and RNase A 
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(both at 10 µg/ml), and incubated at 37 ºC for 45 minutes while protected from 
light. Samples were analysed by Becton Dickinson FACSCalibur using the FL2-
Area detector and CellQuest software. ModFit LT software was used to quantify 
the flow cytometry results. 
 
2.8  Measurement of intracellular calcium level 
Intracellular Calcium level was measured using the Screen QuestTM Fluo-8 
Calcium Kit produced by ABD Bioquest (Ibrahim et al., 2011). Trypanosoma 
brucei brucei–WT cells were used in this experiment and grown in HMI-9/FCS in 
vented flasks incubated at 37ºC + 5% CO2 for 48 h. The cells were then 
centrifuged at 2500 × g for 10 min at 4 ºC, and re-suspended to a final density of 
4 × 106 cells/ml in the Fluo-8 dye-loading solution and further incubated at 37 ºC 
for 30 min. The cells were then washed twice with assay buffer to remove any 
extracellular dye-loading solution. 90 µl of cells were added to each well in a 
black-bottomed 96-well plate. The positive control (Calcium ionophore A23187 
(Sigma) 10 µM) and the negative control (assay buffer) were prepared. The plate 
was then incubated in a FLUOstar OPTIMA fluorimeter at 37ºC, and the 
fluorescence was observed for two minutes at 485 nm excitation and 520 nm 
emission. The fluorimeter was stopped while different concentrations of the 
compound and positive and negative controls were added. The fluorescence was 
observed for a further 15 minutes (250 cycles – 4 sec/cycle). Finally, the 
absorbance values were analysed using GraphPad Prism 5 software to plot the 
data. However, for some compounds there was no short-term response in 
Intracellular Calcium level which was therefore also determined at 0, 4, 8 and 12 
hours. During this time the cells were grown in HMI-9 medium + 10% FCS in 
vented flasks with and without test compounds. At the beginning of the 
experiment, a predetermined amount of cells from each flask (treated and 
control) was removed to microfuge tubes, centrifuged for 10 min (2500 × g, 4 ºC) 
and re-suspended to a final density of 4 × 106 cells/ml in the Fluo-8 dye-loading 
solution, and intracellular calcium was determined as above.    
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2.9 DNA configuration assessment using fluorescence 
microscopy 
DNA configuration from nuclei and kinetoplast were assessed using the dye 4,6-
diamidino-2-phenylindole (DAPI), which fluoresces when bound with DNA. 50 µl 
of cells at ~5  105 cells/ml were spread onto a glass microscope slide, left to air 
dry and fixed in methanol overnight at -20 ºC. The slides were rehydrated with 1 
ml of BPS for 10 minutes which was allowed to evaporate (without completely 
dry). 50 µl of PBS containing 1 μg /ml DAPI and 1% of 1,4-diazabicyclo [2.2.2] 
octane (DAPCO) was added to the slides and spread by coverslip. Slides were 
observed under UV light on a Zeiss Axioplan microscope using a Hamamatso 
digital camera and Openlab software. 500 cells were recorded for each sample, 
and scored for DNA configuration following these groups: 1N1K, 1N2K, 2N2K 
(Early) and 2N2K (Late) (N, nucleus; K, kinetoplast). The effect of test 
compounds on DNA configuration was determined at 0, 8, 12, 16 and 24 h; 
untreated cultured served as control.  
2.10 Giemsa Staining  
Giemsa stain was used to detect overt morphological changes in cells exposed to 
test compounds. The cell density was adjusted to 1×106 cells/ml with and 
without test compounds for the start of the experiment and at each time point, 
1.5 ml of culture was centrifuged at 2500 rpm at room temperature for 10 min. 
Smears were made by resuspending the pellet in 75 µl of HMI 9 + 20% FCS and 
using 25 µl of this suspension. The smear was then air dried and fixed with 100% 
of methanol for 2 min. Staining was performed for 30 minutes with 10% Giemsa 
solution After which the slides were washed with water and air dried. A Zeiss 
Axioskop Mk1 microscope with an oil emersion ×63 objective lens was used for 
observing the slide. For imaging Cooplix, CCD coloured camera was used and 
Rsimage and tsivision software was used for editing the images.  
2.11 Live Cell Imaging 
A cell culture with the density of 1 × 106 cells/ml was made applying the same 
method as described in section 2.10. At each time point 50 µl of culture was 
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taken and covered with a cover slip and observed under Axioplan 2 imaging light 
microscope with resolution of ×100 oil immersion objective lens. A Hamamatsu 
camera was used for taking the images and Openlab and Volocity software were 
used for editing.  
2.12 Transmission Electron Microscopy 
Transmission Electron Microscopy was used to assess the action of test 
compounds on Trypanosoma brucei brucei ultrastructure. The cell density was 1 
× 106 cells/ml. Two 10 ml samples were transferred to 15 ml centrifuge tubes 
and to one of them 1 µM CD38 was added. Cells were centrifuged at 2600 rpm 
for 10 min at room temperature and the pellet contained the supernatant was 
discarded. A 0.5 ml solution of 2.5% of Glutaraldyhyde was prepared in 0.1 M 
phosphate buffer (pH 7.4) and added gently to the centrifuge tubes from the 
side wall to avoid pellet resuspension. The solution was left undisturbed for 10 
min. The pellet was then gently agitated in the fixative and again left 
undisturbed for half an hour. The fixative was sucked back by pipette and 0.5 ml 
of the 0.1 M phosphate buffer was introduced into the tubes to dissolve the 
remaining Glutaraldyhyde in the tube and sample was left at 4 °C overnight. 
1 mm of pellet was taken and then remaining aldehyde was removed by rinsed it 
in fix buffer twicef. 1% osmium tetra oxide was used as a fixative to fix the cells 
and after its addition the cell was left undisturbed for an hour. Distilled water 
washes were performed to remove excess osmium tetra oxide. Then cells were 
kept in the 0.5% Uranyl acetate solution for almost 30 minutes and washing was 
performed with distilled water after it. Different concentrations of alcohol were 
used to wash and dehydrated the cells (30, 50, 70, 90 and 100% ethanol). After 
all the procedures cell infiltration was performed utilizing Epon/Araldite epoxy 
resin. The suspension was kept overnight, rotating at 200 °C. Polymerization of 
cells in the silicon block moulds was done after embedding it in the fresh resin. 
The temperature used for polymerization of cells was 600 °C. The size of the 
section that we used for analysis in Transmission Electron Microscopy was 60-80 
nm. Lead and Uranyl solutions were used to stain the cells and then the sections 
were observed in Zeiss 912 Energy filtering TEM at 120 kv. 
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2.13 Scanning Electron Microscopy 
To check the impact of the CD38 compound on the structure of Trypanosoma 
brucei brucei we employed the Scanning Electron Microscopy. Cells were 
cultured to a concentration of 1 × 106 cells/ml and two separate 10 ml aliquots 
were prepared (1 µM CD38 and control) in 15 ml of centrifuge tubes which were 
spun at 2600 rpm for 10 min at room temperature. The supernatant was 
discarded with great caution without disturbing the pellet. Glutaraldehyde 
solution was prepared with a concentration of 2.5% in PBS and added to the cell 
pellet. The mixture was left at room temperature for an hour after which the 
fixative was removed by washing with 0.5 ml 0.1 M PBS (pH 7.4).  
The samples were fixed in a solution of 1% osmium tetroxide for one hour, 
washed with distilled water and then dehydrated by using a series of increasing 
concentration of acetone (30, 50, 70, 90 and 100 % acetone; 10 min per 
treatment). A Critical Point Dryer was then used to dry the samples. Mounting 
was performed employing silver paint and double sided copper tape. Samples 
were then coated with palladium gold and its thickness was about 20nm and 
then samples were observed in the scanning electron microscope (JEOL 6400). 
2.14 ATP Determination 
ATP was measured using an ATP Determination Kit (Invitrogen) which has D-
Luciferin and Luciferase (firefly recombinant). Briefly, 1×107 cells of both 
treated and untreated Trypanosoma brucei brucei were collected by 
centrifugation at 4 C for 10 min at 2800 rpm. The pellet was washed twice in 
200 µl of 50 mM Tris-HCl, pH 7.4, containing 0.1 mM DTT. The cells were lysed 
by sonication on ice (twice for 10 s separated by 30 s in), using a Soniprep 150 at 
8 µ amplitude. Then they were centrifuged at 14000 rpm for 10 min at 4 C. The 
supernatant was immediately frozen in liquid nitrogen and stored in -80 C. ATP 
levels were determined using the contents of the kit, and the standard reaction 
solution was prepared for a 10 ml volume from 8.9 ml dH2O, 0.5 ml 20× reaction 
buffer, 0.1 ml of 0.1 M DTT, 0.5 ml of 10 mM D-luciferin, and 2.5 µl firefly 
luciferase (5 mg/ml). 90 µl reaction solution was added to each well and the 
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background luminescence was recorded in a FLUOstar OPTIMA fluorimeter; 10 µl 
of each sample was added to the well and the luminescence was recorded. A 
standard curve was prepared using different concentrations of ATP (1 µM–1 nM) 
to calculate the ATP concentrations in the samples. 
2.15 TUNEL Assay 
DNA fragmentation after exposure with different compounds was assessed by 
TUNEL assay. APO-BrdUTM TUNEL Assay Kit (Invitrogen) was used in the detection 
of DNA fragmentation. The cell density of Trypanosoma brucei brucei was 
adjusted to 1×106 cells/ml and incubated with and without test compounds for 
the duration of the experiment. After the specified incubation time the cells 
initially underwent fixation: 2×106 cells were suspended in 500 µl of PBS, and 5 
ml of 1% (w/v) paraformaldehyde in PBS was added to the sample and placed on 
ice for 15 min. The sample was then centrifuged at 2000 rpm for 5 min, and the 
cells were washed twice in 5 ml PBS before they were resuspended in 500 µl 
PBS. Finally, 5 ml of 70% of ethanol was added to the sample and it was stored in 
a -20 C freezer. After storage, the sample was centrifuged for 5 min at 2000 
rpm to remove the ethanol. The cells were resuspended in 1 ml of wash buffer 
and centrifuged again for 5 min at 2000 rpm; this step was repeated. Then 50 µl 
of DNA-labelling solution (10 µl of the reaction buffer, 0.75 µl of Terminal 
deoxynucleotidl transferase (TdT) enzyme, 8 µl of BrdUTP, and 31.25 µl dH2O) 
was added followed by incubation at 37 C for an hour (with the sample shaken 
every 15 min). At the end of the incubation time, 1 ml of the rinse buffer was 
added to the sample and spun at 2000 rpm for 5 min, and this step was 
repeated, with the supernatants removed. Then 100 µl of antibody staining 
solution (5 µl of the Alexa Fluor 488 dye-labelled anti-BrdU antibody and 95 µl of 
the rinse buffer) was added to each sample and incubated at room temperature 
for 30 min in the dark. Finally, 500 µl of propidium iodide/RNase was added to 
each sample and the samples were incubated for 30 min at room temperature 
with the sample protected from light. Finally, the sample was analysed by flow 
cytometry using  both  FL3-width  and Anti-BrdU FITC detectors and CellQuest 
software. 
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2.16 Counting Cells treated with Cycloheximide (CHX) 
CHX was used as a protein synthesis inhibitor and used to investigate whether 
protein synthesis is necessary for CD38-induced cell death in T. brucei. A number 
of culture flasks were set up with 5 × 105 cells/ml with or without 10 µg/ml of 
CHX; preincubation with CHX was 1 h (37 ˚C, 5% CO2). Four groups were set up 
for each concentration of compound: 
1. – CHX, – Compound 
2. + CHX, - Compound 
3. – CHX, + Compound 
4. + CHX, + Compound 
Growth was monitored using manual cell counts after 0, 4, 8, 12, and 24 hours. 
 
2.16.1 Pulse Labelling of Protein Pool in T. b. brucei 
In order to confirm that CHX did indeed inhibit protein synthesis in T. b. brucei 
under the conditions used, proteins were pulse-labelled in the presence or 
absence of CHX. Cells were cultured to 5 × 106 cells/ml and divided over two 
flasks into which either CHX (10 µg/ml) was added or the same volume of DMSO 
(solvent) followed by a 1 h incubation at 37 ˚C and 5% CO2. To each flask 25 µCi 
of [3H]-Lysine was then added followed by a further incubation of 3 h. After 
which cultures were centrifuged at 2800 rpm for 10 minutes at 4 ˚C. The cell 
pellet was solubilised in 1% Sodium dodecyl sulphate (SDS) and the suspension 
was centrifuged to pellet cell debris, which was placed on ice. To the 
supernatant Trichloroacetic acid (TCA) was added to a final concentration of 10% 
after which the solution was centrifuged again (10 min, room temp., 13,000 × g). 
The resulting protein pellet was washed with 10% ice-cold TCA 4 ˚C and 
transferred to a scintillation tube. The tube was left for incubation for half an 
hour at room temperature after the addition of 2% SDS (200 µl).  
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2.17  Induction of T. b. brucei cell lines resistant to AS-
HK014 and curcumin 
Two resistant cell lines were established for AS-HK001 (curcumin) and AS-HK014 
to be used as a model to study drug uptakes levels and other adaptations in 
comparison to the parental cell line. In addition, a new resistant line could help 
in the understanding of mechanism of action that compound. Compounds AS-
HK001 and AS-HK 014 were added to cultures of 5  104 cells/ml bloodstream 
form trypanosomes at different concentrations in HMI9/FCS medium. The 
adaptation was started using a range of test compound concentrations, ranging 
from 2  EC50 to ¼  EC50, with cells grown in a 24-well plate at 37 ºC with 5% 
CO2. 48 hours after incubation, a new 24-well plate was prepared, and the same 
concentration of compounds and 50 µl of cells were transferred from each well 
to the new plate where they were left for another 48-hour incubation in the 
same conditions, then the 24-well plate was observed by light microscopy. The 
maximum concentration at which the parasites were still observed to multiply 
was chosen as the initial maximum tolerated concentration. In this experiment, 
the initial concentrations were 5 μM and 0.25 μM for AS-HK001 and AS-HK 014, 
respectively. The trypanosomes were next passaged into a 24-well plate with 
fresh medium only as a control, fresh medium with initial concentration and 
fresh medium with double the initial concentration, and incubated for 48h. The 
cultures were observed every 48h, and the concentrations increased gradually 
depending on the cells‘ viability. 
2.18 Metabolism of Curcumin in Trypanosomes 
A metabolomic approach was used to examine the effect of some curcumin 
compounds on the bloodstream forms of Trypanosoma brucei brucei. Parasites 
were harvested in normal conditions and were taken at the late logarithmic 
phase before centrifugation at 2600 rpm for 10 min. The cell density was 
adjusted to 2×106 cells/ml in fresh HMI-9/FCS medium. Both adapted and wild-
type cells were used, and incubated with and without the specified 
concentration of the compounds for the duration of the experiment. At the 
specified time of incubation, 25 ml of the cells were taken and directly 
quenched on a dry ice/ethanol bath to decrease the temperature to 4 C; in 
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some cases the compound was added to other untreated cells after quenching. 
The cells were spun at 2600 rpm for 10 min at 4 C. Then 5 µl of the 
supernatants (no cells) was taken and stored for analysis before removing all 
supernatants, but the pellet was kept. Next, 50 µl of 40 mM EPPS (4-(2-
Hydroxyethyl) Piperazine-1-Propanesulfonic acid) + 2 mM EDTA and another 50 µl 
of 2 mM monobromobimane were added to each cell pellet and vigorously 
mixed; the mixture was added to the samples that have no cells as well. Then 
the samples were incubated in a water bath at 70 C for 5 min. They were 
briefly cooled in ice before 100 µl of Acetonitile (100%) was added, followed by 
incubation on ice for an additional 10 min. Finally, the samples were centrifuged 
at 14,000 rpm for 10 min at 4 C, and then the supernatants were taken and 
stored at -80 C until analysis using Orbitrap Mass Spectrometry and IDEOM 
software was used to analysed the metabolomic dataset (Creek et al., 2012). 
Further, 5 µl from the medium and from chemical reagents used in the 
experiment were taken and tested for double-checking if they had any metabolic 
content. 
2.19 Measurement of Plasma Membrane Potential (Vm) 
The membrane potential of trypanosomes was determined by using a fluorescent 
dye,  bisoxonol, as described (de Koning & Jarvis, 1997). T. b. brucei were 
cultured, harvested and washed in assay buffer. The final concentration of cells 
was maintained at a concentration of 107 cells/ml. After bringing the cells to 
room temperature, a 100 µl aliquot was added to 2.9 ml of 0.1 μM bisoxonol. 
The fluorimeter cuvette had a path length of 1 cm and the temperature was set 
to 25 oC. The fluorescent intensity was observed at an excitation wavelength of 
540 nm with bandwidths of 4 nm where emission wavelength size was 580 nm 
with bandwidths of 10 nm. The fluorescent intensity was found to be directly 
proportional to the cell concentration and we added 30 µl of compounds to be 
tested 140 s after cells were added to the cuvette. This allowed the recording of 
stable base lines before and after addition of the cells and the accurate 
recording of the compound‘s effect on the membrane potential. Control traces 
were recorded using the same scheme in the absence of cells in order to 
compensate for dilutions and any effect of the test compound on the read-out by 
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quenching or innate fluorescence. The positive control was Gramicidin and the 
negative control was either assay buffer or 1% ethanol (solvent control). 
2.20 Molecular techniques 
2.20.1 Extraction of Genomic DNA 
Wild-type and the AS-HK014-adapted cell line TA014 were re-cloned by limiting 
dilution; TA014 was cloned out in the presence of 4.5 µM AS-HK014. Genomic 
DNA was isolated from both strains as follows.  
The cells were centrifuged at 2600 rpm for 10 minutes and cell pellets 
resuspended, and washed in PBS buffer and finally resuspended in 500 µl of the 
NTE buffer (Appendix A) along with 25 µl 10% SDS and 50 μl of 10 mg/ml RNase A 
(Sigma). The mixture was incubated at 37 ˚C for 5 min. After a gentle stirring it 
was then allowed to stand undisturbed for 30 min at 37 ˚C. After the addition of 
25 µl of 20 mg/ml Pronase the sample was incubated overnight at 37 ˚C after 
which 600 l of phenol:chloroform:isoamyl alcohol 25:24:1 (Sigma) was added. 
The tube was centrifuged at 12,000 rpm for five min to get a clear top phase 
which was moved to a sterile centrifuge tube and the same volume of the same 
mixture was added followed by another centrifugation. Again the upper phase 
was transferred to another sterile tube and mixed with 600 µl of chloroform and 
centrifuged at 12,000 rpm for five minutes. Again the resultant upper phase was 
transferred to a new sterile polystyrene tube and 2.5 ml of 100% ethanol was 
introduced in the sample for the DNA precipitation. DNA was washed with 70% 
ethanol after being transferred to a new tube. Centrifugation at maximum speed 
was performed and the DNA pellet was air-dried before being dissolved in 50 μl 
TE buffer and the DNA sample was stored until use at 4 °C.  
 
2.20.2 Polymerase Chain Reaction for DNA 
Genomic DNA of T. brucei was amplified by using PCR with specific primers. 
From the databases we obtained gene ID numbers along with the published 
sequences of Trypanosoma brucei strain TREU927 from GeneDB as a reference 
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sequence. Unique 26 base pair upstream and downstream sequences were 
identified used for primer design. Sequences for forwards and reverse primers 
for the amplification of γ-GCS gene were 5‘ ggatccATGGGTCTTCTAACCACTGG 3‘ 
and 5‘ aagcttTCACCCTTCGCGTTGTCTTT 3‘ respectively (Eurofins MWG Operon). 
For GS gene the reverse primer sequence was 5‘ 
aagcttTTACGGTACAACCGCTAAGG 3‘ and 5‘ gctagcATGGTGTTAAAATTGTTGCT 3‘ 
was the primer sequence for forward primer. The Phusion High-Fidelity 
proofreading polymerase (NEB) was used to improve reliability of the PCR. The 
PCR mix contained 15 µl nuclease free water, 5 µl fusion HF buffer, 0.5 µl 
dNTPs, 1.25 µl forward primer (10 µM), 1.25 reverse primer (10 µM), 0.75 µl 
DMSO along with 0.25 µl of DNA polymerase and 1 µl of genomic DNA. A negative 
control was included, which contained all the components of the PCR mix except 
genomic DNA. The programme of the thermal cycler (PTC200 DNA Engine 
Thermal Cycler, MJ Research Incorporated, USA) was used for running the PCR 
reaction was as follows: 
Cycle 1: Hot start denaturation at 98 °C for 30 seconds 
Subsequent cycles: 32 cycles of 
Denaturation: 98 °C for 10 seconds 
Annealing: 58 °C for 30 seconds 
Extension: 72 °C for one minute 
At the end of cycles, final extension at 72 °C for 10 minute  
After the reaction, agarose gel of 1% was run to observe the PCR products. 
Correct size fragments were extracted and purified for further proceedings. 
 
2.20.3 Agarose Gel Electrophoresis of DNA 
Agarose gel was prepared for the analysis of DNA that was isolated by the 
established protocol. 1% agarose was dissolved in 1 × TAE buffer and the solution 
was boiled untill it became clear signifying that agar was dissolved in the TAE 
buffer. After cooling the solution Ethidium bromide (0.5 µg/ ml) was added. Gels 
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were run at 100-120 Volts and the bands were observed on the UV 
transilluminator. 
The bands containing the required DNA fragment were cut out with a scalpel and 
transferred to a micro-centrifuge tube. DNA was extracted using a Gel 
purification kit from Qiagen according to manufacturer‟s instructions (Qiagen).  
 
2.20.4 A-overhang of PCR product 
Blunt ends were obtained after performing PCR, so the generation of adenosine 
overhangs in the sides of PCR product was necessary for cloning into the vector 
pGEM-T Easy and this was done using Taq polymerase. The reaction mix was 
prepared by mixing 45 μl of gel purified product with 12 μl GoTaq reaction 
buffer, 0.5 μl GoTaq polymerase and 1 µl of dATP. The mixture was incubated 
for 30 minutes at 72 ˚C.  
 
2.20.5 Ligation into pGEMT-Easy Vector 
pGEMT-Easy was used for the cloning of amplified PCR product, using a Promega 
Vector System 1 kit. PCR products with an A overhang were ligated to the pGEMT 
vector system using a mix comprised of 5 µl 2× rapid ligation buffer, 1 µl pGEMT-
Easy, 1 µl T4 DNA Ligase and 3 µl of the purified PCR products with A overhangs. 
The mixture was left overnight at 4 ˚C. 
 
2.20.6 Transformation of Escherichia Coli 
XL1 strain E. coli were transformed with the pGEMT-Easy-based constructs using 
the heat shock method. A 50 µl aliquot of bacteria was thawed at low 
temperature, 5 µl of ligation mix was added and it was kept on ice for half an 
hour. Heat shock was given to the cells at 42 ˚C for 60 seconds after which it 
was kept on ice for two more minutes. 1 ml of SOC medium was added to the 
mixture which was subsequently incubated in a shaking incubator at 37oC for half 
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an hour. The mixture was then plated onto LB agar containing ampicillin and 
incubated overnight at 37 ˚C. 
 
2.20.7 PCR for Screening of Colonies 
Bacterial colonies were grown on selective media containing ampicillin allowing 
growth of colonies containing the desired construct. For the confirmation of 
plasmid with insert in those bacteria we conducted a PCR reaction In a total 
volume of 25 µl (16.3 µl nuclease free water, 5 µl Green GoTaq reaction buffer, 
1 µl dNTPs (10mM), 0.75 µl forward primer and 0.75 µl reverse primer along with 
0.2 µl GoTaq DNA polymerase). Colonies were introduced in this mixture 
contained in a PCR tube by the help of a sterilized tip. The remainder of those 
colonies were added to LB broth and incubated overnight at 37 ˚C.  
 
2.20.8 Plasmid DNA Purification 
A single colony was grown up in LB medium (37 ˚C, O/N) in a shaking incubator 
and cells were harvested by centrifugation at 1250 × g for 10 minutes at room 
temperature. A QIAprep spin miniprep kit was used for plasmid purification 
follow the manufacturer‘s instructions.  
 
2.20.9 DNA Sequencing 
Samples were sent for sequencing and it was found that a 900-1000 bp read was 
the maximum to be obtained with acceptable quality. γ- Glutamylcysteine 
synthetase has a size of 2040 base pairs and was sequenced using internal 
primers as well as the primers targeting the 3‘ and 5‘ flanking regions described 
above. The forward primer sequence was 5‘CACCATGGAGAGGACGGTAG 3‘ 
(20bp) and the reverse primer sequence was 5‘CGTAGATGACAAGAGGGTCT 3‘ 
(20pb). Nine colonies each were sequenced for γ-GCS and for GS for each of the 
strains Tb427 and TA014. 
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2.21 Western Blotting 
After harvesting and washing of Trypanosoma brucei, cells were transferred into 
fresh HMI-9 media at a concentration of 1 × 106 cells/ml and then transferred to 
PBS. Cell lysis was performed in 300 µl lysis buffer (20 mM MOPS, pH 8.0, 10 mM 
NaCl, 4 mM MgCl2 + 1 tablet  of cOmplete Lysis Kits –Roche diagnostics_ in 10 ml 
for Protease inhibitor –Roche). The mixture was then mixed vigorously and 
transferred to a 1.5 ml tube. The suspension was flash frozen with liquid 
nitrogen and then thawed in a water bath at 37 ˚C, and this cycle was repeated 
three times. Lysate was centrifuged to remove cell debris (13,000 x g, room 
temperature, 3 min). The Bradford method was employed to determine the 
protein concentration and 40 µg was boiled after assay with mixture 4× SDS 
sample buffer (80% of 4× SDS -Invitrogen, 20% of 0.1 mM DTT) at 98 ˚C for five 
minutes. 15 µl of each sample was separated on a 4-12% NuPAGE Novex Bis-Tris 
gradient gel using MES SDS running buffer (20×), both Invitrogen, at 180 V. The 
proteins were then transferred by blotting to a nitrocellulose membrane 
(Hybond-ECL, Amersham) at 70 V (2h, 4 ˚C). The transfer buffer contained 25 
mM Tris-base, 192 mM Glycine, 20% ethanol. 5% of milk was used a blocking 
agent along with TBS/T (20 mM Tris-base, 137 mM NaCl - pH 7.4-+ 0.1% (v/v) 
Tween 20). The membrane was washed three times with TBS/T, and incubated 
for 2 hours at room temperature with primary antibody (either with Rabbit 
polyclonal anti-gamma GCS antibody or with Rabbit polyclonal anti-GS; both 
antibodies were obtained from Phillips Lab, UT Southwestern Medical Center) 
that was diluted at 1:2000 in 5% milk with TBS/T. Washing with TBS/T was 
performed after incubation with antibodies three times and for 5 min each and 
the blot was incubated with a secondary antirabbit horseradish peroxidase 
antibody (Amersham Biosciences) for 1 hour at room temperature diluted in the 
same mixture used for the primary antibody (dilution 1:1000). The membrane 
was washed three times 5 min with TBS/T and observed on X-ray film after the 
addition of chemiluminesence substrate. 
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3 Chapter Three: Antiparasitic activity of curcumin 
analogues  
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3.1 Introduction 
Curcumin, a polyphenolic compound obtained from the nutritional spice 
turmeric, is derived from the rhizome and roots of the plant Curcuma longa 
(Ammon & Wahl, 1991). It is found in South and South East tropical Asia and is 
generally used as an herb for adding spice, colour and flavour to food (Iqbal et 
al., 2009;Sharma et al., 2005). In addition, curcumin is used as a traditional 
medicine in India(Sharma et al., 2005) . There are three active compound 
classes in Curcuma spp. namely, the curcuminoids, the essential oils (atlantones, 
zingiberene and turmerones) and turmerin (a water-soluble peptide) (Sharma et 
al., 2005). 
Curcumin has been reported as having anti-microbial, anti-inflammatory, anti-
mutagenic, and anti-oxidant activity, as well as wound-healing abilities 
(Maheshwari et al., 2006;Sharma et al., 2005). In addition, curcumin has been 
shown to have anti-parasitic effects against Trypanosoma (Nose et al., 1998) and 
Leishmania  species(Koide et al., 2002).  
Chemotherapy is still important for the control of most parasitic diseases, such 
as trypanosomiasis and leishmaniasis. However, problems associated with 
treatment of these diseases include drug toxicity, resistance, a lack of 
guaranteed supply, and high cost. With the present rapid rate of development in 
the world, the number of people who have parasitic diseases is extreme. 
Consequently, new drugs are urgently needed for the most neglected diseases. 
 
158 curcumin analogues that have been synthesized as anti-leishmanial drugs 
were tested on L. major promastigotes, L. mexicana promastigotes and L. 
mexicana amastigotes. 157 of those analogues exhibit a general structure which 
has a 7-carbon spacer between aromatic rings with the remaining compound 
involving only a 5-carbon spacer (AS-HK129). The first three compounds are the 
parent of the analogues curcumin AS-HK001, demethoxycurcumin AS-HK002 and 
bisdemethoxycurcumin AS-HK003 (Changtam et al., 2010a). 
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The antiparasitic effects of curcumin analogues were investigated using the in 
vitro Alamar blue viability assay, which is based on the blue and non-fluorescent 
dye alamar blue (resazurin)(Raz et al., 1997), which is metabolised to resorufin 
(pink and fluorescent) by live cells only (Gonzalez & Tarloff, 2001). This 
procedure has been used to quantify the sensitivity to different chemical 
entities in many cell types such as, African trypanosomes (Raz et al., 1997) and 
Leishmania spp (Fumarola et al., 2004;Al-Salabi & de Koning, 2005). 
Each compound was tested in triplicate against Leishmania species to identify 
the EC50. Half of those analogues were more active than curcumin itself against 
the L. major promastigote, a third of them were considerably more active than 
curcumin in the L. mexicana promastigote, and almost half of them had an EC50 
less than that of curcumin against the L. mexicana amastigote. 
 
In this study, the structure-activity relationship (SAR) of curcumin analogues as 
compounds against Leishmania species will be investigated. 
 
3.2 Results 
Alamar blue assays were used to obtain the EC50 values for curcumin analogues 
in at least three independent determinations. All results of curcumin compounds 
001-098 were determined by my colleague Hasan Ibrahim (Ibrahim, 2009) 
whereas I determined the values for compounds 100-158 and present here the 
analysis of the full dataset for structural insights. In the below analysis curcumin 
(AS-HK001) is consistently used as reference compound, unless specifically 
stated otherwise. 
Curcumin analogues were divided into ten groups according to type of aromatic 
ring substituents. Curcumin is a symmetrical molecule and has one methoxy 
(positions 2 and 6) and one hydroxyl group (positions 3 and 7) on each aromatic 
ring (Table 3.1). The contribution of the methoxy substituents to antileishmanial 
activity was investigated. Compound AS-HK002, identical to curcumin except for 
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the demethylation at position 6 was equally active as curcumin (AS-HK001). 
Additional demethylation at position 2 (AS-HK032) also did not substantially 
change the antileishmanial activity, whereas the complete loss of methoxy at 
position 2 resulted in loss of activity (AS-HK003).  ASHK019, which has no 
methoxy substituents but hydroxyl groups at positions 2, 3 and 7, has similar 
activity as curcumin. The methylation of curcumin hydroxyl groups at positions 3 
and 7 (AS-HK073) did increase the activity against L. major almost 10-fold, but 
only in the continued presence of the 6-methoxy (see AS-HK074 and AS-HK075) 
group and the effects on L. mexicana were much less pronounced. The 
importance of the 6-methoxy substitution for high antiparasitic activity was also 
evident from AS-HK033, which has hydroxyl groups on the 2,3 and 7 positions but 
the best antileishmanial activity from this series of close curcumin analogues, 
with a better than 8-fold increased activity against L. major promastigotes.  
 
To determine the effect of higher alkyl ether analogues on the activity of the 
parasites, curcuminoids bearing an n-propyl ether (AS-HK079), allyl ethers (AS-
HK044 and AS-HK045), 3,3-dimethylallyl ethers (AS-HK76,AS-HK077 and AS-
HK078) and 2-hydroxyethyl ethers (AS-HK023, AS-HK024 and AS-HK081)were 
tested. These compounds were less active or similar to the parent compound AS-
HK001 for Leishmania species, except AS-HK044 and AS-HK077, which 
demonstrated modestly increased activity by 6 and 4.3-fold against L. major 
promastigotes, respectively. This improvement was not observed against L. 
mexicana promastigotes and amastigotes. 
 
The introduction of a polar group on the aromatic ring, such as nitro at position 
4 in the AS-HK041 analogue, was evaluated for anti Leishmania species activity. 
It was found that the activity was similar to that of the parent compound AS-
HK001 for L. major promastigotes and L. mexicana amastigotes, whereas the 
compound was less active against L. mexicana promastigotes. Introduction of 
(different) charged groups on other ring positions was not explored in the 
current series. However, a series of ester analogues including the acetates AS-
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HK025, AS-HK026 and AS-HK027, and the benzoates AS-HK028, AS-HK029, AS-
HK065 and AS-HK066 were tested on Leishmania species. The acetates showed 
less activity than AS-HK001 against Leishmania species, except in the case of AS-
HK027, which was 2-fold more active against L. mexicana amastigotes. The 
benzoate analogues (compounds 28, 29, 65 and 66) had no discernable effect on 
L. mexicana promastigotes or amastigotes up to the highest concentration tested 
(100 µM) and only moderate effects on L. major promastigotes. Adding an 
ethylacetate group to positions 3 and 7 (AS-HK101) had little effect on the 
activity of curcumin against promastigotes of both Leishmania species but, 
interestingly, increased its activity 8-fold against axenic amastigotes, suggesting 
perhaps a selective uptake system expressed at this lifecycle stage. 
 
Other sizeable ester or ether ring substitutions at positions 3 and 7 showed a 
similar pattern. The introduction of  cyanomethyl ethers (OCH2CN) (AS-HK080) 
completely abolished activity for Leishmania species but replacing the two 
curcumin hydroxyl groups with two groups of O-biotin (AS-HK100) or one or two 
of methacryric acid (AS-HK102 - 106) substitutions resulted in generally poor 
activity against promastigotes (a bit better for L. major than L. mexicana) but 
much better activity against L. mexicana amastigotes. The introduction of 5-
bromopentane ethers (O(CH2)5Br) at positions 3 and/or 7 (ASHK-108 - 113) 
further solidified this trend, with activity against L. mexicana amastigotes 3-6-
fold higher as against promastigotes of the same species. Replacing the end 
bromo for azide (5-azylpentoxy ether (O(CH2)5N3),as in AS-HK116 resulted in the 
loss of residual activity to promastigotes while retaining low micromolar activity 
against amastigotes, reinforcing the conclusion that this sub-class of 
curcuminoids either acts through a different mechanism or a different uptake 
system on amastigotes than on promastigotes.  
 
In contrast, substitutions of one or two pentyl pyridinium ethers (O(CH2)5(NC5H5)) 
on positions 3 and/or 7 (AS-HK119 - 124) led to a similarly increased activity (up 
to 20-fold) against promastigotes and amastigotes. The increased activity was 
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particularly strong for the di-substituted analogues AS-HK119 and AS-HK122 but 
it could be speculated that the apparently different action by pyridinium-
substitutes curcuminoids, compared to uncharged substitutions described above, 
has more to do with the alkyl pyridinium moieties than with curcumin itself. We 
have recently reported a separate series of alkyl pyridinium alkaloids with 
similar anti-leishmanial activity, with uncharged pyridine analogues being 
inactive compared to positively-charged pyridinium compounds (Rodenko et al., 
2011).  
The alteration of the two keto groups in the linker chain of the parent compound 
AS-HK001 to two methoxy imines (=N-OCH3), as found in AS-HK012, did not 
change the activity against Leishmania, whereas modification of these keto 
groups to hydroxyl imine (=N-OH), as in AS-HK042, dramatically reduced the 
anti-leishmanial activity. 
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AS-HK R1 R2 R3 R4 R5 R6 R7 R8 EC50 (µM) of  L. 
major promastigote 
EC50 (µM) of L. 
mexicana 
promastigote 
EC50 (µM) of L. 
mexicana 
amastigote 
001 H O-CH3 OH H H O-CH3 OH H 33 ± 4 26 ± 0.6 16  3 
002 H O-CH3 OH H H H OH H 37 ± 1 46 ± 0.5 37  4 
003 H H OH H H H OH H 72  3 >100 63  3 
019 H OH OH H H H OH H 222 265 21  2 
020 H H O-CH3 H H H OH H 87  5 73  20 32  2 
023 H O-CH3 O-C2H4OH H H O-CH3 O-C2H4OH H 33  8 274 37  5 
024 H O-CH3 OH H H O-CH3 O-C2H4OH H 224 33  3 30  4 
025 H O-CH3 OC(O)CH3 H H O-CH3 OC(O)CH3 H 73  20 >100 34  4 
026 H O-CH3 OC(O)CH3 H H H OC(O)CH3 H >100 >100 43  7 
027 H H OC(O)CH3 H H H OC(O)CH3 H 66 ± 10 32 ± 10 7.1 ± 1 
028 H O-CH3 OH H H O-CH3 OC(O)-C6H5 H 9.3 ± 1 >100 76  10 
029 H O-CH3 OH H H H OC(O)-C6H5 H 20 ± 1 >100 >100 
032 H OH OH H H OH OH H 26 ± 0.1 29 ± 2 12  3 
033 H OH OH H H O-CH3 OH H 4.3 ± 0.5 6.2 ± 0.2 3.2 ± 0.5 
041 H O-CH3 OH NO2 H O-CH3 OH H 28 ± 3 >100 14  4 
044 H O-CH3 O-C3H5 H H O-CH3 OH H 5.7 ± 0.7 35 ± 0.8 12 ± 4 
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045 H O-CH3 O-C3H5 H H O-CH3 O-C3H5 H 25 ± 9 >100 >100 
065 H H OH H H O-CH3 OC(O)-C6H5 H 42  10 >100 >100 
066 H H OH H H H OC(O)-C6H5 H 60  10 >100 >100 
073 H O-CH3 O-CH3 H H O-CH3 O-CH3 H 2.8  0.4 18  5 10  1 
074 H O-CH3 O-CH3 H H H O-CH3 H 23  6 65  20 61  3 
075 H O-CH3 O-CH3 H H H OH H 23  3 50  3 38  6 
076 H O-CH3 O-C5H9 H H O-CH3 O-C5H9 H >100 >100 27  0.8 
077 H O-CH3 OH H H O-CH3 O-C5H9 H 7.6  0.7 27  4 21  4 
078 H O-CH3 O-C5H9 H H H O-C5H9 H 48  9 55  0.4 27  7 
079 H O-CH3 O-C3H7 H H O-CH3 O-C3H7 H 28  2 60  30 34  0.2 
080 H O-CH3 O-CH2CN H H O-CH3 O-CH2CN H >100 >100 >100 
081 H O-CH3 OH H H H O-C2H4OH H 42  10 >100 >100 
100 H O-CH3 O-biotin H H O-CH3 O-biotin H >100 >100 9.2  2 
101 H O-CH3 OCH2C(O)Oet H H O-CH3 OCH2C(O)OEt H 21  3 43  2 2.0  0.3 
102 H O-CH3 OC(O)C(CH2) CH3 H H O-CH3 OC(O)-C(CH2) CH3 H 28  2.6 >100 17.31.7 
103 H O-CH3 OC(O)C(CH2) CH3 H H O-CH3 OH H 9.6  1.8 42  9 5.5  1.2 
104 H O-CH3 OC(O)C(CH2) CH3 H H H OH H 16.6  1.4 57  2.6 6.7  1.4 
105 H O-CH3 OC(O)C(CH2) CH3 H H H OC(O)C(CH2) CH3 H 31  0.4 >100 11.6  2.4 
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106 H H OC(O)C(CH2) CH3 H H H OC(O)C(CH2) CH3 H >100 >100 11.72.1 
108 H O-CH3 O-C5H10Br H H O-CH3 O-C5H10Br H 55  10 75  13 2.5  0.3 
109 H O-CH3 O-C5H10Br H H O-CH3 OH H 15.7  4.3 24  6 3.9  0.5 
111 H O-CH3 O-C5H10Br H H H OH H 16.7  6.3 24  0.6 5.1  0.6 
112 H O-CH3 OH H H H O-C5H10Br H 72  10 >100 10.4  1.6 
113 H O-CH3 O-C5H10Br H H H O-C5H10Br H 41  7.4 32  3.6 3.3  0.4 
116 H O-CH3 O-(CH2)5-N3 H H O-CH3 O-(CH2)5-N3 H >100 >100 5.6  0.8 
119 H O-CH3 O(CH2)5-N-pyridine H H O-CH3 O(CH2)5-N-
pyridine 
H 1.6  0.4 4.5  1.4 9.5  1 
120 H O-CH3 O(CH2)5-N-pyridine H H O-CH3 OH H 19.3  1.8 36  10 16.8  4.5 
122 H O-CH3 O(CH2)5-N-pyridine H H H O(CH2)5-N-
pyridine 
H 1.4  0.3 1.7  0.1 6.5  1.8 
123 H O-CH3 OH H H H O(CH2)5-N-
pyridine 
H 6.5  0.8 15.3  1.7 7.4  2 
124 H O-CH3 O(CH2)5-N-pyridine H H H OH H 8.8  0.5 12.2  0.2 15.6  4.2 
Pentamidine         5.1 ± 1.1 3.1 ± 0.7 4.3 ± 0.8 
Table 3.1. Structure and antileishmanial activity of curcumin analogues with a 3, 5-diketo, 1,6-diheptene linker. EC50 values are the average and SEM of at least 
three independent determinations. 
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The next analogues that were evaluated against the Leishmania species were the 
tetrahydro analogues AS-HK007, AS-HK008, AS-HK009, AS-HK085 and AS-HK087, 
where the double bonds in the C7 linker were saturated (Table 3.2). All these 
analogues display less activity than their parent compounds, except AS-HK085, 
which was more active than the original compound AS-HK001 by 2 to 3-fold 
against L. mexicana and L. major promastigotes, and equally against L. 
mexicana amastigotes. On the other hand, exchanging the two keto groups in 
analogue AS-HK009 with two hydroxyl imine (=N-OH), as in AS-HK047, did not 
measurably change the activity relative to the parent compound AS-HK003 for 
the L. major promastigote. This is similar to the hydroxyl imine substitution in 
ASHK-042 depicted in Table 3.2 with the original, unsaturated curcumin linker. 
Further reduction to hexahydro and octahydro analogues AS-HK030, AS-HK031 
and AS-HK082, AS-HK084 and AS-HK086 displayed very low, if any, activity. 
Indeed, some of these compounds had no affect at 100 μM on Leishmania 
species. The number and position of hydroxyl and methoxy groups on the rings 
had little influence on the activities, confirming that the increased saturation of 
the linker caused the loss of antileishmanial activity. It is instructive to compare 
these compounds directly with the corresponding curcumin analogues with the 
original conjugated di-ketone linker. For example, AS-HK086 was 9 to 25-fold 
less active against Leishmania species than the corresponding ‗conjugated‘ 
compound AS-HK033 (Table 3.3). 
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Isoxazole and Isoxazoline analogues: 
 
Exchanging the keto groups in the aromatic ring in parent compounds 1, 2 and 3 
with an isoxazole ring did not change the overall anti-leishmanial activity 
relative to the corresponding compounds with original linkers (Table 3.4). 
Activity increased slightly for compound AS-HK004 for Leishmania species 
AS-HK R1 R2 R3 R4 R5 R6 R7 R8 EC50 (µM) of  
L. major 
promastigote 
EC50 (µM) of 
L. Mexicana 
promastigote 
EC50 (µM) of 
L. Mexicana 
amastigote 
007 H O-CH3 OH H H O-CH3 OH H 90  20 59 43  9 
008 H O-CH3 OH H H H OH H >100 >100 >501 
009 H H OH H H H OH H 80  10 >100 64 ± 10 
083 H O-CH3 OH H H H OH H >100 5730 827 
087 H OH OH H H OH OH H >100 >100 533 
Table 3.2. Antileishmanial activity of some tetrahydro curcumin compounds, with saturated 
C7 linkers. 
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>100 55  3 40  5 
Table 3.3. The activity of hexahydro and octahydro curcumin analogues against Leishmania 
promastigotes and amastigotes. 
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(relative to curcumin), whereas the activity was slightly reduced for AS-HK005 
and AS-HK006 compared with their parent compounds (AS-HK002 and 003, 
respectively). Acetylation of the position 3 and 7 hydroxyl groups of AS-HK004 to 
the di-acetyl ester (AS-HK043) had no significant effect on activity, but the 
monopentyl ether (position 3) of  AS-HK022, displayed 2-fold improved activity, 
consistent with similar observations made with the original linker series 
(compare Table 3.1). Also consistent with those observations, loss of conjugation 
(AS-HK046) led to reduced anti-leishmanial activity, especially against L. 
mexicana.  
Introducing an methacrylic acid group at positions 3 and 7 to analogue AS-HK004, 
which gave AS-HK107, led to a >3-fold increase in activity against L. mexicana 
amastigotes, and an apparent decline in activity against the L. mexicana 
promastigote. Similarly, AS-HK115, which is created from AS-HK004 by 
introducing one group of bromopentane (C5H10Br) at position 3, was 8-fold more 
active against L. mexicana amastigotes, and significantly less active against the 
L. mexicana promastigote. Substitutions of one or two pentyl pyridinium ethers 
(O(CH2)5(NC5H5)) on positions 3 and/or 7 also increased anti-leishmanial activity, 
particularly against promastigotes of both species, with EC50 values from 0.8 to 
2.1 µM (Table 3.4).  
It is very clear that curcuminoids with isoxazole linkers are almost 
indistinguishable from their counterparts with the original conjugated di-keto 
linkers, and that the anti-leishmanial activity can be modulated in much the 
same way, by the same substitutions, for both sets of analogues. No doubt this 
reflects the same overall, rigid structure with a straight C7 linker between the 
identical aromatic rings. However, the isoxazole ring is much more stable than 
the di-keto motif, where the linker stabilisation is dependent on keto-enol 
tautomerism to produce a semi-conjugated π-electron structure (Figure 3.1). It 
follows that it is the precise structure rather than a reaction of curcumin or its 
analogues that is responsible for its antiprotozoal activity.  
R7
N O
R2
R3
R6
R8 R4
R5 R1
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AS-
HK 
R1 R2 R3 R4 R
5 
R6 R7 R8 EC50 (µM) of  
L. major 
promastigote 
EC50 (µM) of 
L. Mexicana 
promastigote 
EC50 (µM) 
of L. 
Mexicana 
amastigote 
004 H O-
CH3 
OH H H O-
CH3 
OH H 20 ± 0.8 20 ± 0.3 18  3 
005 H O-
CH3 
OH H H H OH H 61 ± 3 >100 54  8 
006 H H OH H H H OH H >100 81  30 >100 
022 H O-
CH3 
O-C5H11 H H H OH H 16 0.2
 16 0.8 8.1  2 
107 H O-
CH3 
C4H8O2 H H O-
CH3 
C4H8O
2 
H 8±0.4 >100 5.3±0.5 
115 H O-
CH3 
O-C5H10Br H H O-
CH3 
OH H 6.5±1.7 35±5.6 2±0.2 
125 H O-
CH3 
OC10H20Br
N 
H H O-
CH3 
OC10H
20BrN 
H 0.8±0.2 1.3±0.1 10±2.5 
126 H O-
CH3 
OC10H20Br
N 
H H O-
CH3 
OH H 2.1±0.2 2.1±0.2 3.7±1 
Table 3.4. The activity of isoxazole curcumin compounds 
 
 
Compound 
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L. major 
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mexicana 
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EC50 (µM) of 
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19 ± 5 27 ± 0.3 10  4 
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13 ± 0.7 >100 20  5 
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Figure 3.1. The curcumin linker is stabilised by keto-enol tautomerism 
 
It follows that significant bending of the linker chain would be expected to 
abolish most of the anti-leishmanial activity of the curcumin analogues. This was 
accomplished by replacing the isoxazole ring with an isoxazoline  ring in a 
saturated C7 linker (Table 3.5), which causes a stable bend of almost 90° in the 
linker (Figure 3.2), greatly distorting the 3D structure, although all ring-
substituents were the same. Compounds AS-HK088 - AS-HK090 correspond to 
compounds AS-HK004-AS-HK006 in Table 3.4. These are unfortunately not the 
most active compounds themselves, but the activity of the analogues with the 
bend linker does appear reduced, and indeed is virtually absent - similarly for 
AS-HK091, which has an additional ethyl ether substituent on positions 3 and 7. 
However, the isobutyryl ether or pentyl pyridinium substitutions would have 
been more informative comparisons as these are very active compounds with 
either the original or isoxazole linkers.  
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Figure 3.2. Three dimensional structure of curcumin, and the corresponding isoxazole and 
Isoxazoline  ring anaologues. The structures were generated using ChemDraw 3D Ultra 
version 10.0 (CambridgeSoft) using energy minimalisation, (arrows indicate double bonds). 
 
 
AS-
HK 
R1 R2 R3 R4 R5 R6 R7 R8 EC50 (µM) of  
L. major 
promastigote 
EC50 (µM) of 
L. mexicana 
promastigote 
EC50 (µM) of 
L.mexicana 
amastigote 
088 H O-
CH3 
OH H H O-
CH3 
OH H 75 ± 0.8 89 ± 4 43  6 
089 H O-
CH3 
OH H H H OH H 70± 30 56 ± 30 >100 
090 H H OH H H H OH H >100 >100 >100 
091 H O-
CH3 
O-
C(O)
CH3 
H H O-
CH3 
O-
C(O
)CH
3 
H 66 ± 20 >100 45  8 
Table 3.5. The activity of isoxazole curcumin compounds 
Abdulsalam Alkhaldi, 2012                                                                                      Chapter 3       80 
 
Monoketo analogs: 
 
The monoketo analogue AS-HK014 was prepared by the dehydration of analogue 
AS-HK030. This monoketo analogue appeared to be 3 to 12-fold more active 
against Leishmania species than AS-HK030. However, its activity did not really 
change in comparison with compound AS-HK001 except against L. major 
promastigotes, for which its activity increased 4-fold. The position 3 
monomethylated analogue AS-HK018 and the 3,7-dimethylated AS-HK036 
displayed essentially the same activity as AS-HK014, whereas demethylation of 
the 6-methoxy group (AS-HK034) slightly increased activity against L. mexicana. 
Yet, the 6-mono-methoxy analogue AS-HK048 displayed reduced activity against 
this species, showing that for this asymmetric curcuminoid series the two rings 
are not to be considered equal. The di-demethylated analogue AS-HK035 lost all 
activity against promastigotes of both species while retaining activity against 
axenic amastigotes. The low activity of AS-HK035 against promastigotes seems 
attributable to the 2-position hydroxyl group; its removal (AS-HK051 and 
057)(Table 3.6) restores anti-promastigote activity, while activity against 
amastigotes remains essentially unchanged. The above shows clearly that, for 
enone linker analogues at least, optimisation for activity against promastigotes 
would not necessarily increase activity against amastigotes, and vice versa.  
A number of position 3 and/or 7 alkyl ethers and acetates were generated to 
explore the effect of such substitutions on the enone linker curcuminoids. 
Addition of cyanomethyl to position 7 appeared only to decrease the activity 
against amastigotes (AS-HK092), whereas further addition of cyanomethyl to 
position 3 reversed this and somewhat increased activity to promastigotes (AS-
HK093). Substitutions with pentyl ether on positions 3 and/or 7 (AS-HK094-095), 
or acetylation of these positions (AS-HK096-097), equally failed to improve anti-
leishmanial activity, as did the introduction of an 1,2-ethanediol ether on 
position 3 (AS-HK098). Indeed, even the pentylpyridinium substitutions on 
position 3 (AS-HK128) or on both positions 3 and 7 (AS-HK127) were unsuccessful 
in increasing activity against L. mexicana amastigotes, although they increased 
activity against the promastigotes of this species.  
In this series, the most successful substitution was found to be a 5-bromopentyl 
ether on position 3 (AS-HK118), although the same substation on positions 3 and 
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7 was much less active, especially against promastigotes (AS-HK117). These final 
observations highlight the main observations concerning the enone linker series, 
that a different relationship exists for activity against promastigotes and 
amastigotes; that the substitutions that increased activity with a conjugated 
linker (di-ketone or isoxazole) did not increase activity with this linker; and that 
on the whole substitutions on positions 3 and 7 were unsuccessful. The latter 
point is powerfully illustrated when considering that the only compound without 
substitutions on either position (AS-HK057) displayed very nearly the best 
activity against amastigotes. Especially substitutions on position 7 would seem to 
be detrimental to anti-leishmanial activity, and the larger groups contributed to 
worse activity than a hydroxyl group at this position. 
Finally, analogue AS-HK053, which had a slightly different enone linker, 
conjugated with one aromatic ring, displayed an EC50 value higher than 100 μM. 
The introduction of methyl at position 4 for carbon in the linker chain, to create 
a branched chain linker otherwise identical to AS-HK036, resulting in AS-HK037, 
reduced the activity against Leishmania species. 
R7
O
R2
R3
R6
R8 R4
R5 R1
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EC50 (µM) of  
L. major 
promastigote 
EC50 (µM) of 
L. mexicana 
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EC50 (µM) of 
L. mexicana 
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8.9 ± 0.8 34 ± 1 17 ± 2 
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86 ± 20 >100 >100 
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AS-
HK 
R1 R2 R3 R4 R5 R6 R7 R8 EC50 (µM) of  
L. major 
promastigote 
EC50 (µM) of 
L. mexicana 
promastigote 
EC50 (µM) of 
L. mexicana 
amastigote 
018 H O-
CH3 
O-CH3 H H O-CH3 OH H 13 ± 1 38 ± 1 28 ± 6 
034 H O-
CH3 
OH H H OH OH H 10 ± 2 19 ± 6 7.4 ± 1 
035 H OH OH H H OH OH H >100 >100 17 ± 5 
036 H O-
CH3 
O-CH3 H H O-CH3 O-CH3 H 12 ± 1 42 ± 1 28 ± 8 
048 H H OH H H O-CH3 OH H 15 ± 2 85 ± 30 23 ± 4 
051 H H OH H H H OH H 9.9 ± 1 46 ± 3 21 ± 8 
057 H H H H H H H H 8.9 ± 2 30 ± 0.1 12  2 
092 H O-
CH3 
OH H H O-CH3 O-CH2CN H 14 ± 0.7 25 ± 0.1 50  30 
093 H O-
CH3 
O-
CH2CN 
H H O-CH3 O-CH2CN H 4.5 ± 0.7 12 ± 0.5 25  4 
094 H O-
CH3 
O-
C5H11 
H H O-CH3 O-C5H11 H 6.6 ± 1.0 51 ± 0.8 53  8 
095 H O-
CH3 
OH H H O-CH3 O-C5H11 H 4.0  1.3 27  0.8 19  4 
096 H O-
CH3 
O-
C(O)-
CH3 
H H O-CH3 O-C(O)-
CH3 
H 7.8  1.0 31  0.8 35  1 
097 H O-
CH3 
O-
C(O)-
CH3 
H H O-CH3 OH H 7.5  0.8 33  0.8 29  0.8 
098 H O-
CH3 
O-
C2H4O
H 
H H O-CH3 OH H 15  0.1 38  4 41  4 
117 H O-
CH3 
OC5H10
Br 
H H O-CH3 OC5H10Br H 182 >100 9.32.4 
118 H O-
CH3 
OC5H10
Br 
H H O-CH3 OH H 50.6 15.31.6 50.8 
127 H O-
CH3 
OC10H1
5N 
H H O-CH3 OC10H15N H 91.4 5.50.4 26.46.7 
128 H O-
CH3 
OC10H1
5N 
H H O-CH3 OH H 10  1.3 18  3 14.80.8 
Table 3.6. The activity of mono keto curcumin analogues 
 
The contribution of the olefinic group of the AS-HK014 linker to its 
antileishmanial activity was further investigated using a series of mono-keto 
analogues in a saturated C7 linker (Table 3.7). The dihydro analogue of AS-
HK014, AS-HK038, exhibited decreased activity against Leishmania. Likewise, a 
loss of activity was noted in the saturated keto compound AS-HK049 and in 
analogue AS-HK050, in which the keto group in AS-HK014 was reduced to a 
hydroxyl group. On the other hand, replacing the keto group in AS-HK038 with a 
hydroxyl imine (=N-OH) as in compound AS-HK010 or with a methoxyl imine (=N-
O-CH3) as in compound AS-HK013, did not have a clear effect on the anti-
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leishmanial activity, given the already low activity of compound 38. In addition, 
the introduction or removal of hydroxyl or methoxyl substitutes on one or both 
of the rings of AS-HK038, as in analogues AS-HK011, AS-HK50, AS-HK052, AS-
HK058 and AS-HK061, did also not result in any remarkable change in 
antileishmanial activity.  
R7
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R6
R8 R4
R5 R1
R9
 
 
Compound 
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36  1 >100 35  8 
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50 ± 4 82 ± 20 64 ± 20 
 
AS- K R1 R2 R3 R4 R5 R6 R7 R8 EC50 (µM) of 
 L. 
majorpromasti
gote 
EC50 (µM) of L. 
mexicana 
promastigote 
EC50 (µM) of 
L. mexicana 
amastigote 
011 H H O
H 
H H H OH H >100 >100 67 
038 H O-CH3 O
H 
H H O-
CH
3 
OH H 37 ± 3 >100 >50 
049 H O-CH3 O
H 
H H H OH H 55 ± 3 >100 >100 
052 H H H H H H OH H 97 ± 1 >100 >100 
058 H H H H H H H H 92 ± 20 >100 >100 
061 H H H H H H H H 83 ± 4 41 ± 3 >100 
Table 3.7. The EC50 values of different curcumin analogues after introduction and reduction 
some chemical groups. 
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Replacing the keto group in compound AS-HK014 with a hydoxylimine (=N-OH) 
group, as in analogue AS-HK039, led to decreased activity by 2 to 9-fold against 
the Leishmania species tested (Table 3.8). Similarly, AS-HK040, which has 
methoxyimine (N-O-CH3) in place of the keto group, showed also less activity 
than AS-HK014 (up to 4-fold), particularly against L. major promastigotes. 
Overall, the substitution of keto groups for imines has tended to not improve 
anti-leishmanial activity, and in some cases reduced it. 
 
Compound 
EC50 (µM) of  
L. major 
promastigote 
EC50 (µM) of 
L. Mexicana 
promastigote 
EC50 (µM) of 
L. Mexicana 
amastigote 
N
OMe
OHHO
MeO
OH
AS-HK039
 
76 ± 9 >100 43 ± 20 
N
OMe
OHHO
MeO
O
CH3
AS-HK040
 
40 ± 2 64 ± 4 23  7 
Table 3.8. . Anti-leishmanial activity of imine analogues of AS-HK014. 
 
Next, the importance of the location of the double bond was investigated, with 
a shift from C4-C5 to C1-C2. Although there is no exact C4-C5 equivalent for AS-
HK053 (Table 3.9), the results strongly suggest that this position, conjugated 
with the aromatic bonds, is unfavourable to anti-leishmanial activity despite the 
linker remaining unbend (Chem3D Ultra; Fig. 3.3) and the overall structure being 
perhaps more stable than with a C4-C5 double bond.  
A further change in double bond location was to position C6-C7 of the linker 
chain, creating AS-HK059, the equivalent of the C4-C5 olefinic analogue AS-HK057 
(Table 3.6), but with at least 10-fold less anti-leishmanial activity. With this 
olefinic position, the linker shape is in fact slightly bend (Fig. 3.3), affecting the 
orientation of the aromatic rings. Once again substitution of the keto group of 
AS-HK059 to hydroxylamine (AS-HK060) or methoxyimine (AS-HK062) failed to 
improve activity. 
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Compound 
EC50 (µM) of  
 L. major 
promastigote 
EC50 (µM) of 
L. Mexicana 
promastigote 
EC50 (µM) of  
L. mexicana 
amastigote 
O
OH
AS-HK053
 
86 ± 20 >100 >100 
O
AS-HK059
 
76 ± 20 >100 >100 
N-OH
AS-HK060
 
71 ± 6 74 ± 20 >50 
N-OMe
AS-HK062
 
69 ± 20 >100 >100 
Table 3.9. Anti-leishmanial activity of AS-HK014 analogue with a different olefinic position. 
 
 
Figure 3.3. 3D structure of compounds 53 and 59, modelled with Chem3D Ultra 
(CambridgeSoft), (arrows indicate double bonds). 
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A further series of olefinic linker modifications constituted the inclusion of three 
double bonds, at positions C1-C2, C3-C4 and C6-C7, giving a highly rigid linear 
linker with a fully conjugated π-electron system that includes both aromatic 
rings. Indeed the dispersed π-electron system is the main difference with 
compounds such as AS-HK053 (Table 3.9 and Fig. 3.3). However, the dienone and 
trienone linker series presented in Table 3.10 was generally much more effective 
than the mono-enone series, especially against amastigotes. Out of the 4 
dienone, three (compounds 15, 16 and 55) had a straight linker, whereas AS-
HK056 had a slightly bent linker like AS-HK059 (Fig. 3.3). While AS-HK056 did 
indeed display the worst activity (of this series) to L. major promastigotes (42 ± 
2 µM), its activity against L. mexicana amastigotes was surprisingly good (6.8 ± 
1.2 µM), although this could be because the rings were almost completely 
unsubstituted and their orientation was therefore less critical. The activity of 
AS-HK015, with a C4-C5 + C6-C7 dienone linker (Table 3.10), was the least 
promising in the dienone series and a direct comparison with AS-HK016 (same 
ring substitutions) affords the clear conclusion that a C1-C2 + C4-C5 dienone 
displays superior antileishmanial activity. Indeed, a direct comparison with AS-
HK014 also shows that the C6-C7 double bond was at best neutral, but probably 
slightly detrimental with respect to anti-leishmanial activity. Furthermore, the 
trienone compound AS-HK017 exhibited a small decrease in anti-leishmanial 
activity compared with AS-HK016. The hydroxyl and methoxy substitutions on 
the ring appear to be far more important for activity against promastigotes than 
against amastigotes (compare AS-HK016 and AS-HK 055). 
A substantial series of trienone analogues was next evaluated for antileishmanial 
activity (Table 3.10). These included analogues with substitutions on positions 1, 
4, 5 and 8 that were previously unexplored. The entire trienone series displayed 
low micromolar activity against L. mexicana amastigotes, showing definitively 
(a) that different optimisation occurs for promastigotes and amastigotes and (b) 
that small ring substitutions such hydroxyl, methoxy and chloride are of at most 
marginal importance for activity against axenic amastigotes. Even the 
introduction of a nitro group on position 2 (AS-HK131) had no effect on activity 
against amastigotes, although it increased activity against promastigotes of both 
species 3-4-fold (compare AS-HK139). Substitutions of methoxy or chloro on 
position 1 had little effect on activity against promastigotes either (compare AS-
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HK139 with AS-HK138 and AS-HK130). Indeed, it is hard to distil a clear trend 
explaining the substantial variation in anti-promastigote activity from the data 
in Table 3.10, with EC50 values ranging from 3.7 to >100 µM. It is hoped that a 
QSAR approach based on ComFA and ComSIA 3D computer modelling software 
will be able to give more definitive insights. 
 
R7
O
R2
R3
R6
R8 R4
R5 R1
  
 
 
Compound 
EC50 (µM) of  
L. major 
promastigote 
EC50 (µM) of 
L. mexicana 
promastigote 
EC50 (µM) of 
L. mexicana 
amastigote 
HO
O
O
OH
CH3
O
H3C
AS-HK015  
30 ± 2 48 ± 1 22  7 
HO
O
O
OH
CH3
O
H3C
AS-HK016  
2.7 ± 0.7 14 ± 2 4.6 ± 0.7 
O
AS-HK055  
13 ± 1 >100 4.0 ± 0.7 
O
HO AS-HK056  
42 ± 2 46 ± 2 6.8 ± 1.2 
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AS-HK R1 R2 R3 R4 R5 R6 R7 R8 EC50 (µM) of  L. 
major 
promastigote 
EC50 (µM) of L. 
Mexicana 
promastigote 
EC50 (µM) of L. 
Mexicana 
amastigote 
017 H O-CH3 OH H H O-CH3 OH H 7.4 ± 0.1 21 ± 2 4.8 ± 1.0 
130 O-CH3 H O-CH3 H O-CH3 H H O-CH3 38.3±5 53±11 6.4 ± 1.8 
131 H NO2 H H O-CH3 H H O-CH3 5.8±0.6 7.2±0.7 4.7 ± 0.6 
132 H OH O-CH3 H O-CH3 H H O-CH3 11.7±1.2 11.7±2 3.9 ± 1.0 
133 O-CH3 H O-CH3 H H H Cl H >100 >100 5.9 ± 2.0 
134 H H Cl H H H Cl H 36.5±2.5 49.2±5 5.1 ± 0.8 
135 O-CH3 H H O-CH3 O-CH3 H H O-CH3 19.2±4.3 22.8±4.4 5.4 ± 1.7 
136 H H O-CH3 H O-CH3 H H O-CH3 45.1±2.7 57.5±6.7 4.2 ± 1.1 
137 H OH H H O-CH3 H H O-CH3 7.5±0.2 9.2±1 6.7 ± 1.9 
138 Cl H H H O-CH3 H H O-CH3 16.2±1.3 32.4±11 4.4 ± 0.5 
139 H H H H O-CH3 H H O-CH3 20.6±3.5 25.3±4.8 5.0 ± 0.5 
140 H OH O-CH3 H H H Cl H 13.7±2.4 21.2±0.7 4.9 ± 1.0 
141 H OH O-CH3 H H OH H H 8.3±0.5 9.5±1.8 4.6 ± 1.1 
142 H H O-CH3 H H H O-CH3 H >100 97.9±6.5 2.8 ± 0.6 
143 H OH H H H H O-CH3 H 14.9±0.4 16.6±3.2 2.8 ± 0.2 
144 H OH H H H H Cl H 14.1±3 17.6±3.3 3.2 ± 1.3 
145 OH O-CH3 H H H O-CH3 O-CH3 H 3.7±0.01 6.3±1.3 4.9 ± 1.0 
146 H OH O-CH3 H H O-CH3 O-CH3 H 7.5±0.2 9.2±2.5 3.1 ± 0.7 
147 H H OH H H O-CH3 O-CH3 H 15±0.1 21.4±4.3 4.9 ± 0.8 
148 H H OH H H H O-CH3 H 31.7±0.8 37.2±3.8 5.1 ± 0.6 
149 H OH O-CH3 H O-CH3 H O-CH3 H 12.2±1.1 10.8±0.8 2.5 ± 0.3 
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150 O-CH3 H O-CH3 H O-CH3 H O-CH3 H 50.7±12.3 42.7±2.4 5.3 ± 1.4 
151 H H H H H H H H 30.1±1.3 39.1±3.6 4.8 ± 1.2 
152 H H OH H H H H H 25.6±3.4 23.8±1.8 4.7 ± 0.5 
153 H H O-CH3 H H H H H >100 75.8±5.6 5.7 ± 1.2 
154 H OH H H H H H H 10.7±1.8 14.2±2.6 1.3 ± 0.3 
157 OH O-CH3 H H H H H H 10.6±0.5
 16±2.5 4.7 ± 1.7 
158 O-CH3 H H O-CH3 H H H H 34±4 31±1.5 3.1 ± 1.3 
pentamidine         5.1 ± 1.1 3.1 ± 0.7 4.3 ± 0.8 
Table 3.10. The effect of the dienone and trienone curcumin compounds 
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Conclusions  
 
Several conclusions may be drawn from this structure activity analysis of 158 
curcumin analogues: 
 There was no change in the activity for compounds which have methoxy 
substitutions, whereas the mono-O-demethylated and di-O-demethylated 
compounds exhibited increased activity. 
 Adding one or two pentyl pyridinium (C10H15N) groups to positions 3 
and/or 7 of curcumin leads to an increased antileishmanial activity. 
 Replacing the diketo groups (C=O) with an isoxazole group generally 
improved the activity of curcumin analogues. 
 Introduction of further double bonds to the C7 linkers generally increases 
activity, especially against amastigotes. 
 Reduction of one of the diketo groups to a monoketo group increases 
activity, particularly against promastigotes. 
 Removing ring all substitutions in curcumin compounds reduces activity. 
 Changing the locations of the double bond locations does not affect 
activity against Leishmania species. 
 The trienone analogues displayed potently increased activity against 
Leishmania amastigotes.
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3.3 Multi-drug resistant strains of T. b. brucei are not 
cross-resistant with curcumin analogues 
Resistant strains can be used as a model to investigate cross-resistance between 
existing treatments and potential new trypanocides. Any new trypanocidal drugs 
to be developed, whether for human or veterinary use, should at a minimum not 
be cross-resistant with the current diamidine and arsenic-based drugs. It is 
exactly because of high levels of resistance to these classes of drugs that the 
development of new drugs has become such a priority. We therefore tested 
whether curcumin-based trypanocides would be effective against well-
characterised laboratory strains resistant to diamidines and melaminophenyl 
arsenicals. 
In this study, all experiments were performed at least three times for each 
compound and each experiment included two positive controls, pentamidine, 
diminazene; drug-free incubations were used as negative controls . Fluorescence 
intensity was analysed using GraphPad Prism 5 software and the data was 
plotted to a sigmoid curve by non-linear regression, in order to determine the 
EC50 values (Effective Concentration that inhibits 50% of maximal growth). 
One hundred and fifty-eight synthesized curcumin analogues were tested on 
three strains of trypanosomes: wild type strain (s427-WT), TbAT1 knock out (KO) 
and TbAT1-B48 - listed in decreasing sensitivity to diminazene, pentamidine and 
cymelarsan (Matovu et al., 2003;Bridges et al., 2007). The tests on curcumin 
compounds AS-HK001-098 were conducted by my colleague Hasan Ibrahim 
(Ibrahim, 2009) and some of the results were subsequently published (Changtam 
et al., 2010a) . Results from the Alamar blue assays with compounds AS-HK100-
158 are presented here. Figure 3.4 shows typical results, of one such essay, with 
all three strains performed in parallel and only the EC50 values for the diamidine 
controls shifting to higher resistance levels in TbAT1-KO and B48 (Table 3.11). 
There was no significant difference in the EC50 values of the 59 curcumin 
analogues for the three strains of T. b. brucei (Table 3.11). This was consistent 
with the earlier findings with compounds AS-HK001-098. 
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Figure 3.4. The effect of some curcumin compounds on bloodstream forms of three T. b. 
brucei strains, Tb427-WT (A), TbAT1-KO (B) and B48 (C) by using Alamar blue assay. 
Diminazene and pentamidine were used as positive controls. 
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Compound T. b. b. 
(WT) µM ± SEM 
T. b. b. 
(KO) µM ± SEM 
T. b. b. 
(B48) µM ± SEM 
AS-HK 100 2.1 ± 0.28 3.16 ± 0.45 2.82 ± 0.34 
AS-HK 101 0.12 ± 0.02 0.66 ± 0.18 0.45 ± 0.08 
AS-HK 102 2.56 ± 0.5 4.25 ± 1.15 2.97 ± 1.01 
AS-HK 103 1.09 ± 0.22 1.03 ± 0.25 0.86 ± 0.09 
AS-HK 104 1 ± 0.15 0.88 ± 0.04 1.09 ± 0.07 
AS-HK 105 1.96 ± 0.31 1.95 ± .068 1.63 ± 0.25 
AS-HK 106 2.25 ± 0.21 1.72 ± 0.13 2 ± 0.2 
AS-HK 107 1.43 ± 0.11 1.23 ± 0.07 1.34 ± 0.11 
AS-HK 108 4.01 ± 1.37 3.09 ± 0.6 3 ± 0.96 
AS-HK 109 3.08 ± 1.06 3.87 ± 1.34 2.56 ± 0.92 
AS-HK 111 4.6 ± 1.36 3.97 ± 1.24 3.95 ± 1.52 
AS-HK 112 5.44 ± 1.7 4.19 ± 1.19 4.66 ± 1.82 
AS-HK 113 5.97 ± 1.17 6.25 ± 0.92 6.23 ± 1.47 
AS-HK 115 2.07 ± 0.02 2.95 ± 0.44 2.89 ± 0.16 
AS-HK 116 13.06 ± 2.89 12.2 ± 2.91 8.82 ± 2.37 
AS-HK 117 1.15 ± 0.13 0.79 ± 0.17 1.61 ± 0.45 
AS-HK 118 0.51 ± 0.14 0.1 ± 0.03 0.45 ± 0.24 
AS-HK 119 0.07 ± 0.024 0.15 ± 0.05 0.1 ± 0.04 
AS-HK 120 0.018 ± 0.01 0.05 ± 0.02 0.04 ± 0.02 
AS-HK 122 0.064 ± 0.018 0.06 ± 0.001 0.08 ± 0.01 
AS-HK 123 0.042 ± 0.018 0.08 ± 0.03 0.03 ± 0.01 
AS-HK 124 0.033 ± 0.007 0.06 ± 0.02 0.04 ± 0.006 
AS-HK 125 0.031 ± 0.004 0.07 ± 0.02 0.06 ± 0.01 
AS-HK 126 0.015 ± 0.003 0.05 ± 0.01 0.03 ± 0.007 
AS-HK 127 0.35 ± 0.05 0.65 ± 0.1 0.57 ± 0.06 
AS-HK 128 1.24 ± 0.23 1 ± 0.15 1.04 ± 0.12 
AS-HK 129 47.75 ± 4.8 70.1 ± 8 86.5 ± 23.7 
AS-HK 130 15.09 ± 1.43 13.13 ± 1.07 12.6 ± 1.5 
AS-HK 131 0.99 ± 0.15 1 ± 0.07 0.87 ± 0.08 
AS-HK 132 1.05 ± 0.04 0.93 ± 0.02 0.86 ± 0.07 
AS-HK 133 34.97 ± 3 32.42 ± 4.1 21.56 ± 3.2 
AS-HK 134 12.45 ± 0.76 12.74 ± 1.15 10.3 ± 1.04 
AS-HK 135 4.73 ± 0.42 4.46 ± 0.3 3.60 ± 0.15 
AS-HK 136 3.76 ± 0.17 4.06 ± 0.16 3.65 ± 0.1 
AS-HK 137 0.62 ± 0.03 0.55 ± 0.02 0.58 ± 0.08 
AS-HK 138 3.3 ± 0.34 2.5 ± 0.17 2.19 ± 0.24 
AS-HK 139 3.04 ± 0.15 2.48 ± 0.27 2.25 ± 0.12 
AS-HK 140 2.33 ± 0.23 1.83 ± 0.15 1.57 ± 0.14 
AS-HK 141 0.54 ± 0.07 0.45 ± 0.02 0.37 ± 0.04 
AS-HK 142 4.86 ± 0.82 4.33 ± 0.43 4.02 ± 0.29 
AS-HK 143 0.58 ± 0.01 0.71 ± 0.06 0.72 ± 0.07 
AS-HK 144 0.34 ± 0.05 0.44 ± 0.01 0.41 ± 0.05 
AS-HK 145 0.37 ± 0.03 0.40 ± 0.05 0.3 ± 0.02 
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AS-HK 146 0.69 ± 0.06 0.49 ± 0.05 0.47 ± 0.06 
AS-HK 147 1.08 ± 0.07 1.13 ± 0.09 0.93 ± 0.04 
AS-HK 148 1.95 ± 0.09 1.79 ± 0.06 1.83 ± 0.16 
AS-HK 149 1.89 ± 0.36 1.21 ± 0.06 1.41 ± 0.23 
AS-HK 150 12.62 ± 0.1 10.87 ± 0.5 11.8 ± 0.9 
AS-HK 151 1.09 ± 0.02 1.02 ± 0.02 1.38 ± 0.18 
AS-HK 152 2.01 ± 0.07 1.71 ± 0.13 1.65 ± 0.18 
AS-HK 153 3.67 ± 0.14 2.8 ± 0.14 3.24 ± 0.35 
AS-HK 154 0.40 ± 0.01 0.45 ± 0.01 0.43 ± 0.03 
AS-HK 155 0.73 ± 0.14 0.62 ± 0.06 0.67 ± 0.07 
AS-HK 156 3.28 ± 0.21 3.32 ± 0.26 3.06 ± 0.31 
AS-HK 157 1.58 ± 0.05 1.47 ± 0.1 1.41 ± 0.21 
AS-HK 158 6.25 ± 0.06 6.26 ± 0.31 5.61 ± 0.08 
Diminazene 0.12 ± 0.01 0.54 ± 0.086 0.73 ± 0.2 
Pentamidine 0.004 ± 0.001 0.01 ± 0.005 0.41 ± 0.02 
Table 3.11. Average EC50 values for curcumin compounds against T. b. brucei wild type, 
TbAT1- knockout and B48 blood stream form plus standard errors. All data are the average 
of at least 3 independent experiments. 
 
 
3.4 Structural determinants of curcumin analogues 
important for antileishmanial activity – comparison 
with T. b. brucei 
The structural determinants for activity of  curcumin analogues against T. b. 
brucei are similar to those found to be important for antileishmanial activity. 
The first similarity is that the mono-O-demethylated analogue AS-HK033 showed 
increased effectiveness against both the Leishmania species and T. b. brucei 
when comparing the original compound, AS-HK001, and the O-demethylated 
analogue, AS-HK073. The second similarity is that the addition of one or two 
pentyl pyridinium (C10H15N) groups leads to an increase of activity in both the 
Leishmania species and T. b. brucei, as it is found in compounds AS-HK119, 122, 
123, 124, 125 and 126. Additionally, the activity was greater when replacing the 
diketo group with an isoxazole ring as found in compounds AS-HK125 and 126. 
Furthermore, the omission of one of the keto groups, resulting in a enone linker 
such as in compound AS-HK014, resulted in a slight increase in the activity 
against parasites, although this was much more pronounced in T. b. brucei 
(Changtam et al., 2010a). Moreover, adding one pentyl bromide (OC5H10Br) as in 
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AS-HK118 led to the improvement of activity against both Leishmania species as 
well as T. b. brucei. Finally, when compared with the original compound AS-
HK001, more than half of the trienone analogues increased their activity against 
all parasites that were tested in this study. It is thus clear that some of the main 
structural motifs highlighted in the current study ensure broad activity against 
kinetoplastid parasites and should be investigated for further anti-infective 
activity. However, it is vital to first assess, at this point, whether the general 
anti-kinetoplastid activity is merely a reflection of a general cellular toxicity 
that would disqualify the compounds from further therapeutic development. 
 
3.5 Selectivity of curcuminoids: therapeutic index 
relative to Human Embryonic Kidney cells 
Compound T.  brucei 
WT s427 
L.  mexicana 
amastigotes 
HEK cells Therapeutic 
index 
Trypanosoma 
Therapeutic 
index 
Leishmania 
EC50  (µM) EC50  (µM) EC50  (µM) 
AS-HK 100 2.14 ± 0.28 9.2 ± 1.9 47.8 ± 3 22.3 5.2 
AS-HK 101 0.12 ± 0.02 2.0 ± 0.3 40 ± 9.1 333 20 
AS-HK 102 2.56 ± 0.5 17.3 ± 1.7 195 ± 44 76 11.2 
AS-HK 103 1.09 ± 0.22 5.5 ± 1.2 59.4 ± 15.7 54.5 10.8 
AS-HK 104 1.00 ± 0.15 6.7 ± 1.4 61.3 ± 14.7 61 9.1 
AS-HK 105 1.96 ± 0.31 11.6 ± 2.4 229.5 ± 44.2 117 20 
AS-HK 106 2.25 ± 0.21 11.7 ± 2.1 > 400 > 177 > 35 
AS-HK 107 1.43 ± 0.11 5.3 ± 0.5 > 400 > 280 > 75.5 
AS-HK 108 4.01 ± 1.37 2.5 ± 0.3 > 400 > 100 > 160 
AS-HK 109 3.08 ± 1.06 3.9 ± 0.5 59.5 ± 19 19.3 15.25 
AS-HK 111 4.60 ± 1.36 5.1 ± 0.6 70 ± 15.6 15.2 13.7 
AS-HK 112 5.44 ± 1.7 10.4 ± 1.6 186.5 ± 50.6 34.3 18 
AS-HK 113 5.97 ± 1.17 3.3 ± 0.4 > 400 > 67 > 121 
AS-HK 115 2.07 ± 0.02 2.0 ± 0.2 > 400 > 193 > 200 
AS-HK 116 13.06 ± 2.9 5.6 ± 0.8 > 400 > 30.6 > 71.4 
AS-HK 117 1.15 ± 0.13 9.3 ± 2.4 34 ± 3.4 29.5 3.6 
AS-HK 118 0.51 ± 0.14 5.0 ± 0.8 17.1 ± 0.6 33.5 3.4 
AS-HK 119 0.07 ± 0.02 9.5 ± 0.9 43.5 ± 3.1 621 4.6 
AS-HK 120 0.02 ± 0.01 16.8 ± 4.5 > 400 > 20000 > 32.8 
AS-HK 122 0.06 ± 0.018 6.5 ± 1.8 63 ± 1 562 5.5 
AS-HK 123 0.042 ± 0.01 7.4 ± 2 46.7 ± 1 1112 6.3 
AS-HK 124 0.03 ± 0.007 15.6 ± 4.2 56 ± 0.5 1697 3.6 
AS-HK 125 0.03 ± 0.004 10.0 ± 2.5 38.8 ± 3.6 1251 3.9 
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AS-HK 126 
0.01 ± 0.003 3.7 ± 1 
56.4 ± 4.1 
3760 
15.2 
AS-HK 127 0.35 ± 0.01 26.4 ± 6.7 > 400 > 1142 > 15 
AS-HK 128 1.24 ± 0.23 14.8 ± 0.8 254 ± 16 205 17 
AS-HK 129 47.75 4.86 7.1 ± 0.4 > 400 > 8.3 > 56.3 
AS-HK 130 15 ± 1.43 4.9 ± 1.0 310 ± 70 20.5 63 
AS-HK 131 0.99 ± 0.15 6.4 ± 1.8 55 ± 6 55.5 8 
AS-HK 132 1.05 ± 0.04 4.7 ± 0.6 23 ± 3 22 5 
AS-HK 133 34.9 ± 1 3.9 ± 1.0 >400 >11.5 >103 
AS-HK 134 12.4 ± 0.76 5.9 ± 2.0 420 ± 50 34.8 71 
AS-HK 135 4.73 ± 0.42 5.1 ± 0.8 230 ± 40 48.6 45 
AS-HK 136 3.76 ± 0.17 5.4 ± 1.7 > 400 > 106 > 74 
AS-HK 137 0.62 ± 0.03 4.2 ± 1.1 26.1 ± 3.4 42 6 
AS-HK 138 3.3 ± 0.34 6.7 ± 1.9 105.5 ± 18.9 32 16 
AS-HK 139 3.04 ± 0.15 4.4 ± 0.5 92.8 ± 13.1 30.5 21 
AS-HK 140 2.33 ± 0.7 5.0 ± 0.5 50.6 ± 4.5 21.8 10 
AS-HK 141 0.54 ± 0.07 4.9 ± 1.0 26.6 ± 2.4 49 5 
AS-HK 142 4.86 ± 0.82 4.6 ± 1.1 326.4 ± 60.9 67.2 71 
AS-HK 143 0.58 ± 0.01 2.8 ± 0.6 19.6 ± 2.6 33.8 7 
AS-HK 144 0.34 ± 0.05 2.8 ± 0.2 29.8 ± 6.2 87.6 11 
AS-HK 145 0.37 ± 0.03 3.2 ± 1.3 21.6 ± 2.5 58.4 6 
AS-HK 146 0.69 ± 0.06 3.1 ± 0.7 15.8 ± 1.8 22.9 5 
AS-HK 147 1.08 ± 0.07 4.9 ± 0.8 27.1 ± 3.1 25 5 
AS-HK 148 1.95 ± 0.09 5.1 ± 0.6 34.3 ± 6.6 17.6 7 
AS-HK 149 1.89 ± 0.36 2.5 ± 0.3 30.9 ± 4.0 16.4 12 
AS-HK 150 12.62 ± 0.1 5.3 ± 1.4 423.9 ± 129.0 33.5 80 
AS-HK 151 1.09 ± 0.02 4.8 ± 1.2 112.9 ± 17.3 103.6 24 
AS-HK 152 2.01 ± 0.07 4.7 ± 0.5 43.0 ± 4.3 21.4 9 
AS-HK 153 3.67 ± 0.14 5.7 ± 1.2 > 400 > 108 > 70 
AS-HK 154 0.40 ± 0.01 1.3 ± 0.3 12.9 ± 2.8 32.3 10 
AS-HK 155 0.73 ± 0.14 4.0 ± 0.7 191.1 ± 15.1 261.8 48 
AS-HK 156 3.28 ± 0.21 6.8 ± 1.2 240.6 ± 44.9 73.4 35 
AS-HK 157 1.58 ± 0.05 4.7 ± 1.7 62.2 ± 11.7 39.4 13 
AS-HK 158 6.25 ± 0.06 3.1 ± 1.3 > 400 > 64 > 129 
PAO   2.6 ± 0.1   
Table 3.12. : Average EC50 values for curcumin compounds against T. b. brucei wild type 
blood stream form, L.  mexicana amastigotes plus standard errors. Also shown are the 
average EC50 values with Human Embryonic Kidney (HEK) cells and standard errors, plus 
the Selectivity Index (EC50 of HEK cells / EC50 of parasites). PAO (Phenyl Arsine Oxide) as 
a positive control for HEK cells. 
 
Curcuminoids compounds (AS-HK100-158) were tested by Alamar blue for their 
effects on human embryonic kidney (HEK) cells in order to determine whether 
the antiprotozoal activity is the result of general toxicity or is more specifically 
antiprotozoal (Table 3.12). Toxicity assays for HEK cells showed that the 
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curcumin compounds that have an effect on L. mexicana amastigotes and T. b. 
brucei have a much lower activity on HEK cell growth and viability. Therapeutic 
index rates (EC50 of HEK cells / EC50 of parasites) for Trypanosoma and 
Leishmania are shown in table 3.12. The highest of therapeutic index values 
were > 20000, 3760, 1697 and 1697-fold for wild-type T. brucei with   with AS-
HK120, AS-HK126 and AS-HK124 respectively. These were all pentylpyridinium 
analogues, which all displayed mid - to low nanlomolar activity against the 
trypanosomes. The best therapeutic indices with respect to L. mexicana 
amastigotes were >200, >160 and >129-fold for AS-HK115, AS-HK 108 and AS-HK 
158 respectively. Compounds 115 and 158 contain rigidly linear C7 linkers with 3 
double bonds, either partly integrated in an isoxazole ring or trienone motif, 
respectively; AS-HK108 is a direct analogue of curcumin, with bromopentyl ether 
substitutions on positions 3 and 7. It is worth mentioning that in many cases, the 
higher limit of the therapeutic index could not be obtained as the highest 
concentration tested in our HEK cell screen was 400 µM and a significant 
percentage of compounds had no growth retarding effects on the human cell line 
at that concentration. While the results presented here are highly encouraging, 
it is acknowledged that far more pharmacological and toxicological tests must be 
performed to develop this series of curcuminoids into genuine lead compounds 
for anti-parasitic drug development. 
At the same time, there is no steady line correlation between the activity of 
these compounds on amastigotes and HEK cells, as shown in Figure 3.5. 
Therefore, it is possible to optimise for activity against amastigotes without 
increasing toxicity to HEK cells at the same time. 
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3.5. Correlation between EC50 values against axenic L. Mexicana amastigotes and cultured 
HEK cells. Trend line was calculated by linear regression yielding a correlation coefficient of 
0.05; the slope was not significantly different from zero (runs test) and thus there is no 
significant correlation between the two data sets. In some cases the value 400 was entered 
as the EC50 value for HEK cells could not be determined and 400 µM was the highest 
concentration used in the assay. 
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3.6 Discussion 
158 curcumin analogues were tested against L. major promastigotes, L. 
mexicana promastigotes and L. mexicana amastigotes. Alamar blue assays were 
used to obtain the EC50 for curcumin analogues in at least three independent 
determinations for studying the structure-activity relationship (SAR) of curcumin 
analogues as compounds against Leishmania species. A number of curcumin 
compounds have  activities similar or better than  current clinical drugs such as 
pentamidine (Ibrahim et al., 2011). Curcumin compounds AS-HK119 and AS-
HK122, containing one or two pentyl pyridinium (C10H15N) groups, displayed at 
least the same antileishmanial activity as pentamidine in all Leishmania species 
tested. The replacement of the diketo motif with an isoxazole ring as in 
compounds AS-HK125 and 126 resulted in similar activity. Most importantly 
perhaps the trienone motif produced a series with consistently high activity 
against amastigotes, allowing the selection of some members of the series that, 
like AS-HK158, display low toxicity to the human cell line. In all 18 out of 158 
curcumin compounds exhibited the same or higher activity than pentamidine 
against L. mexicana amastigotes.  
Curcumin analogues  were also tested against Trypanosoma brucei brucei in 
order to obtain EC50 values. 59 out of 158 curcumin compounds (AS-HK100-158) 
are reported in this study because the first compounds already were studied by 
my colleague Hasan Ibrahim. As it is essential for any new compound considered 
for development  to be active against resistant strains comparisons of the 
activity of curcumin analogues against  different strains of Trypanosoma brucei 
brucei (WT, KO and B48) were made. The results show that there is no 
significant cross-resistance between the entire class of curcumin  compounds 
and the diamidine or melaminophenyl arsenical classes of trypanocides. As 
diamidine and arsenical resistance in these strains has been linked to loss of the 
P2 transporter and the HAPT transporter (Bridges et al., 2007;Matovu et al., 
2003), it is concluded that uptake of curcumoids is not dependent on the 
expression of these transporters.  
The cytotoxicity of curcumin analogues towards HEK cells showed substantial 
differences, and this screen will be only a first filter to narrow down compounds 
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from the substantial library for further testing. However, all of these compounds 
show lower toxicity towards HEK cells than to Trypanosoma brucei brucei and 
Leishmania species. The calculated therapeutic index value for T. b. brucei 
exceeded 100-fold for 19 out of 59 curcumin compounds; 5 out of 59 of those 
compounds displayed a  therapeutic index >100 for L. mexicana amastigotes. 
This finding is completely consistent with the data published by Changtam and 
his colleagus (2010) who reported that the curcumin analogues have lower 
toxicity to human cells than to kinetoplastid parasites. 
One of the more significant findings to emerge from this study is that there are 
some curcumin analogues were very active against the parasites in this study, 
such as, mono-O-demethylated, O-demethylated, pentyl pyridinium, isoxazole, 
monoketo and pentyl bromide analogues. 
Curcumin has been reported effective against parasites in many studies. For 
example, the EC50 value for L. major promastigotes was 37.6 µM (Koide et al., 
2002), which is very close to the EC50 in this study  33 µM. The Curcuminoids AS-
HK001, AS-HK002 and AS-HK003 have been tested on L. major promastigotes and 
P. falciparum and the IC50 values were between 3 and 21 µM (Rasmussen et al., 
2000). In addition, previous studies have reported that curcumin analogues AS-
HK001, AS-HK004, AS-HK025 and AS-HK073 are effective against P. falciparum 
with IC50 ranges between 2.3 and 8.5 µM (Mishra et al., 2008).  AS-HK073 thus 
has a similar activity against Plasmodium  (Mishra et al., 2008) and Leishmania 
species, IC50 of  7.8, 2.8, 18 and 10 µM of IC50 for P. falciparum, L. major 
promastigotes, L. mexicana promastigotes and L. mexicana amastigotes, 
respectively. 
The antimycobacterial activity of some curcumin compounds has also been 
investigated. Curcumin compounds, such as AS-HK001, AS-HK043 and AS-HK046, 
were tested against Mycobacterium tuberculosis and the activities for 
compounds 43 and 46 were higher than for curcumin itself (Changtam et al., 
2010b). Moreover, Changtam and his colleagues discovered that the isoxazole 
analogues are the most active compound series against these bacteria, which 
correlates with the results of the present study, which show that the isoxazole 
analogues have very clear activity against Leishmania spp. Recently, curcumin 
has been reported to be also effective against Trypanosoma cruzi; it caused 
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reduced parasitemia in infected mice and killed the parasites in vitro 
(Nagajyothi et al., 2012).  
Finaly, the Alamar Blue method is a widely-used tool for primary screening of 
compound libraries on numerous cell types, including protozoa (Raz et al, 1997; 
Fumarola et al., 2004; Al-Salabi & de Koning, 2005). However, it is essential that 
hit compounds identified in such a screen are followed on by more informative 
techniques. For instance, screening axenic Leishmania amastigotes using the 
Alamar Blue assay can eliminate from consideration a high percentage of 
compounds screened. The remainder can then be screened using the far more 
predictive parasite burden assays with intra-macrophage amastigotes to further 
narrow down the number of hits by eliminating those that do not adequately 
penetrate the macrophage and the phagolysosome, or are too toxic to the 
macrophages. This will then yield a final set of hit compounds to be tested in an 
animal model of leishmaniasis. 
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4 Chapter four: Investigation into the mechanism 
of the trypanocidal activity of curcumin 
analogues bearing the enone motif 
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4.1 Introduction 
An overview of the results in Chapter 3 (Changtam et al., 2010;Ibrahim, 2009) 
shows that there are strong trypanocidal effects for some curcumin analogues. 
For instance, curcumin AS-HK014 has a strong effect on trypanosome and a low 
toxicity activity on human embryonic kidney cells (T293), which means this 
compound holds great promise in the future. Therefore, its mechanism of action 
must be elucidated in order to initiate structure activity relationship studies and 
rational lead compound optimisation. 
An earlier work by my colleague Hasan Ibrahim showed that, in bloodstream 
trypanosomes, curcumin and its analogues have no effect on normal cell cycle 
progression and mitochondrial membrane potential, do not cause DNA 
fragmentation, and do not increase the levels of reactive oxygen species in 
trypanosomes. However, one curcumin compound (AS-HK014) rapidly decreased 
the glutathione content in the hepatocytes of rat (Ibrahim, 2009). 
In this study, further tests on the mechanism of action of curcumin are 
conducted. In particular, the fast action of enone curcumins was suggestive of a 
rapid change in the cells, possibly mediated by changes to the plasma membrane 
permeability or effects on levels of second messengers such as cAMP or 
intracellular calcium. The possibility of a plasma membrane event was further 
confirmed by the observation of Hasan Ibrahim that the enone curcumins but not 
the di-ketone curcumins induced rapid plasma membrane permeabilisation in T. 
brucei brucei (Ibrahim, 2009). 
Induction of T. b. brucei-resistant cell lines could help in the understanding of 
the mechanism of action of drug (Bridges et al., 2007;Barrett et al., 1995). Two 
resistant cell lines were established, for AS-HK001 (curcumin) and AS-HK014, 
respectively, in order to study the effect of curcumin compounds on these cell 
lines and to compare the effect with parental cell line. The concentrations were 
increased gradually depending on the cells‘ viability. Several studies that 
focused on resistant cell lines were used to understand the mechanism of action 
of drug, including the metabolomic assessment of curcumin and AS-HK014 on T. 
b. brucei, which pointed to changes in thiol content.  This prompted an 
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investigation of expression levels of glutathione synthetase (GS) and γ-
glutamylcysteine synthetase (GGS), as well as sequence analysis of GS and γ-
glutamylcysteine synthetase genes in wild-type and resistant trypanosomes 
clones.  
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4.2 Effect of curcuminoids on intracellular cAMP levels in 
trypanosomes 
The intracellular cAMP level was investigated by my colleague Dr. Neils Quashie 
who worked in Dr. Harry De Koning‘s laboratory. cAMP was assessed using an 
enzyme-linked immunosorbant assay (ELISA) kit. The trypanosomes were 
incubated with two enone curcumin compounds (AS-HK014 and AS-HK096) at 500 
nM for 15 min in order to determine their effect on intracellular cAMP levels.  
The results show that curcumin compounds 14 and 96 had no significant effect 
on the cAMP levels compare with Drug free (negative control), whereas the 
positive control (CpdA at 1 µM) has a very clear effect on the cAMP levels (figure 
4.1). CpdA is an inhibitor of T. brucei phosphodiesterase B1 and B2 and increases 
cellular cAMP levels (de Koning et al., 2012). 
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Figure 4.1.  Average intracellular cAMP in bloodstream-form T. b. brucei incubated at 
different concentrations for 15 min. cAMP was measured with the use of ELISA kit. The 
density of the cells was 5 × 10 6 cell/mL. All results were obtained by Dr. Neils Quashie. The 
experiment was performed on three separate occasions, and the data shown are the 
average  SEM of these three experiments. The data expressed as % difference of cAMP 
content from the control (drug free), P-values calculated using the unpaired Student’s t-test 
(** P<0.01). 
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4.3 Modulation of plasma membrane potential and 
intracellular calcium by curcuminoids 
Differences in the extracellular and intracellular concentration of ions result in 
the plasma membrane potential Vm. All eukaryotic cells maintain such a 
potential, which plays a central role in transport mechanisms and signal 
transduction. Any change in this potential leads to changes in the cellular 
concentration of ions and consequently to loss of homeostasis and eventual loss 
of viability. Therefore, a study on the effect of curcumin compounds on Vm and 
intracellular calcium levels (Ca2+) was conducted. 
4.3.1 Effect of curcumin compounds on membrane potential 
A set of curcumin compounds with different concentrations was tested on 
trypanosomes to monitor in vitro plasma membrane potential. This potential was 
determined using the fluorescent dye bis-(1,3 dibutylbarbituric acid)trimethine 
oxonol (Invitrogen). The negative control was an assay buffer that contained 1% 
ethanol, and the positive control consisted of 10 µM gramicidin. As shown in 
Figure 4.2, none of the curcumin compounds had an effect on membrane 
potential over 10 min after the addition of the compounds, even at 
concentrations up to 20-fold their Ec50 values. In contrast, gramicidin had a very 
clear depolarising effect on membrane potential, resulting in a strong increase 
in fluorescence.     
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Figure 4.2. Effect of curcumin compounds on the fluorescence of bisoxonol in bloodstream-
form T. b. brucei. Cells (1×10
7
 /mL) were pre-incubated in an assay buffer containing 0.1 µM 
of bisoxonol at room temperature. The fluorescence was read for 160 sec before different 
compounds (at the final concentration presented in the figure) were added to the cells 
(arrow), and the fluorescence was recorded for an additional 10 min. Separate traces were 
recorded in the absence of cells and were subtracted from those presented in the figure. 
 
4.3.2 Effect of curcumin compounds on intracellular calcium level  
Intracellular Ca2+ was measured with the use of the Screen QuestTM Fluo-8 
Calcium Kit (ABD Bioquest). Fluo-8 can cross the cell membrane to bind with 
intracellular calcium, and this binding causes Fluo-8 to fluoresce. The effect of 
some curcumin compounds on intracellular Ca2+ was determined; calcium 
ionophore A23187 was used as the positive control (10 µM). Figure (4.3) shows 
that three curcumin analogues, namely, AS-HK001 (50 µM), AS-HK014 (10 µM) 
and AS-HK096 (20 µM), had no effect on intracellular calcium levels. 
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Figure 4.3. Effect of curcumin compounds on the intracellular calcium level in bloodstream-
form T. b. brucei. Parasites (4×10
6
 /mL) were loaded with Fluo-8 dye, and the fluorescence 
intensity was measured. The fluorescence was read for 120 sec before addition of the 
curcumin compound or calcium ionophore (at the final concentration presented in the 
figure) was added to the cells (see arrow), and the fluorescence was recorded for an 
additional 18 min. Separate traces were recorded in the absence of cells and were 
subtracted from those presented in the figure, in order to compensate for any innate 
fluorescence of the compounds or buffer components. 
 
4.4 Extracellular L-glutathione affects the trypanocidal 
activity AS-HK001 and AS-HK014 
    
As mentioned in the Introduction, earlier observations show that AS-HK014 but 
not AS-HK001 rapidly depletes glutathione in primary cell suspensions of fresh 
murine hepatocytes. Therefore, additional experiments on the relationship of 
glutathione with curcumin activity were conducted. The Alamar blue test was 
used to determine the EC50 of curcumin compounds with different 
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concentrations of L- Glutathione in the medium (0, 10, 100, 1000 µM). The 
experiment was exactly the same as the standard Alamar blue experiment, 
except for the different L-Glutathione content of the medium. 
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Figure 4.4. EC50 values for AS-HK001 and AS-HK014 in the presence of various 
concentrations of glutathione, as determined by Alamar blue assay on s427 WT T. b. brucei. 
The experiment was performed on three separate occasions, and the data shown are the 
average  SEM of these three experiments. 
  
Indeed, co-incubation of AS-HK014 with different concentrations of L-glutathione 
led to a gradual decrease in the activity of the drug with an increase in the 
concentration of L-glutathione. By contrast, the activity of curcumin (AS-HK001) 
did not show any change when it was co-incubated with different concentrations 
of L-glutathione (Figure 4.4). 
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4.5 Induction of T. b. brucei cell lines resistant to AS-
HK014 and to curcumin 
Two resistant cell lines were established for AS-HK001 (curcumin) and AS-HK014, 
and in the experiment; the initial media concentrations were 5 and 0.25 μM for 
AS-HK001 and AS-HK 014, respectively. The concentration was slowly increased 
over many passages until the maximum concentration at which the cells did not 
grow anymore was reached. After 11 months, the concentration of AS-HK001 
reached only 8 µM indicating an inability of T. brucei to meaningfully adapt to 
curcumin, but for AS-HK014, the concentration reached 4.5 µM (Figure 4.5). In 
addition, the results obtained from Alamar blue showed that there is no 
significant difference in EC50 between the AS-HK001-exposed clonal line and the 
‗wild-type‘ cells of T. b. brucei (s427-WT), as shown in Figure 4.6 A. By contrast, 
there were significant differences between the AS-HK014-adapted line 
(designated TA014) and the parental cells of T. b. brucei (s427-WT). The EC50 
values, which were determined using the Alamar Blue assay, were more than six-
fold higher for TA014 (3.1 μM ± 0.12) than for the parental cells, which displayed 
an EC50 value of 0.53 μM ± 0.05 as shown in Figure 4.6 B. In vitro growth rates of 
WT 427 and TA014 trypanosomes were identical (Figure 4.7). 
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Figure 4.5. Creation of the TA014 cell line. The drug concentration steadily increased for a 
period of about 11 months. 
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Figure 4.6. Average EC50 values of the clonal lines that were long-term exposed to AS-
HK001 (A) or AS-HK014 (B) compared with wild-type T. b. brucei bloodstream forms, 
determined using the Alamar blue assay. The experiment was performed on three separate 
occasions, and the data shown are the average  SEM of these three experiments. 
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Figure 4.7. Growth rates of WT 427 and TA014 trypanosomes. The cells were seeded at 5 × 
10
4
 cells/ml in fresh HMI-9 + 10% FCS. Data represents three independent experiments of 
growth for 9 days involving 4 passages at 5 × 10
4
 cells/ml.   
 
4.6 Assessment of cross-resistance between T. b. brucei-
WT and TA014 cell lines 
Alamar Blue EC50 values were obtained for the Tb427-WT and TA014 resistance 
lines. The purpose was to examine the level of resistance of the TA014 cell line 
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obtained through induction of TA014 to some curcumin analogues, and to study 
cross-resistance to current clinical trypanocides. 
 
The TA014 cell line shows significant resistance to some curcumin analogues. As 
mentioned previously, the EC50 value for AS-HK014 was 0.53 ± 0.05 µM and 3.1 ± 
0.12 µM for the Tb427-WT and TA014 cell lines, respectively, with a resistance 
factor of 5.8-fold (P<0.001) (Table 4.1). The compound AS-HK093 showed an EC50 
value that increased from 0.56 ± 0.02 µM to 1.45 ± 0.04 µM in the TA014 line 
(P<0.001), which represents a 2.6-fold increase; AS-HK097 and AS-HK096 
demonstrated about 2.5-fold resistance (P<0.001 for both; AS-HK018 also showed 
a 2.3-fold increase in resistance from 1.79 ± 0.08 µM to 4.19 ± 0.39 µM in EC50 in 
the TA014 line (P<0.01). 
 
No significant cross-resistance was demonstrated by the resistance line TA014 to 
any of the trypanocide chemotherapies used in the present study. Furthermore, 
for other curcumin compounds, there was also no significant cross-resistance 
(Table 4.1). Indeed, this very clear indicator that significant cross-resistance was 
only for curcumin analogues with a mono-enone linker as mention below.  
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Compound Tb427-WT 
EC50 (µM)  
TA014 EC50 
(µM) 
Resistance 
Factor  
P-values 
(different from 
Tb427-WT) 
AS-HK001 8.24 ± 0.97 8.78 ± 0.43 1.06 NS 
AS-HK014 0.53 ±0.05 3.1 ± 0.12 5.85 P < 0.001 
AS-HK015 15.07 ± 0.49 16.3 ± 0.9 1.08 NS 
AS-HK016 0.65 ± 0.02 0.53 ± 0.04 0.81 NS 
AS-HK017 1.34 ± 0.05 1.3 ± 0.02 0.97 NS 
AS-HK018 1.79 ± 0.08 4.19 ± 0.39 2.34 P < 0.01 
AS-HK028 1.15 ± 0.07 1.08 ± 0.02 0.94 NS 
AS-HK033 3.19 ± 0.02 2.94 ± 0.22 0.92 NS 
AS-HK034 7.24 ± 0.4 8.82 ± 0.94 1.2 NS 
AS-HK073 1.45 ± 0.11 1.59 ± 0.1 1.1 NS 
AS-HK085 5.24 ± 0.27 4.72 ± 0.35 0.9 NS 
AS-HK093 0.562 ± 0.02 1.45 ± 0.04 2.6 P < 0.001 
AS-HK096 1.48 ± 0.06 3.74 ± 0.02 2.5 P < 0.001 
AS-HK097 1.29 ± 0.01 3.34 ± 0.06 2.6 P < 0.001 
AS-HK118 2.57 ± 0.11 2.54 ± 0.03 1 NS 
AS-HK131 1.67 ± 0.09 1.54 ± 0.08 0.92 NS 
Diminazene 0.13 ± 0.03 0.15 ± 0.04 1.15 NS 
Pentamidine 0.005 ± 0.001 0.003 ± 0.001 0.6 NS 
Eflornithine 39.5 ± 3.76 43.17 ± 3.64 1.1 NS 
Nifurtimox 9.27 ± 1.09 7.21 ± 1.38 0.78 NS 
Suramin 0.025 ± 0.005 0.036 ± 0.006 1.44 NS 
Table 4.1. Average EC50 values of some curcumin compounds and trypanocides as 
determined by Alamar Blue assay in bloodstream-form Tb427-WT and TA014. Also shown is 
the resistance factor which is the ratio EC50 TA014 / EC50 WT. The values are averages ± 
SEM of three independent experiments, and statistical significance was calculated with the 
use of paired student’s t-test (NS= not significant). 
 
4.7 Resistance profile of the ASHK014-adapted line 
TA014 and effect of L-glutathione on resistance 
As mentioned in Section 4.4, Alamar Blue test was again used to determine the 
EC50 of AS-HK014 compounds with different concentrations of L- Glutathione in 
the medium for the s427 WT T. b. brucei and TA014 resistance lines. 
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Figure 4.8. EC50 values for curcumin AS-HK014 with various concentrations of glutathione, 
as determined by Alamar Blue assay for the s427 WT T. b. brucei and TA014 resistance 
lines. The experiment was performed on three separate occasions, and the data shown are 
the average  SEM of these three experiments. P-values are significant different with control 
(0 µM of L-glutathione), * P<0.05, ** P<0.01, *** P<0.001. 
   
The results in Figure 4.8 show that although there was a clear effect of L-
glutathione on the EC50 of T. b. brucei –WT, the same was not the case on the 
EC50 of the TA014 resistance line. Indeed, the EC50 increased with an increase in 
the L-Glutathione concentration for T. b. brucei –WT from 0.55 ± 0.03 µM at 0 
µM of L-Glutathione to 3.21 ± 0.12 µM at 1000 µM of L-Glutathione (P<0.001). In 
contrast, the EC50 was not significantly different with different concentrations of 
L-glutathione for the TA014 line, indicating that the residual effect of AS-HK014 
in the resistant line might not be due to the same glutathione-sensitive 
mechanism. 
 
4.8 AS-HK014 makes a chemical adduct with glutathione  
To determine whether curcumin AS-HK014 reacts with glutathione to form an 
adduct, Apichart Suksamrarn (Department of Chemistry, Ramkhamhaeng 
University, Thailand) conducted the reaction in his laboratory. Added to the 
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phosphate buffer (1.5 mL, pH 7.4), which contained 130 mg (0.42 mmol) of 
glutathione, was 130 mg (0.37 mmol) of AS-HK014 in 3 mL ethanol. The reaction 
was stirred at ambient temperature (30 ºC – 32 ºC), and the reaction was 
observed by thin layer chromatography. The plate was developed using an 
anisaldehyde reagent, followed by heating on a hot plate in order to visualise 
spots. The adduct 2 (Figure 4.9) was detected in the 15 min sample.   
 
Figure 4.9. Chemical reaction between curcumin AS-HK014 and glutathione (performed by 
Apichart Suksamrarn). 1: AS-HK014 and 2: adduct. 
 
 
4.9 Metabolomic assessment of ASHK014 action on T. b. 
brucei  
The initial experiments with glutathione presented in this chapter show that 
that glutathione may play an important role in the mode of action of curcumin 
AS-HK014. Therefore, glutathione and trypanothione metabolism was examined 
further to determine the effect of AS-HK014 on T. b. brucei –WT and TA014 
resistance lines. 
 
4.9.1 Experimental design     
A fairly extensive investigation of how fast these compounds act on cell 
proliferation and cell survival is necessary to design and interpret experiments 
on their mode of action. Measurements of cellular parameters must be taken at 
appropriate time points after incubation with appropriate concentrations of 
compounds. First, as mentioned previously, the EC50 values for both cell lines 
are about 0.5 and 3 µM for T. b. brucei–WT and resistance line TA014, 
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respectively. Second, the growth curve was determined at different 
concentrations of AS-HK014 (0, 0.5 and 1 µM) for both strains.    
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Figure 4.10. Effect of different concentrations of AS-HK014 on the growth curve of 
bloodstream form T. brucei brucei WT and TA014 resistance lines. The results shown are 
the average of three independent determinations; error bars depict standard errors. 
 
 
Cell density was adjusted to the desired concentration (which was 1×105 
cells/mL in this experiment). The cell count was taken in triplicate at 0, 4, 8, 12 
and 24 h for each concentration. From Figure 4.10, the AS-HK014 compound 
clearly showed an effect on the cell survival of T. b. brucei–WT at 0.5 µM, and 
the growth curve was steady for 24 h, whereas no growth was observed at 1 µM 
after 4 h. For the TA014 resistance line, there was no effect for AS-HK014 at 0.5 
and 1 µM at 24 h, and there was no significant difference between these 
concentrations and the drug-free control.  
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Figure 4.11. Dose response curve of the AS-HK014 compound for bloodstream-form T. b. 
brucei and TA014 resistance line. The different concentrations were incubated with and 
without parasites in HMI-9 medium which has 10% FCS at 37 ºC with 5% CO2. The drug was 
tested at 50 µM (a), 25 µM (b), 6.25 µM (c), 1.56 µM (d), 0.78 µM (e), 0.39 µM (f), 0.19 µM (g) 
and drug free (h) conditions. Propidium iodide was added at 9 µM, and the fluorescence was 
measurement over 8 h at 544 nm excitation and 620 nm emission. Separate traces were 
recorded in the absence of cells and were subtracted from those presented in the figures. 
 
 
Finally, monitoring the speed of action of the test compound on trypanosomes in 
real time is important. Cells become fluorescent as propidium iodide enters the 
cells and binds to nucleic acids. This binding occurs only upon breach of the 
plasma membrane, i.e. loss of cellular integrity. AS-HK014 rapidly killed WT 
trypanosomes at concentrations >1.56 M (approximately 30 min). At 0.78 µM 
the cells started to die after 60 min. By contrast, for the TA014 strain, the 
compound killed the cells after 2 h at concentrations > 25 M (Figure 4.11). 
Consequently, according to previous results on cellular parameters, 0.75 µM of 
the AS-H014 compounds was selected for further mechanism of action studies in 
both cell lines at an incubation time of 30 min.  
 
4.9.2 Metabolism of curcumin AS-HK014 in trypanosome: 
possible reactions with glutathione 
This section utilises untargeted metabolomics to assess the impact of AS-HK014 
treatment on trypanosomes. In untargeted metabolomics there is no a priori 
assumption on a mechanism of action and the entire metabolome is analysed to 
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the limit of the technology. We directly compared metabolic changes between 
WT and TA014 of trypanosomes. It was immediately obvious from a global 
overview of most-changed metabolites that AS-HK014 impacted particularly on 
intracellular thiol levels (Figure 4.12), with trypanothione content down by >99% 
and glutathione and S-glutathionyl-L-cysteine levels reduced by >90% in AS-
HK014-treated WT cells. In the subsequent metabolomic analyses described 
below the cellular levels of the relevant thiols (cysteine, glutathione and 
trypanothione) were determined by a modification of the monobromobimane 
method (Fahey & Newton, 1983;Fairlamb et al., 1987). This method can 
derivatise intracellular sulfhydryls, to prevent their oxidation and allow 
detection of both oxidised and reduced forms of intracellular thiols. 
 
 
 
Figure 4.12. Relative abundance of 915 putative metabolites from cells treated with ASHK-
014 relative to untreated cells. Untargeted metabolomics was conducted with LC-MS , 
metabolite abundance is measured by raw peak height and putative identification was 
based on accurate mass. Metabolites are grouped by metabolic pathways where red = 
amino acid metabolism, blue = carbohydrate metabolism, green = lipid metabolism, orange 
= metabolism of cofactors and vitamins , purple = nucleotide metabolism, black = peptides 
and brown = unknown pathways. 
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The relevant pathway (depicted in Fig 4.13) starts with the biosynthesis of 
glutathione from three amino acids: cysteine, glutamate and glycine. Two 
molecules of glutathione are then coupled consecutively to spermidine to form 
trypanothione, the main trypanosomal thiol.  
 
Figure 4.13. Trypanothione pathway. 1- Gamma glutamylcysteine synthetase, 2- 
Gluthathione synthetase, 3- Trypanothione synthetase 
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In WT trypanosomes, treatment with just 0.75 µM of AS-HK014 for 30 min led to 
very clear reductions in thiol levels (Figure 4.14). Trypanothione levels, both in 
reduced form (detected as di-monobromobimane adduct (di-mBBr)) and as 
disulfide, were dramatically reduced under these conditions (to 12 ± 3% (P<0.01) 
and 6 ± 2% (P<0.001), respectively). Similar reductions in glutathione mBBr 
(P<0.01), S-glutathionyl-L-cysteine (P<0.02) and glutathionylspermidine mBBr 
(P<0.01) were also observed, opening the strong possibility that biosynthesis of 
trypanothione was inhibited due to a depletion of glutathione. Further 
upstream, there was a slight but significant (P<0.05) reduction in levels of L-
cysteine mBBr and of glycine, but there was no change in glutamate levels 
(Figure 4.14). All three of these amino acids are present at high levels in the 
HMI-9 culture medium so any changes might be difficult to unearth with the 
conditions used. In addition, the pathway leading up to spermidine (Figure 
4.15)was analysed. There was no change in spermidine levels upon treatment 
with AS-HK014, nor in any of the metabolites of its biosynthesis pathway: 
ornithine, S-adenosyl methionine and putrescine (Figure 4.14). Furthermore, 
there was no significant change in the level of 5'-methylthioadenosine (data not 
shown), the reaction product after the aminopropyl donation by S-AdoMet in the 
synthesis of spermidine. 
The above shows that the only metabolomic perturbations upon incubation with 
AS-HK014 were the dramatically reduced levels of thiols, whereas the 
constituent metabolites in their biosynthetic pathways displayed at most very 
minor changes. This contrasts with treatment of the same trypanosome strain 
with the inhibitor of ornithyl decarboxylase, eflornithine, which resulted in rapid 
changes in intracellular levels of putrescine, ornithine (and both of their 
acetylated forms) and 5‘-thioadenosine metabolites (Vincent et al., 2012). 
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Figure 4.14. Metabolomic analysis of the AS-HK014 compound in the T. b. brucei-WT and TA014 resistance line cell extracts. For each cell sample, 25 mL of 
cell culture (2 ×10
6
 cells/mL) was incubated for 30 min at 37 ºC with and without AS-HK014 (0.75 µM) for both strains. *P<0.05, **P<0.02, ***P<0.01, ****P<0.001. 
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Figure 4.15. Spermidine pathway, 1- Ornithine decarboxylase, 2- S-adenosylmethionine 
decarboxylase, 3- Spermidine synthase. 
 
 
One explanation for the rapid depletion of thiols would be the reaction with AS-
HK014 to form a stable adduct. This type of mechanism has been proposed for 
melarsoprol which forms the trypanothione adduct MelT (Fairlamb et al., 1989), 
which in turn inhibits trypanothione reductase (Cunningham et al., 1994). MelT 
can be exported from the cells by ABC transporters (Shahi et al., 2002), 
although, unlike ASHK-014, melarsoprol treatment does not significantly 
decrease cellular trypanothione concentration (Fairlamb et al., 1992), 
presumably because it is used at a much lower concentration than AS-HK014. 
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Stable adducts were indeed found in AS-HK014-exposed trypanosomes, both with 
trypanothione and glutathione (Figure 4.16). However, the adducts were 
observed not only  in cells exposed to AS-HK014 for the ‗standard‘ 30 min at 37 
°C, but also when AS-HK014 was added after 30 min drug-free incubation, after 
the cells had been rapidly cooled to 4 °C in a dry-ice/ethanol bath; these cells 
were then immediately processed for metabolite extraction (quenched cells). 
Indeed, the levels of adduct were almost identical in the incubated and in the 
quenched cells, showing clearly that the AS-HK014 reaction with thiols is a rapid 
chemical reaction with free thiols, rather than an enzymatic reaction.  
Thus, we conclude that AS-HK014 undergoes a rapid chemical reaction with 
reactive intracellular thiols, particularly glutathione and trypanothione, 
effectively depleting these essential thiols and leading to cell death. It is 
possible that the compound furthermore reacts with additional thiols, perhaps in 
proteins, leading to irreversible inhibition of the function of these proteins. As 
curcuminoids are most likely able to efficiently diffuse into the cells (AS-HK014 
has a cLogP of 3.84; ChemDraw Pro 10.0, CambridgeSoft), it is highly likely that 
uptake is driven by the reaction and continues until thiol content is effectively 
depleted. It might thus be expected that the ASHK-014 adducts would 
accumulate to a very high level. To the contrary, adduct levels were not greater 
than those obtained from unexposed, quenched cells (Figure 4.16), which did 
not exhibit significant thiol depletion (data not shown). This suggests that the 
adducts may undergo metabolic degradation, or be released from the cell 
through ABC transporters, much like the trypanothione-melarsoprol adduct MelT. 
The metabolomics data does not provide any direct evidence for either pathway, 
as no novel metabolite signals were specifically enriched in cells exposed to drug 
for 30 minutes, and no adduct peaks were detected in the spent medium. 
However, it is possible that the latter metabolites fall below the limit of 
detection after dilution in the extracellular medium. As an alternative to thiol 
depletion directly by chemical reaction with AS-HK014, the depletion could be 
explained by inhibition of glutathione synthesis, but it is unlikely that this 
mechanism would cause such as dramatic effect on the total thiol pool within 30 
minutes.  
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Figure 4.16. Adduct levels of Trypanothione and Glutathione, *P<0.05, **P<0.02 
 
The entire metabolomic analysis was performed in parallel with the AS-HK014-
resistant line TA014 as well. The same trend on thiol levels as in WT T. b. brucei 
was apparent (Figure 4.14), but none of the reductions in thiol concentrations 
reached significance under the assay conditions of 0.75 µM for 30 minutes - 
consistent with the lack of impact that this concentration has on the TA014 
cells. More interesting was that the levels of thiols, polyamines, relevant amino 
acids and 5‘-thioadenosine metabolites were all statistically identical in 
unexposed WT, unexposed TA014 and AS-HK014 exposed TA014 cells (Figure 
4.14). This shows that the resistance adaptation was not the result of 
significantly higher cellular levels of trypanothione and/or glutathione. Nor was 
AS-HK014 prevented from entering the cells (loss of import transporter or 
expression of export transporter), as AS-HK014 (detected intact or as a C10H10O2 
MS-generated fragment) levels were equivalent in both wild-type and resistant 
cells (Figure 4.17). Furthermore, much higher levels of glutathione (P<0.05) and 
trypanothione (P<0.02) adducts were found in AS-HK014 exposed TA014 cells 
than in WT trypanosomes (Figure 4.16), possibly reflecting the higher thiol levels 
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present in the exposed TA014 cells. This observation provides strong 
confirmation that it is not the adduct that is deleterious to the cells and is 
consistent with the diffusion model of AS-HK014 uptake. Yet, in the resistant 
cells, the thiol depletion is minimal, indicating an increased synthetic capacity 
that allows the cells to maintain their glutathione and trypanothione levels in 
the presence of the drug.  
 
Figure 4.17. Levels of AS-HK014 in WT s427 and TA014 trypanosomes as determined in a 
metabolomic experiment performed without mBBr treatment. Incubation was with 0.75 µM 
AS-HK014 for 30 minutes at 37 °C. Data shown are the average of triplicate determinations 
within a single experiment. Error bars are Standard Errors. There were no significant 
differences between the cell lines (P>0.05). Experiments analysed after extraction in the 
presence of mBBr showed essentially similar results but with much lower relative 
intensities (not shown). 
 
4.10 Analysis of the protein expression levels of 
glutathione synthetase and γ-glutamylcysteine 
synthetase in wild-type and TA014 trypanosomes 
The metabolomic analysis to determine the effect of AS-HK014 on two strains of 
trypanosomes as described in Section 4.9.2 showed a clear difference in 
glutathione and trypanothione levels between the strains and presented a 
possible explanation for this difference. Two enzymes are involved in 
glutathione synthesis: γ-glutamylcysteine synthetase (γ-GCS) and glutathione 
synthetase (GS). Therefore, western blotting was used to analyse the protein 
expression of these two enzymes. Primary antibody (either with rabbit 
polyclonal anti-gamma GCS antibody or with rabbit polyclonal anti-GS; both 
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antibodies were obtained from Professor Margaret Phillips, University of Texas 
Southwestern Medical Center) was used to measure the protein expression level. 
For both strains, 1×106 cells/mL were treated with 0.75 µM of AS-HK014 for 30 
min, with untreated cells incubated in parallel serving as controls, and their 
extracts were used to run the gel and subsequent western blot. The results 
showed that there was no difference between the treated and the untreated 
cells, and the level of expression was almost the same in both strains for both 
enzymes (Figure 4.18). 
 
    
Figure 4.18. Western blot of the T. b. brucei-WT and TA014 resistance lines at 1x10
6
 
cells/mL. The cells were incubated for 30 min in the presence or absence of 0.75 µM of AS-
HK014 and. Two antibodies were used for both strains: γ-GCS and GS. (1) T. b. b. WT, drug 
free, (2) T. b. b. WT + AS-HK014, (3) TA014, drug free, (4) TA014 + AS-HK014. 
  
 
4.11 Identification of Tb427.10.12370 and Tb427.07.4000 
genes   
As mentioned previously, two genes are involved in glutathione synthesis: 
Tb427.10.12370 (γ-GCS) and Tb427.07.4000 (GS). Although the protein level of 
γ-GCS and GS was shown not to be different in WT and TA014 trypanosomes 
(Section 4.10) the possibility of functional mutations in the coding regions of the 
genes also needed to be explored as an explanation for the difference in 
AS0HK014 sensitivity. The amplificatrion and cloning of these genes from WT and 
TA014 strains, and their sequence analysis, is reported in this section. 
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4.11.1 Polymerase chain reaction 
Polymerase chain reaction (PCR) was used to verify the presence of both genes 
in trypanosome wild-type and resistance lines. Forward and reverse PCR primers 
were designed, and Go Taq polymerase was used as described in Chapter 2. PCR 
products were run on 1% agarose gel to observe the PCR products (Figure 4.19). 
Bands of the expected size were amplified from both strains.      
 
 
Figure 4.19. PCR amplification of G1 (γ-GCS) and G2 (GS) for both strains of bloodstream-
form T. b. b. WT and TA014 resistance line, NG: negative control which consists of all PCR 
components except genomic DNA.     
 
 
4.11.2 Sequence analysis  
As mentioned in Chapter 2, several steps must be performed before sending the 
plasmid DNA of multiple bacterial colonies for sequencing, namely, PCR, 
extraction of gel, A-overhang of PCR product, ligation into the pGEM-TEasy 
Vector, transformation of competent Escherichia coli and purification of plasmid 
DNA from individual E. coli colonies. For the analysis of the γ-GCS and GS ORFs, 
band of the correct size, from three independent PCR reactions, were extracted 
from their gels, cloned in to pGEM-TEasy and amplified in E. coli. For each gene, 
nine colonies were sent for sequencing. The data received from Eurofins was 
analysed using CLC Genomics Workbench 4.8 software to form the full open 
reading frame (ORF) for both genes in both strains. 
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The sequencing for γ-GCS from the wild-type and TA014 strains  (see Appendix F 
& E) were not very different from each other, with the differences found in 
TA014 following the treatments found also in the wild-type strain. One notable 
difference was that at base-pair 187 of the ORF the base was Adenine in four out 
of nine colonies in both cell lines, and Guanine in the other five colonies.  
For GC, also there were only two notable changes. First, at base-pair 1568 of the 
ORF, seven out of nine colonies in the TA014 had a Cytosine while the other two 
have Adenine, whereas only one out of nine colonies had Cytosine in the wild-
type. Second, at the same at base-pair 931, four out nine colonies in the TA014 
had Cytosine and the others Adenine, while only one had Cytosine in the wild-
type.            
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4.1    Discussion 
The potential mechanism of action of curcumin analogues is explored in this 
study. As mentioned in the Introduction (Section 4.1), curcumin analogues are 
used against T. b. brucei bloodstream form (Changtam, 2010), some of which 
have potent antiparasitic activity and low toxicity, such as AS-HK014 (mono-
enone linker). An early study by my colleague Hasan Ibrahim (Ibrahim, 2009) 
investigated  the mechanism of action of curcumin compounds and did not 
confirm specific effects: for example, there was no effect on cell cycle, 
mitochondrial membrane potential or levels of reactive oxygen species for the T. 
b. brucei bloodstream form. 
Curcumin analogues have rapid effects on parasite cells, so cellular parameters 
were investigated to elucidate the mechanism of action of curcumin compounds 
on T. b. brucei bloodstream form. We found no effects on signal transduction 
(intracellular calcium, cAMP, membrane potential) for curcumin compound or 
AS-HK014. 
On the other hand, in early work also by Ibrahim, toxicological and 
pharmacological results on glutathione (GSH) content in rat hepatocytes treated 
with different curcumin compounds showed no significant effect of curcumin and 
its close analogue AS-HK009, whereas there was a significantly reduced GSH 
content when treated with the enone AS-HK014. This result indicates that AS-
HK014 leads to a depletion of GSH. Furthermore, it was observed that co-
incubation of curcumin and AS-HK014 compounds with different concentrations 
of L-glutathione led to decreased activity of AS-HK014 (Figure 4.4), while no 
change in the activity of curcumin compound was observed. It was shown that 
AS-HK014 but not curcumin reacts with glutathione to form an adduct in a 
chemical, non-enzymatic reaction. 
As part of the effort to understand the mechanism of action, trypanosome 
cultures were long-term exposed to increasing concentrations of curcumin or AS-
HK014 in order to induce resistance. After 11 months of exposure, a resistant 
line was obtained for AS-HK014, but not for curcumin (Figure 4.6). In view of the 
chemical structure for both compounds, the di-keto linker of curcumin (AS-
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HK001) is fairly unreactive, making the compound quite stable in a biological 
environment. In contrast, the mono-enone linker of AS-HK014 is much more 
reactive, and indeed was shown to be instrumental in forming the adduct with 
glutathione, making it highly likely that this group is responsible for the much 
higher activity of this compound, compared to curcumin, and by a different 
mechanism of action from that of AS-HK001. For the purpose of this thesis, 
resistance is used as a statistically significant reduction in vitro susceptibility to 
the drug under investigation. However, a more useful definition would be that 
resistance is the lack of effect of a clinical dosage of treatment on the pathogen 
in vivo, due to genetic adaptations by the pathogen.  
The study of cross-resistance for TA014 resistance lines with different curcumin 
analogues and trypanosomiasis chemotherapies appeared to show that although 
the TA014 line did not display cross-resistance with different trypanosomiasis 
chemotherapies such as pentamidine, suramin and nifurtimox, there was a 
significant loss of sensitivity for some curcumin compounds. Specifically, there 
was cross-resistance for curcumin analogues with a mono-enone linker such as 
AS-HK018, AS-HK093, AS-HK096 and AS-HK097 (Table 4.1). Certainly, this seems 
to show that the TA014 resistance line is resistant to the mono-enone moiety, 
and also confirm that this linker has responsibility for drug activity. Additionally, 
repeat testing for the activity of AS-HK014 on wild-type and TA014 resistance 
line cells with the inclusion of glutathione in the growth medium led, as 
mentioned, to a drop of EC50 of AS-HK014 in wild-type cells, but glutathione 
caused no significant change  in AS-HK014 sensitivity for resistant line TA014 
(Figure 4.8). 
These data led to the testing of the effect of the AS-HK014 compound on the 
metabolome of wild-type and resistant cell lines. Parasites incubated with 0.75 
µM for 30 minutes contained a much-reduced level of glutathione, trypanothione 
and trypanothione disulfide for the wild-type (7, 9 and 17-fold respectively) but 
no significant changes in thiol levels were observed in resistant cells. That 
appears to support our hypothesis that AS-HK014 reacts with glutathione to form 
an adduct and cause depletion of GSH. This situation is reminiscent of the report 
by  Yarlett et al (Yarlett et al., 1991), which describes how arsenicals rapidly 
deplete Trypanosoma brucei rhodesiense of trypanothione, but not in resistant 
lines during 30 minutes of incubation time. This result was confirmed (Section 
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4.8) when curcumin AS-HK014 was found to produce a chemical adduct with 
glutathione, both as a controlled reaction in ethanol, or under standard culture 
conditions and in the presence of WT T. b. brucei. Moreover, it has been 
reported that glutathione can form adducts with a number of other compounds 
(Kang et al., 2007;Naylor et al., 1988;Stock et al., 1986). 
To study the adaptation change which led to resistance, analysis of protein 
expression and sequence analysis was performed for Tb427 WT and resistant 
lines to identify any change in the activity of the two genes (γ-GCS and GC). 
Analysis of glutathione synthetase (GS) and γ-glutamylcysteine synthetase 
(γGCS) protein levels by Western blot showed no change in resistant 
trypanosomes, in the presence or absence of drug challenge. Neither were 
mutations found in the GS and γGCS open reading frames. This is consistent with 
the absence of any significant changes in thiols or glutathione biosynthesis 
metabolites between unchallenged WT and TA014 trypanosome cultures. 
The nature of reduced AS-HK014 susceptibility in TA014 was clearly linked to the 
prevention of thiol depletion, as the same 30 minute exposure had only minor 
effects (not significant) on cellular thiol levels. However, no detectable increase 
in γ-GCS or GS expression was detected using Western blotting, nor were any 
potentially activating mutations found in these enzymes, and no increases were 
found in steady state levels of relevant metabolites in TA014 cells. This seems to 
rule out any significant increase in trypanothione production as the resistance 
mechanism. Furthermore, the same level of a fragment of AS-HK014 was 
detected in the metabolome of WT and TA014 strains, giving no indication of 
reduced uptake. Nor have we found clear evidence of segregation of AS-HK014 in 
the resistant cells, as the level of AS-HK014 adduct with trypanothione and with 
glutathione was 8.5 and 4-fold higher in resistant cells, probably reflecting the 
high thiol levels in these cells as compared to similarly exposed WT cells. It 
therefore remains unclear by which mechanism the TA014 trypanosomes prevent 
the rapids depletion of thiols. 
It can be concluded that AS-HK014 forms an adduct with glutathione and 
trypanothione which leads AS-HK014 to rapid depletion of trypanothione in 
trypanosomes, and that this does not happen in resistant T. brucei. The rapid 
death of trypanosomes exposed to AS-HK014 correlates with thiol depletion, 
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which is a different mechanism of action from that of the parent compound 
curcumin. 
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5 CHAPTER Five: Phosphonium salts compounds 
as novel trypanocidel agents 
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5.1 Introduction 
In 1979, Kinnamon (Kinnamon et al., 1979) reported the potent 
antitrypanosomal activity of benzyltriphenylphosphonium salts against T. brucei, 
and mentioned that a few of these compounds were usable in the murine model 
of T. b. rhodesiense infection. Despite this major discovery, for the past 30 
years, further evaluation of the phosphonium salts with regard to their 
antiprotozoal properties has been discontinued both due to lack of experience 
and scarcity of information and guidance on this topic.  
Recently, the salt derivatives of benzophenone-derived bisphosphonium have 
been synthesised, which has reopened the research on phosphonium salts having 
anti parasitic properties. The benzophenone-derived bisphosphonium salt 
derivatives produced a strong antileishmanial activity in vitro (Luque-Ortega et 
al., 2010). The most potent activity against Leishmania spp was found to be 
exhinited by 4,4‘-bis((tri-n-pentylphosphonium) methyl) 
benzophenonedibromide). This compound inhibited complex II of the 
mitochondrial respiratory chain.  
 
 
 
As some of the anti-leishmanial compounds also displayed promising trypanocidal 
activity (Dardonville & Brun, 2004) 60 new variable phosphonium derivatives 
were prepared in order to systematically examine the structure-activity 
relationship for Trypanosoma spp. This investigation included variations in (a) 
linker type, (b) linker length, (c) number of cations, (d) nature of the 
counterion, and (e) nature of the phosphonium groups substituents R1, R2, R3 
(Chart 1). 
O
P+
C5H11
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C5H11
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Figure 5.1. General structure of benzophenone-derived bisphosphonium salt derivatives 
with antileishmanial and antitrypanosomal activity (Luque-Ortega et al., 2010) and the new 
series being studied (Chart reproduced from Taladriz et al., 2012). 
 
The following parameters were obtained for these compounds: (1) EC50 value 
against T. b. brucei; (2) assessment of cross-resistance with current 
trypanocides; (3) toxicity to human cells; (4) dynamics of trypanosomal action 
(trypanocidal or trypanostatic); (5) speed of the effects on trypanosomal 
proliferation and viability; and (6) minimum time of exposure. Finally, an 
analysis of the structure activity relationship (SAR) was performed. 
Much of the content of this chapter has already been published as (Taladriz et 
al., 2012).  
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5.2 Assessment of the activity of phosphonium 
compounds on wild-type and multi-drug resistant 
trypanosome lines; determination of in vitro 
therapeutic index    
The antiparasitic effects of phosphonium analogues were investigated using the 
in vitro Alamar blue viability assay. In addition, resistant strains were used as a 
model to investigate the cross-resistance between the existing treatments and 
potential new trypanocides. Any new trypanocidal drugs to be developed, 
whether for human or veterinary use, should at a minimum not be cross-resistant 
with the current diamidine and arsenic-based drugs. The toxic effect of 
phosphonium compounds on HEK cells was evaluated using Alamar blue to 
determine the level of toxicity to human cells. 
5.2.1  In vitro activity on T. b. brucei bloodstream form 
83 compounds were obtained from Dr Christophe Dardonville (Instituto de 
Química Médica, Madrid, Spain) and tested for their effect on the Trypanosoma 
brucei brucei bloodstream form using the Alamar blue method (Raz et al., 1997). 
All experiments were performed at least three times for each compound, 
including two positive controls, pentamidine and diminazene, plus drug-free 
incubations as negative controls in each experiment. Fluorescence intensity was 
plotted to a sigmoid curve equation using GraphPad Prism 4 software to plot the 
data and to determine the EC50 values. 
The Alamar Blue results demonstrated a strong trypanocidal activity of the 
phosphonium compounds against the wild-type s427 bloodstream forms, and the 
majority of these compounds displayed an EC50 of less than 1 μM. In addition, 19 
of 83 compounds displayed EC50 values <100 nM. Among the bisphosphonium 
compounds the most potent activity was displayed by AHI17 and EFpI27, with 
EC50 values of 24 and 29 nM, respectively. However, some monophosphonium 
compounds displayed even higher levels of activity, with AT31 and AT33 
displaying EC50 values of 11 and 15 nM, respectively. Moreover, 22 compounds 
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were more active than the standard veterinary drug diminazene, showing that 
this class of compounds has highly promising anti-protozoal activity (Table 5.1).   
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Compound WT-s427 
EC50 (µM) 
TbAT1-KO 
EC50  (µM) 
Resistance 
Factor –KO 
TbAT1-B48 
EC50  (µM) 
Resistance 
Factor –B48 
HEK cells EC50  
(µM) 
Selectivity Index 
CD38 0.204±0.005 0.17±0.01 0.83 0.18±0.01 0.87 68.7±4.9 336 
CDIV20 0.24±0.07 0.36±0.07 1.51 0.38±0.06 1.59 >300 >1250 
CDIV22 >100 >100 ND >100 ND ND ND 
CDIV23 19.7±4.1 27.15±3.8 1.38 31.3±4.1 1.6 ND ND 
CDIV24 20.5±5.2 33.4±6.2 1.63 38.8±6.4 1.9 ND ND 
CDIV25 2.62±0.7 8.34±3.08 3.18 6.30±1.4 2.4 >300 >114.5 
CDIV26 8.6±2.14 17.75±2.03 2.07 15.17±3.7 1.7 >300 >34.9 
CDIV27 0.70±0.24 1.43±0.41 2.03 1.33±0.26 1.9 >300 >428.5 
CDIV28 1.53±0.38 2.08±0.63 1.36 2.05±0.38 1.34 >300 >196 
CDIV29 19.17±7.17 28.77±5.62 1.50 24.55±4.8 1.3 ND ND 
CDIV31 >100 >100 ND >100 ND ND ND 
CDIV33 0.14±0.03 0.23±0.05 1.63 0.25±0.04 1.8 >300 >2142 
CDIV34 0.97±0.27 2.10±0.54 2.16 1.76±0.3 1.8 >300 >309 
CDIV35 0.48±0.11 1.32±0.46 2.73 1.63±0.46 3.4 >300 >625 
CDIV48 0.042±0.002 0.06±0.001 1.44 0.045±0.001 1 26.7±1.52 637 
CDIV49 36.9±1.2 33.8±1.2 0.92 21.7±1.2 0.6 ND ND 
CDIV50 0.20±0.01 0.24±0.03 1.22 0.22±0.02 1.13 213.2±8.6 1065 
CDIV52 0.18±0.002 0.18±0.01 1.01 0.18±0.00 1 272±33 1511 
CDIV53 0.24±0.03 0.26±0.04 1.11 0.29±0.03 1.25 >300 >1250 
CDIV57 0.33±0.10 0.52±0.03 1.57 0.32±0.09 0.96 273.03±34.7 827 
AHI04 7.22±0.15 6.5±0.4 0.9 6.15±0.9 0.85 >300 >41 
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AHI05 5.45±1.09 4.6±0.8 0.84 3.84±1.2 0.7 >300 >55 
AHI07 0.59±0.06 0.8±0.10 1.35 1.06±0.34 1.8 >300 >508 
AHI08 0.7±0.03 0.88±0.10 1.26 0.88±0.06 1.26 >300 >430 
AHI09 0.082±0.01 0.08±0.00 0.94 0.064±0.01 0.77 239.4±8.62 >2900 
AHI10 0.24±0.04 0.19±0.03 0.80 0.18±0.02 0.75 >300 >1250 
AHI15 0.037±0.004 0.045±0.005 1.21 0.04±0.002 1.1 21.87±0.87 590 
AHI16 0.033±0.006 0.033±0.005 1 0.04±0.002 1.2 18.09±2.6 550 
AHI17 0.024±0.005 0.025±0.004 1.04 0.02±0.001 0.87 85.2±6.62 3550 
AHI18 0.08±0.002 0.08±0.003 1.0 0.074±0.001 0.9 231.57±14 2900 
AHI19 0.16±0.011 0.14±0.01 0.88 0.13±0.002 0.8 112.7±15 710 
AHI20 0.135±0.017 0.17±0.04 1.26 0.14±0.014 1 161.5±17.4 1200 
AHI21 0.056±0.011 0.057±0.008 1.01 0.045±0.004 0.8 140.1±6 2500 
AHI22 0.080±0.004 0.074±0.003 0.92 0.066±0.002 0.8 203±13.5 2530 
AHI30 0.23±0.014 0.25±0.002 1.11 0.27±0.008 1.2 >300 >1310 
AHI40 16.65±0.5 13.57±2.22 0.81 13.3±1.55 0.8 ND ND 
AHI43 0.322±0.012 0.30±0.009 0.94 0.3±0.009 0.9 >300 >930 
EFpl1 0.29±0.06 0.41±0.01 1.4 0.31±0.04 1.1 >300 >1040 
EFpl2 1.08±0.21 1.37±0.02 1.26 1.08±0.19 1 63.18±7.66 58.5 
EFpl3 0.856±0.30 2.10±0.03 2.47 1.16±0.22 1.35 >300 >350 
EFpl4 0.35±0.12 0.52±0.02 1.5 0.27±0.07 0.8 172.27±6.9 493 
EFl11 0.128±0.03 0.16±0.01 1.25 0.09±0.028 0.7 131.27±16.94 1025 
EFpl6 0.286±0.06 0.32±0.02 1.14 0.207±0.074 0.7 106.65±16.05 372 
EFpl7 0.106±0.04 0.18±0.01 1.7 0.093±0.041 0.9 141±9.33 1330 
EFpl8 0.916±0.18 1.02±0.02 1.13 1.26±0.3 1.3 >300 >327 
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EFpl10 0.197±0.07 0.34±0.00 1.8 0.19±0.068 1 91.47±4.57 464.3 
EFpI27 0.029 ± 0.005 0.049 ± 0.007 1.7 0.053 ± 0.003 1.8 25.8 ± 1.7 897 
EFpI28 0.15 ± 0.06 0.15 ± 0.02 1.0 0.15 ± 0.06 1.0 32.4 ± 2.4 213 
EFpI32 1.27 ±0.33 1.37 ± 0.11 1.1 1.09 ± 0.38 0.9 >300 >230 
EFpI33 2.59 ± 0.64 2.62 ± 0.16 1.0 1.8 ± 0.58 0.5 >300 >110 
CRMI46 0.038 ± 0.001 0.05 ± 0,01 1.3 0.035±0.003 0.9 16.55±0.74 435 
VHI1 5.05 ± 1.84 8.51 ± 1.98 1.7 2.73 ± 0.76 0.5 >300 >60 
VHI13 0.077 ± 0.022 0.043 ± 0.009 0.6 0.048 ± 0.007 0.6 5.6 ± 0.2 73 
VHI14 0.125 ± 0.027 0.094 ± 0.023 0.8 0.089 ± 0.017 0.7 12.8 ± 0.9 103 
VHI19 0.100 ± 0.034 0.066 ± 0.005 0.7 0.062 ±0.004 0.6 12.7 ± 0.5 127 
VHI20 0.058 ± 0.026 0.030 ± 0.008 0.5 0.045 ± 0.018 0.8 23.3 ± 0.4 404 
VHI22 0.094 ± 0.023 0.065 ± 0.002 0.7 0.073 ± 0.025 0.8 24 ± 1.2 254 
AT1 21.5 ± 0.3 18.5 ± 0.4 0.9 19.3 ± 0.2 0.9 >300 >14 
AT2 36.5 ± 3.5 34.9 ± 0.2 1.0 36.6 ± 0.6 1.0 >300 >8 
AT6 0.373 ± 0.003 0.40 ± 0.01 1.1 0.43 ± 0.08 1.1 >300 >800 
AT7 0.44 ± 0.04 0.40 ± 0.03 0.9 0.43 ± 0.09 1.0 >300 >680 
AT8 0.14 ± 0.02 0.14 ± 0.01 1.0 0.13 ± 0.02 0.9 72.6 ± 7.1 524 
AT9 2.68 ± 0.05 3.79 ± 0.09 1.4 2.74 ± 0.02 1.0 >300 >110 
AT11 >100 >100 ND >100 ND >300 ND 
AT15 0.25± 0.03 0.28 ± 0.01 1.1 0.3 ± 0.01 1.2 233 ± 31 914 
AT16 0.33 ± 0.02 0.33 ± 0.01 1.0 0.33 ± 0.01 1.0 >300 >900 
AT17 0.057 ± 0.013 0.043 ± 0.004 0.7 0.088 ± 0.024 1.5 45.4 ± 12.4 792 
AT19 23.2 ± 3.1 9.9 ± 1.9 0.4 6.68 ± 1.65 0.3 >300 >10 
AT20 >100 >100 ND >100 ND >300 ND 
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AT37 0.23 ± 0.06 0.37 ± 0.09 1.6 0.28 ± 0.04 1.2 77.1 ± 8.6 338 
AT38 0.24 ± 0.06 0.32 ± 0.05 1.3 0.28 ± 0.05 1.2 174 ± 23 723 
AT05 0.04±0.002 0.03±0.01 0.75 0.02±0.001 0.5 >300 >7500 
AT10 0.023 ± 0.001 0.024 ± 0.002 1.0 0.023 ± 0.001 1.0 >300 >12500 
AT21 
0.064 ± 0.004 0.012 ± 0.002 0.2 0.011 ± 0.003 0.2 32.5 ± 3.6
 
505 
AT33 
0.015 ±0.002 0.013 ± 0.0006 0.8 0.010 ± 0.001 0.7 17.6 ± 1.2 1145 
AT22 
0.17 ± 0.05 0.15 ± 0.03 0.8 0.11 ± 0.03 0.7 48.2 ± 2.4 281 
AT34 
0.028 ± 0.002 0.021 ± 0.002 0.8 0.017 ± 0.0003 0.6 24.5 ± 2.3 876 
AT27 
5.9 ± 0.7 6.1 ± 0.9 1.0 6.28 ± 0.85 1.1 >300 >50 
AT28 
0.15 ± 0.03 0.15 ± 0.02 1.0 0.10 ± 0.01 0.7 76.8 ± 2.0 504 
AT29 
>100 >100 ND >100 ND >300 ND 
AT30 
0.21 ± 0.05 0.22± 0.06 1.1 0.15 ± 0.03 0.7 63.2 ± 4.4 306 
AT31 
0.011 ± 0.004 0.008 ± 0.003 0.7 0.022 ± 0.011 1.9 13.4 ± 0.3 1198 
AT39 
42.7 ± 6.2 46.6 ± 2.3 1.1 45.8 ± 12.8 1.1 >300 >7 
Diminazene 
0.12±0.05 0.54±0.086 4.5 0.736±0.2 6.13 ND ND 
Pentamidine 
0.004±0.001 0.01±0.00 2.5 0.55±0.054 137 ND ND 
PAO 
ND ND ND ND ND 8.65±1.35 ND 
Table 5.1. Average EC50 values for phosphonium compounds against T. b. brucei wild type, TbAT1- knockout, and B48 bloodstream form plus standard 
errors. In addition, it shows the resistance factor for the KO and B48 strains. Also shown are the average EC50 values with Human Embryonic Kidney (HEK) 
cells and standard errors, plus the Selectivity Index (EC50 of HEK cells / EC50 of T. b. b.-WT). Diminazene and Pentamidine are the positive controls against 
parasites, and phenylarsine oxide (PAO) is used as a positive control of HEK cells. The averages of EC50 values ± SEM of three independent experiments 
are shown. Highlighted cells indicate monophosphonium compounds; others are bisphosphonium compounds. ND = not determined.
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5.2.2 Assessment of cross-resistance 
Resistant strains can be used as a model to investigate cross-resistance between 
existing treatments and potential new trypanocides. Any new trypanocidal drugs 
to be developed, whether for human or veterinary use, should at a minimum not 
be cross-resistant with the current diamidine and arsenic-based drugs. It is 
exactly because of high levels of resistance to these classes of drugs that the 
development of new drugs has become such a priority. Therefore, we 
investigated whether phosphonium-based trypanocides would be effective 
against well-characterised laboratory strains resistant to diamidines and 
melaminophenyl arsenicals. 
Eighty three phosphonium analogues were tested on three strains of 
trypanosomes: wild type strain (s427-WT), TbAT1 knockout (KO), and TbAT1-B48 
—listed in decreasing sensitivity to diminazene, pentamidine, and cymelarsan 
(Matovu et al., 2003;Bridges et al., 2007). EC50 values were found to be 
statistically identical for the s427, TbAT1-KO, and B48 strains in all cases 
(Student t-test; P>0.05), indicating that the phosphonium cations are not cross-
resistant with the crucial diamidine and melaminophenyl arsenical classes of 
trypanocides (Table 5.1). 
5.2.3 Cytotoxic activity of phosphonium compounds on Human 
Embryonic Kidney (HEK) cells and Therapeutic index values 
The toxic effect of phosphonium compounds on HEK cells was assessed using the 
Alamar blue assay, as explained in Chapter 3, at a maximum concentration of 
300 µM of the phosphonium compounds. Toxicity assays for HEK cells showed 
that the phosphonium compounds that have an effect on T. b. brucei have a 
much lower activity on HEK cell growth and viability. Therapeutic index rates 
(EC50 of HEK cells / EC50 of T. b. brucei) are shown in Table 5.1. The highest 
therapeutic index (TI) values were >12500, 7000, 3567, and 2930-fold with AT10, 
AT5, AHI17, and AHI9, respectively. In addition, 60 of 83 phosphonium 
compounds displayed a TI >200.  
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5.3 Analysis of structural determinants of phosphonium 
analogues contributing to trypanocidal activity 
The antiparasitic effects of phosphonium analogues were investigated using the 
in vitro Alamar blue viability assay to determine the EC50 values. In addition, the 
structure-activity relationship (SAR) of phosphonium analogues as compounds 
against the Trypanosoma brucei brucei bloodstream form was analysed. 
Phosphonium analogues were divided into five groups according to type of 
substituents.  
The activity of bisphosphonium salts having aliphatic and phenyl substituents 
was different; compounds with three short alkyl substituents (Me, Et, or Pr) on 
the phosphonium cations were weakly active against trypanosome (EC50 ≥ 20 µM) 
(Table 5.2, compounds 1–6). The activity was improved with the increase in 
chain length (n-octyl ≈ n-hexyl > c-hexyl ≈ n-pentyl > n-Bu > i-Bu) and 8 of 11 
compounds had an EC50 less than 500 nM (Table 5.2, compounds 7–17). 
Replacement of one short alkyl substituent (e.g. methyl, ethyl) with phenyl rings 
(R1, R2 = alkyl; R3 = Ph) increased the activity against Trypanosoma brucei brucei 
(Table 5.2, compounds 19–24); further replacement of such short aliphatic 
groups with phenyl (R1 = alkyl (R2, R3 = Ph)) continued to increase the activity, 
with EC50 < 1 µM (Table 5.2, compounds 26–31). 
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No Compound L R1 R2 R3 WT-s427 
EC50 (µM) 
1 CDIV31 CO Me Me Me >100 
2 CDIV22 CO Et Et Et >100 
3 AT 1 CH2 Et Et Et 21.5 ± 0.3 
4 AT 2 O Et Et Et 36.5 ± 3.5 
5 CDIV23 CO n-Pr n-Pr n-Pr 19.73 ± 4.11 
6 CDIV24 CO iPr iPr iPr 20.55 ± 5.19 
7 CDIV35 CO n-Bu n-Bu n-Bu 0.48 ± 0.11 
8 CDIV25 CO iBu iBu iBu 2.62 ± 0.69 
9 AHI08 CH2 
iBu iBu iBu 0.70 ± 0.03 
10 AHI07 O iBu iBu iBu 0.59 ± 0.06 
11 AHI40 SO2 
iBu iBu iBu 16.7 ± 0.5 
12 CD38 CO n-pentyl n-pentyl n-pentyl 0.20 ± 0.03 
13 CRMI46 CO n-hex n-hex n-hex 0.038 ± 0.001 
14 AHI16 CH2 n-hex n-hex n-hex 0.03 ± 0.006 
15 AHI15 O n-hex n-hex n-hex 0.037 ± 0.004 
16 CDIV33 CO c-hex c-hex c-hex 0.14 ± 0.03 
17 CDIV48 CO n-octyl n-octyl n-octyl 0.042 ± 0.002 
18 CDIV29 CO Me Me Ph 19.17 ± 7.17 
19 AHI05 CH2 Me Me Ph 5.45 ± 1.09 
20 AHI04 O Me Me Ph 7.22 ± 0.16 
21 EFpI 33 (CH2)2 Me Me Ph 2.59 ± 0.64 
22 EFpI 32 (CH2)3 Me Me Ph 1.27 ± 0.33 
23 CDIV26 CO Et Et Ph 8.59 ± 2.16 
24 CDIV53 CO c-hex c-hex Ph 0.24 ± 0.03 
25 CDIV28 CO Me Ph Ph 1.53 ± 0.38 
26 CDIV34 CO Et Ph Ph 0.97 ± 0.27 
27 AT 6 CH2 n-Pr Ph Ph 0.37 ± 0.003 
28 AT 15 O n-Pr Ph Ph 0.25± 0.03 
29 AT 7 CH2 
iPr Ph Ph 0.44 ± 0.04 
30 AT 16 O iPr Ph Ph 0.33 ± 0.02 
31 EfpI 1 CO c-hex Ph Ph 0.30 ± 0.03 
Table 5.2. Antitrypanosomal activity of bisphosphonium salts having aliphatic and phenyl 
substituents. The averages of EC50 values ± SEM of three independent experiments are 
shown; c-hex, cyclohexane; 
i
Bu, isobutyl; 
i
Pr, isopropyl. 
 
The effect of phosphonium compounds on WT-s427 when including substituents 
on the aromatic ring was investigated. The results are shown in Table 5.3. It 
appeared that the activity was superior to the small aliphatic substituents, but 
similar to aliphatic chains of Cn ≥5. All compounds had an EC50 <1 µM. In this 
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series the best activity was displayed by AHI17, which has 4-methylphenyl 
substituents on all 6 positions, with an EC50 value of 24 ± 5 nM. The substituent 
pattern for the phenyl ring, in order of increasing activity, was 4-Me > 3-Me > H 
and 2-OMe > 4-OMe > 4-Cl ≈ 4-F > 4-CF3. This seems to confirm a pattern seen 
with the aliphatic substituents that activity correlates with increased shielding 
of the phosphonium cations and increased hydrophobic surface area. 
 
No Compound L R1 R2 R3 WT-s427 
EC50 (µM) 
1 CDIV20 CO H H H 0.24 ± 0.07 
2 CDIV50 CO H H 2-Me 0.20 ± 0.01 
3 CDIV52 CO H H 4-Me 0.180 ± 0.002 
4 AHI10 CH2 H H 4-Me 0.24 ± 0.04 
5 AHI09 O H H 4-Me 0.082 ± 0.014 
6 EfpI 2 CO 4-Cl 4-Cl 4-Cl 0.94 ± 0.14 
7 EfpI 3 CO 4-F 4-F 4-F 0.85 ± 0.17 
8 EfpI 4 CO 4-OMe 4-OMe 4-OMe 0.32 ± 0.07 
9 EfpI 6 CO 2-OMe 2-OMe H 0.24 ± 0.04 
10 EfpI 11 CO 2-OMe 2-OMe 2-OMe 0.11 ± 0.02 
11 AHI22 CH2 2-OMe 2-OMe 2-OMe 0.080 ± 0.004 
12 AHI21 O 2-OMe 2-OMe 2-OMe 0.056 ± 0.011 
13 VHI1 CO 4-CF3 4-CF3 4-CF3 5.05 ± 1.84 
14 AT37 CH2 4-CF3 4-CF3 4-CF3 0.23 ± 0.06 
15 AT38 O 4-CF3 4-CF3 4-CF3 0.24 ± 0.06 
16 EfpI 7 CO 4-Me 4-Me 4-Me 0.11 ± 0.02 
17 VHI 22 CO 4-Me 4-Me 4-Me 0.094 ± 0.023 
18 AHI18 CH2 4-Me 4-Me 4-Me 0.080 ± 0.002 
19 EFpI 28 (CH2)2 4-Me 4-Me 4-Me 0.15 ± 0.06 
20 VHI20 (CH2)2 4-Me 4-Me 4-Me 0.058 ± 0.026 
21 EFpI 27 (CH2)3 4-Me 4-Me 4-Me 0.029 ± 0.005 
22 VHI19 (CH2)3 4-Me 4-Me 4-Me 0.100 ± 0.034 
23 AHI17 O 4-Me 4-Me 4-Me 0.024 ± 0.005 
24 AHI30 SO2 4-Me 4-Me 4-Me 0.23 ± 0.01 
25 AHI43 NAc 4-Me 4-Me 4-Me 0.32 ± 0.01 
26 AT 8 CH2 3-Me 3-Me 3-Me 0.14 ± 0.02 
27 AT 17 O 3-Me 3-Me 3-Me 0.057 ± 0.013 
Table 5.3. Antitrypanosomal activity of bisphosphonium salts having substituted phenyl 
substituents. The averages of EC50 values ± SEM of three independent experiments are 
shown. 
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Next, the activity was evaluated for bisphosphonium salts that have aryl groups 
or hetrocycle substituents. Replacement of the phenyl substituents of the 
phosphonium cation by 2-thienyl groups (Table 5.4, compounds 1–2) or 1-
naphthyl substituents (Table 5.4, compounds 10–12) maintained the activity. In 
contrast, the introduction of an oxygenated (2-furanyl) and thus more polar 
heterocycle led to a decreased EC50 by 150-fold; also, the introduction of an 
amino (2-pyridyl) heterocycle decreased the EC50 by 3-fold (Table 5.4, 
compounds 3–4). Similarly, the replacement of one phenyl substituent by a more 
polar phenylsulphonate or pentafluorophenyl ring abolished the trypanocidal 
activity (Table 5.4, compounds 6–9). All these observations reinforce the notion 
that maximum trypanocidal activity correlates directly with increased 
hydrophobicity and that the introduction of either hydrogen bond donors or 
acceptors is deleterious to activity. 
    
No Compound L Ar1 Ar2 Ar3 WT-s427 
EC50 (µM) 
1 CDIV20 CO Ph Ph Ph 0.24 ± 0.07 
2 CDIV57 CO 2-thienyl 2-thienyl 2-thienyl 0.33 ± 0.06 
3 CDIV49 CO 2-furanyl 2-furanyl 2-furanyl 36.9 ± 1.2 
4 CDIV27 CO Ph Ph 2-pyridyl 0.70 ± 0.24 
5 EFpI 8 CO Bn Ph Ph 0.81 ± 0.12 
6 AT 9 CH2 Ph Ph C6F5 2.68 ± 0.05 
7 AT 19 O Ph Ph C6F5 23.2 ± 3.1 
8 AT 11 CH2 Ph Ph 3-(SO3Na)Ph >100 
9 AT 20 O Ph Ph 3-(SO3Na)Ph >100 
10 EFpI 10 CO 1-naphthyl 1-naphthyl 1-naphthyl 0.18 ± 0.04 
11 AHI20 CH2 1-naphthyl 1-naphthyl 1-naphthyl 0.14 ± 0.02 
12 AHI19 O 1-naphthyl 1-naphthyl 1-naphthyl 0.16 ± 0.01 
Table 5.4. Antitrypanosomal activity of bisphosphonium salts having aryl groups or 
heterocycle substituents. The averages of EC50 values ± SEM of three independent 
experiments are shown. 
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The more surprising correlation is with the removal of one of the phosphonium 
cations to create monophosphonium salts. The trypanocidal activity was 
generally higher for the mono-phosphonium than for the corresponding 
bisphosphonium compound (Table 5.5). Specifically, slightly lower EC50 values 
were observed for AT21, AT33, AT34, AT28, and AT31 compared with their 
bisphosphonium salt compound (VHI22, AHI17, AT17, CDIV52, and CRMI46, 
respectively). The SAR of substituents was identical to that observed for the 
bisphosphonium compounds. Interestingly, the replacement of the carbonyl 
group by an ether linker further increased the activity between 6 and 4-fold 
against WT-s427 (compare AT21 with AT33 and AT22 with AT34), yielding 
compounds with low nanomolar activity. 
        
 
No Compound L R1 R2 R3 WT-s427 
EC50 (µM) 
1 AT10 (Cl)     0.023 ± 0.001 
2 AT5 (Br)     0.043 ± 0.001 
3 AT21 CO 4-Me-Ph 4-Me-Ph 4-Me-Ph 0.064 ± 0.004 
4 AT33 O 4-Me-Ph 4-Me-Ph 4-Me-Ph 0.015 ±0.002 
5 AT22 CO 3-Me-Ph 3-Me-Ph 3-Me-Ph 0.17 ± 0.05 
6 AT34 O 3-Me-Ph 3-Me-Ph 3-Me-Ph 0.028 ± 0.002 
7 AT27 CO iBu iBu iBu 5.9 ± 0.7 
8 AT28 CO 4-Me-Ph Ph Ph 0.15 ± 0.03 
9 AT29 CO Et Et Et >100 
10 AT30 CO 2-MeO-Ph 2-MeO-Ph 2-MeO-Ph 0.21 ± 0.05 
11 AT31 CO n-hex n-hex n-hex 0.011 ± 0.004 
12 AT39 CO Me Me Ph 42.7 ± 6.2 
Table 5.5. Antitrypanosomal activity of monophosphonium salts. The averages of EC50 
values ± SEM of three independent experiments are shown. 
AT10: X= Cl 
AT5 :  X= Br 
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5.4 Effect of test compounds on trypanosome 
proliferation after limited exposure 
Two bisphosphonium compounds (AHI15 and AHI16) were selected for 
determining the inhibition of trypanosome proliferation after exposure of a 
limited duration. Trypanosomes need only to be incubated briefly with some 
drugs, like the diamidines, even though cell death does not occur for hours after 
the exposure has ceased. In other words, their early effects are irreversible and 
cells will not recover. Clearly this is important in the evaluation of potential 
trypanocides, with major implications for any dosage regimen. 
First, cells were incubated in the continuous presence of three concentrations 
for each compound (0.05, 0.25, and 1 µM) as well as without drugs (control) to 
choose the best concentration for inhibiting growth during 48 h using 
microscopic cell counts every 4 h. The results (Figure 5.2) show that the 
concentration of 0.25 µM was the most active concentration that did not lead to 
extensive cell death during the incubation. 
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Figure 5.2. 1 Effect of bisphosphonium compounds AHI15 (A) and AHI16 (B) on the growth 
curve of the T. b. b. bloodstream form with different concentrations: (●) drug free, () 0.05 
µM, (▲) 0.25 µM, and (ᴏ) 1 µM. Cells were set up at 10
5
 cells/ml. Microscopic cell counts 
were performed in triplicate using a haemocytometer. 
 
In the next experiment, the cell density was adjusted to 1×105 cells/ml and the 
bloodstream form s427 trypanosomes were exposed for two durations (0.5 and 4 
h) to the compounds. At the predetermined time, the culture was transferred to 
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centrifuge tubes, spun at 1100 × g for 10 min, and washed twice in fresh medium 
or continued with fresh medium has 0.25 µM for both compounds. The cell count 
was taken in triplicate at four time points (0, 4, 8, and 12 h/day) for each 
concentration of compounds for 48 h. 
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Figure 5.3. Effect of bisphosphonium compounds AHI15 (A) and AHI16 (B) on Tb427 wild 
type bloodstream form trypanosome proliferation. Growth inhibition by 0.25 µM for both 
compounds was determined by centrifugation (1100 × g) after either 30 min or 4 h (as 
mentioned in the figure) and replacement with drug-free fresh medium or fresh medium with 
0.25 µM of compounds or control culture (drug free) was used. Cultures were seeded at 10
5
 
cells/ml. Microscopic cell counts were performed in triplicate using a haemocytometer. The 
results shown are the average of three independent experiments; error bars depict standard 
errors. 
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Although trypanosomes died slowly on incubation with phosphonium compounds, 
only a relatively short exposure time was required. Figure 5.3 shows that the 
removal of these compounds after a mere 30 min of incubation allowed for only 
limited resumption of growth, reaching a maximum density of 14.2 ± 2.7 ×105 
cells/ml at 48 h and 20% of the drug-free control for AHI15, and 21.5 ± 5.2 ×105 
cells/ml at 48h and 30% of the drug-free control for AHI16. Removal of drugs 
after 4 h did not lead to any resumption of growth at all, and the trypanosome 
population either remained stable or, for some compounds, slowly dwindled over 
the following 36 h (Fig. 5.2; Taladriz et al., 2012). Continuous exposure to the 
drug resulted in sterilisation of the culture after approximately 30 h.  
5.5 Monitoring the speed of action of test compound on 
Trypanosomes by using propidium iodide 
The purpose is to monitor the speed of action of the test compounds on 
trypanosomes in real time. Cells become fluorescent as PI enters the cell and 
binds to nucleic acids. This occurs only upon breach of the plasma membrane 
(i.e., loss of cellular integrity). Serial dilutions of bisphosphonium compounds 
were used to study the effect of the CD38 compound on the cell viability for 
three strains of trypanosomes (WT, KO, and B48) during 8 h. 
Figure 5.4 indicates that CD38 only affected cellular viability during 8 h at 
concentrations >15-fold its EC50 and there was no significant difference among 
the three strains of trypanosomes. Similar observation were made for several 
bisphosphonium compounds (Taladriz et al., 2012). 
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Figure 5.4. Dose response curve of the CD38 compound for the bloodstream form of various 
strains of T. b. brucei. The different concentrations were incubated with and without 
parasites in HMI-9 medium, which has 10% FCS at 37 ºC with 5% CO2. Propidium iodide at 9 
µM was added, and the fluorescence was measured over 8 h at 544 nm excitation and 620 
nm emission. Separate traces were recorded in the absence of cells and were subtracted 
from those presented in the figures. 
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5.6 Discussion 
The heavily substituted phosphonium salts that are here shown to have potent 
anti-protozoal activity are lipophilic cations bearing a greatly delocalized and 
shielded charge. Therefore, they have the advantage of being able to diffuse 
through biological membranes, with the membrane potential providing a driving 
force for accumulation. Thus, phosphonium compounds are known to accumulate 
not only in the Leishmania mitochondria (Luque-Ortega et al., 2010), but also in 
mammalian mitochondria (Murphy, 2008;Porteous et al., 2010;Smith & Murphy, 
2010). Thus, the various benzophenone-derived bisphosphonium salts present in 
Leishmania accumulated in the parasite‘s mitochondria as a result of the strong 
inside-negative mitochondrial membrane potential (Luque-Ortega et al., 2010). 
It is reasonable to hypothesise that a similar mitochondrial targeting underlies 
their trypanocidal activity and this will be investigated in chapter six. 
The SAR of the compounds under study here for their effects against African 
trypanosomes shared considerable similarity with the SAR against Leishmania. 
For example, for compounds with homoalkyl groups, optimum activity was 
observed with 5- to 8-carbons, independently of the linker (Tables 5.2 and 5.5). 
Similarly, the addition of two phenyl groups (with their alkyl substituents) 
provided it with a submicromolar activity. However, the addition of one phenyl 
group with two short alkyl substituents (Me, Et) provided a micromolar EC50. 
These observations are clearly supported by the CoMFA models that show that a 
minimum bulk around the phosphonium cations is favourable to the activity, but 
this volume is also limited in size (Taladriz et al., 2012). 
Clearly, the SAR findings are entirely consistent with increased membrane 
penetration being the determining factor for anti-protozoal activity for both bis-
phosphonium and mono-phosphonium salts. This is achieved by increased 
shielding of the positively charged phosphorous atom(s) and distribution of the 
charge over aromatic substituents. These cations are thus eminently capable of 
diffusing across biological membranes independent of drug T. b. brucei 
transporters such as P2, HAPT1, and LAPT1. This explains the absence of cross-
resistance with diamidine and arsenical drugs, which has been shown to be 
correlated with the loss of these transporters (de Koning, 2008). 
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Although various bisphosphonium compounds have the ability to dose-dependent 
inhibit the HAPT1 and LAPT1 transporters (Taladriz et al., 2012), with IC50 values 
of 5.2 and 2.2 µM for compound CD38. However, these compounds are likely too 
big to be a substrate (as opposed to an inhibitor) of such transporters because 
their molecular weights ranged from 800 to 1300, compared with 340 for 
pentamidine. In contrast, di-cationic diamidines do require transporters 
including HAPT1 and LAPT1 to cross membranes (de Koning, 2001;Teka et al., 
2011). Yet, cationic compounds such as the symmetrical choline-derived 
experimental trypanocides with long aliphatic linkers that we recently described 
compounds (Ibrahim et al., 2011) were also not dependent on transporters, for 
the same reasons as the bisphosphonium compounds described here. The 
observation that substituents such as furan, pyridine, and phenylsulphonate, 
which can form H-bonds display low antitrypanosomal activity, as their diffusion 
rates across plasma and mitochondrial membranes. 
An important aspect of the SAR analysis presented here is that mono-
phosphonium compounds are at least as active as the equivalent bis-
phosphonium compounds with the same substituents, despite the fact that 
molecules with the higher charge (bisphosphonium) would be expected to have a 
higher mitochondrial accumulation rate than mono-cations. Consistent with the 
redundancy of the second phosphonium group was that the introduction of 
increasingly flexible linkers, such as ethylene instead of methylene linkers, had 
very little effect on trypanocidal activity. The equivalence or superiority of the 
mono-phosphonium compounds is of considerable value considering that the 
smaller mono-cations are likely to have a better pharmacokinetic behaviour in 
vivo. 
In the paper presented by Kinnamon (Kinnamon et al., 1979) it was observed 
that the chloride salt monophosphonium compound AT10 showed a 100% curative 
activity (53 mg/kg sc) against T. b. rhodesiense infection in a murine model; the 
bromide analogue AT5 was reported to be less efficient in vivo compared to its 
chloride counterpart. The invitro screening reported here is in agreement with 
that report as AT10 displayed excellent activity against T. b. brucei and T. b. 
rhodesiense.  
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The excellent in vitro trypanocidal activities and high in vitro selectivity indices 
obtained for this set of phosphonium compounds, indicates that this class may 
have therapeutic potential. The compounds also have the ability to irreversibly 
inhibit trypanosome growth, which eventually leads to the extinction of a 
specific population after minimum exposure time. This situation is similar to the 
diamidine trypanocides, which also require only a short exposure time to inhibit 
population growth, and ultimately kill the trypanosomes in 1–2 days (Ward et al., 
2011). This observation supports keeping the dose of the drug low, and suggests 
that a single dose can suffice just like a single dose of the diamidine diminazene 
aceturate is sufficient for the routine treatment for animal trypanosomiasis 
(Delespaux & de Koning, 2007) In addition, the association of lipophilicity with 
membrane penetration ability will cause a more efficient penetration into the 
central nervous system, which is very important for cure of the cerebral stage of 
trypanosomiasis (Rodgers, 2009), as well as oral availability. However, a note of 
caution must be that preclinical development of this class may have to further 
optimise specificity as a potential concern is that the compounds will also 
accumulate in mammalian mitochondria. With section of the most potent 
trypanocides, allowing for minimal dosages, it may be possible to overcome this 
hurdle. 
In conclusion, the in vitro screening of 83 phosphonium compounds against 
African trypanosomes allowed the discovery of some trypanocidal compounds 
that have nanomolar activities and much lower toxicity against HEK cells. The 
structure activity relationship demonstrated that large substituents around 
phosphonium cations (i.e., any 5 to 8 homoalkyl chains of C5 – C8 length, or 
phenyl rings) are essential for optimised activity, while the exact nature of the 
linkers have less effect on the activity – at least for bisphosphonium salts as the 
diphenyl ether linker seemed to be more clearly preferred in the case of 
monophosphonium compounds.  
Phosphonium compounds displayed a similar structure activity relationship 
against T. brucei and Leishmania. This observation strongly suggests a similar 
mechanism of action against the two parasite species, and indicates that this 
class may have broad anti-protozoal activity. This is the topic of Chapter 6, 
which focuses on the mode of action of bisphosphonium compounds in the T. b. 
brucei bloodstream form.  
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Importantly, the screening reported here confirmed that the new compounds 
were not cross-resistant with existing diamidines and arsenical trypanocides, 
such as pentamidine and melarsoprol, currently in clinical use — an essential 
condition for any new preclinical candidate. 
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action of Bisphosphonium compounds in T. b. 
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6.1 Introduction 
This chapter investigates the effect of selected bisphosphonium compounds in 
vitro on bloodstream-form Trypanosoma brucei brucei to attempt to understand 
the mode of action. Many cellular parameters were determined in an unbiased 
investigation of the trypanocidal activity of this class of compounds, including 
their effects on the mitochondrial membrane potential, intracellular calcium 
levels, cellular ATP level, the cell cycle, as well as an assessment of the 
morphology of cells exposed to bisphosphonium analogues. 
A recent paper described promising anti-leishmanial activity of bisphosphonium 
compounds. It was also found that these agents act on the Leishmania 
mitochondria, specifically by inhibition of Complex II formation, which leads to 
the alteration of cell shape. Specifically, it caused cellular swelling, decreased 
levels of ATP, as well as a reduction of the mitochondrial membrane potential 
and the O2 consumption rate (Luque-Ortega et al., 2010). It has also been 
reported that the bisphosphonium compound, 4,4‘-bis[(tri-n-
pentylphosphonium)methyl] benzophenone dibromide displays in vitro activity 
against T. brucei (Dardonville & Brun, 2004). However, we have not assumed 
that the trypanocidal mode of action action is, identical to the reported 
antileishmanial activity, as bloodstream trypanosomes, in contrast to procyclic 
forms, are not believed to express Complex II (Acestor et al., 2011;Chaudhuri et 
al., 2006). 
Cellular parameters are important as the first stage of studying the mode of 
action. As a first step, T. brucei growth curves in the presence of various 
concentrations of active compound were made in order to determine suitable 
combinations of concentration and incubation time for the study of cellular 
effects. The effects of bisphosphonium compounds on the life cycle of T. brucei 
were studied using flow cytometry for DNA content, and by fluorescent 
microscopy with the DNA stain4′, 6′-diamidino-2-phenylindole hydrochloride 
(DAPI), allowing the evaluation of the effects these compounds have on cell 
division. These tests were used to assess the distribution of DNA with respect to 
time. With the flow cytometry, the DNA of content of fixed cells stained with 
propidium iodide is evaluated. However, this method gives no information about 
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the (number of) kinetoplasts, whereas the microscopic assessment with DAPI 
accurately reveals the number of nuclei and kinetoplasts per cell, and may 
additionally reveal morphological changes to the DNA-containing organelles. 
Light microscopy was performed in order to study the effects of the 
bisphosphonium compounds on the overall morphology of the parasite. Bright 
field, differential interference contrast (DIC), transmission electron microscopy 
(TEM), and scanning electron microscopy (SEM), were all employed to study the 
cellular changes occurring in the cell and DNA of the organism as a result of 
exposure to bisphosphonium compounds.  
Finally, to investigate whether exposure to these compounds led to programmed 
cell death (PCD), also known as apoptosis, two tests were performed. Firstly, 
cells were treated with the protein synthesis inhibitor cycloheximide (CHX), 
followed by treatment with bisphosphonium compounds. The inhibition of 
protein synthesis would have inhibited any PCD. Secondly, as it is known that 
PCD leads to DNA fragmentation or DNA breaks, a TUNEL assay was used to 
detect DNA fragmentation in trypanosomes after they were treated with 
bisphosphonium compounds.   
 
6.2 Effect of test compounds on trypanosome growth 
A set of bisphosphonium compounds were tested on trypanosomes at different 
concentrations (0, 0.1, 0.3, and 1 µM), in order to monitor in-vitro cell growth, 
using microscopic cell counts. Wild-type T. b. brucei were taken from cultures at 
the late logarithmic phase of growth, and cell density was calculated using a 
haemocytometer. Cell density was adjusted to the desired concentration, which 
was 1×105 cells/ml in this experiment, and diluted with fresh HMI9 medium and 
10% FCS. The cell count was taken in triplicate at four time points (0, 4, 8, and 
12 h/day) for each concentration of the compounds, for 96 h. 
 
Untreated and treated cells were seeded for up to 96 h with selected 
bisphosphonium compounds, which were CD38, CDIV48, EFpI7 and AHI9, and 
three different concentrations of each compound were used. There were no 
Abdulsalam Alkhaldi, 2012                                                                                      Chapter 6       159 
dramatic effects on the growth rates for these compounds at 0.1 µM, while the 
growth was inhibited at 0.3 µM after 24h for all compounds except CD38. At 1 
µM, the compounds killed the trypanosome population, so no live parasites were 
detected after 24 – 28 hours (figure 6.1). 
CD38  had no effect at 0.1 µM due to the fact that this concentration was less 
than EC50 (0.20 µM). There was a slight inhibition at 0.3 µM, which is slightly 
more than EC50, whereas at 1 µM, the growth was inhibited after 12 h. CDIV48 
did inhibit growth at 0.1 µM, consistent with the concentration being 2.5-fold its 
EC50 value of 42 nM. In contrast, there was only a minor effect at this 
concentration for EFpI7 and AHI9 due to the fact that this concentration is 
almost equal to their respective EC50 values (110 and 82 nM, respectively). These 
observations are consistent with the results presented in Chapter Five, which 
indicated that phosphonium compounds have no immediately effect on the 
growth of cells (Section 5.5) and that they need more than 8 h to affect cellular 
viability at a concentration >15-fold of EC50. 
These growth curves allow us to choose between the various concentrations of 
different bisphosphonium compounds in order to study the mode of action. 
These are CD38, CDIV48, EFpI7, and AHI9 at 0.7, 0.5, 0.5, and 0.7 µM, 
respectively.        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
P+
C5H11
C5H11
C5H11
P+
C5H11 C5H11
C5H11
Br-
Br-
CD38
O
P+
C8H17
C8H17
C8H17
P+
C8H17 C8H17
C8H17
Br-
Br-
CDIV48
O
P+ P+
Br-
Br-
EFpI-7
CH3
CH3
H3C
CH3
H3C
H3C
O
P+ P+
Br-
Br-
AHI-9
H3C CH3
Abdulsalam Alkhaldi, 2012                                                                                      Chapter 6       160 
0 8 16 24 32 40 48 56 64 72 80 88 96
0
10
20
30
40
50
60
70
80
Drug free control
CD38 (0.1 M)
CD38 (0.3 M)
CD38 (1 M)
 
0 4 8 12 16 20 24
0
2
4
6
Time( h)
1x
1
0
5
 c
el
ls
/m
l
Time(h)
1
x
1
0
5
 c
e
ll
s
/m
l
0 8 16 24 32 40 48 56 64 72 80 88 96
0
10
20
30
40
50
60
70
80
Drug free control
CDIV48 (0.1 M)
CDIV48 (0.3 M)
CDIV48 (1 M)
 
0 4 8 12 16 20 24
0
2
4
6
T ime (h )
1
x1
05  
ce
lls
/m
l
Time(h)
1x
10
5  
ce
lls
/m
l
 
0 8 16 24 32 40 48 56 64 72 80 88 96
0
10
20
30
40
50
60
70
80
Drug free control
EFpI7 (0.1 M)
EFpI7 (0.3 M)
EFpI7 (1 M)
 
0 4 8 12 16 20 24
0
2
4
6
T im e( h )
1
x
10
5  
c
el
ls
/m
l
Time(h)
1x
10
5  
ce
lls
/m
l
0 8 16 24 32 40 48 56 64 72 80 88 96
0
10
20
30
40
50
60
70
80
Drug free control
AHI9 (0.1 M)
AHI9 (0.3 M)
AHI9 (1 M)
 
0 4 8 12 16 20 24
0
2
4
6
Time(h)
1x
10
5
 c
el
ls
/m
l
Time(h)
1
x
1
0
5
 c
el
ls
/m
l
 
Figure 6.1. Effect of different concentrations of four bisphosphonium compounds on the 
growth of bloodstream form T. brucei brucei WT over 96 h. Cell cultures were seeded at 10
5
 
cells/ml.  Inset shows the same data, but only for 24 h. Microscopic cell counts were 
performed in triplicate using a haemocytometer. The results shown are the average of three 
independent determinations; error bars depict standard errors. 
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6.3 Bisphosphonium compounds strongly affect 
mitochondrial membrane potential (Ψm)  
As mentioned in the introduction, bisphosphonium compounds have a strong 
effect on the mitochondrial membrane potential (Ψm) of the parasite Leishmania 
(Luque-Ortega et al., 2010). Accordingly, we investigated whether these 
compounds affect mitochondrial function in African Trypanosomes. 
The mitochondrial membrane potential of treated and untreated cells were 
assessed by using Tetramethylrhodamine ethyl ester (TMRE) (Denninger et al., 
2007a). The cell density was adjusted to 1×106 cells/ml with and without test 
compounds for the duration of the experiment. One millilitre of sample was 
transferred into microfuge tubes at each time point and spun at 2500 rpm for 10 
min at 4 C and was then resuspended in 1 ml PBS containing 25 nM TMRE. Cells 
were then incubated at 37 C for 30 min in the presence or absence of test 
compounds; valinomycin (100 nM) and troglitazone (10 µM) were used as controls 
because they are known to induce mitochondrial mitochondrial membrane 
depolarisation and hyperpolarisation, respectively (Ibrahim et al., 2011).  All 
samples were analysed via flow cytometry by using a FL2-heigth detector and 
CellQuest software. Values are given as the percentage of cells with 
fluorescence above 100 arbitrary units (AU), which was set at about 50% for the 
controls (untreated cells). A shift to higher fluorescence indicates an increase of 
Ψm (hyperpolarisation), whereas a shift to lower fluorescence indicates a 
decrease of Ψm (depolarization) (Denninger et al., 2007b). 
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Figure 6.2. Effect of Bisphosphonium compounds on mitochondrial membrane potential 
(Ψm) as measured by flow cytometric analysis of bloodstream-form T. b. b. incubated with 
25 nM tetra-methylrhodamine (TMRE). The results shown are the average of three 
independent determinations; error bars depict standard errors. 
 
   
  
Results are presented in histograms of TMRE fluorescence (Appendix C). The 
results summary, shown in Figure 6.2, shows the Ψm at 0, 1, 4, 8 and 12 h. As 
expected, no change in Ψm for untreated cells appeared during 12 h, 
valinomycin induced a rapid and profound depolarisation of the mitochondrial 
membrane, and troglitazone caused a clear hyperpolarisation. There were clear 
effects on Ψm with CD38, CDIV48, and EFpI7, and at 1 h, the Ψm was already 
reduced, which continued until 12 h. In contrast, the Ψm appeared to be without 
change after 1 h of incubation with compound AHI9, after which it sharply 
decreased after 4 h. These results indicate that bisphosphonium cause 
adepolarisation of mitochondrial membrane potential.   
 
6.4 Effects of bisphosphonium compounds on ATP levels 
in T. b. brucei 
As it was found in the above that the bisphosphonium compounds led to the 
depolarisation of mitochondrial membrane potential and it has been established 
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that the oligomycin-sensitive ATP synthase is accountable for maintaining the 
mitochondrial membrane potential in bloodstream form Trypanosoma brucei 
brucei (Brown et al., 2006), we tested these compounds, at the same 
concentrations as above, for their effects on ATP levels.  
ATP was measured by using an ATP determination kit (Invitrogen), which has D-
Luciferin and Luciferase (firefly recombinant), as mentioned in Chapter Two 
(Section 2.14).  A time course that was used to determine the ATP levels at 1, 4, 
8, and 12 hours in Trypanosoma brucei brucei. During this time, the cells were 
grown in HMI-9 medium + 10% FCS in vented flasks with and without test 
compounds. Oligomycin (2 µg/ml) was used as positive control. The 
luminescence was recorded for each sample after subtracting the background 
luminescence. A standard curve was prepared using different concentrations of 
ATP standard solution (0, 10, 50, 100, 500 and 1000 nM) in order to calculate the 
ATP concentration of the samples from the standard (Figure 6.3).  
 
Figure 6.3. ATP standard curve. A standard curve was generated by serial dilutions of ATP 
to 0, 10, 50, 100, 500, and 1000 nM.  10 µl of the solution was added to the wells of a 96-well 
plate, which contained 90 µl of standard reaction solution. Luminescence was read by using 
a luminometer. 
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Figure 6.4. ATP concentration was measured using the ATP Determination Kit (Invitrogen) 
as described in section 2.12. 1 × 10
6 
cells/ml of untreated and treated T. b. brucei 
bloodstream forms were incubated with different of bisphosphonium compounds and with 
oligomycin for up to 12 hrs. ATP concentrations were calculated from the standard curve 
and presented in this graph as the percent of untreated control. Results are the average of 
four independent determinations and error bars are SEM. P-values were calculated using 
the unpaired Student’s t-test (* P<0.05, ** P<0.01). 
  
 
The results showed the effects of the bisphosphonium compounds CD38, CDIV48, 
EFpI7, and AHI9 (at 0.7, 0.5, 0.5, and 0.7 µM, respectively) on intracellular ATP 
levels of T. b. brucei (figure 6.4). It is very clear that all these compounds 
inhibited ATP levels after one hour by more than 50%. This decline tended to 
continue with the progress of time, and at 12 h, the ATP levels were at about 
30% for most of the compounds. Interestingly, there is a correlation between 
depolarisation of mitochondrial membrane potential and the reduction in 
intracellular ATP levels. However, the question is which of these actions will 
happen first. However, it is quite difficult to answer this from the data 
presented because these compounds affected both Ψm and ATP levels as early as 
1 h. 
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6.5 Effects of bisphosphonium compounds on 
intracellular calcium levels 
The mitochondria have a large ability to sequester Ca2+, and it was found in the 
above that there was depolarization of the mitochondrial membrane potential 
when they were treated with bisphosphonium compounds, so it could be 
speculated that this would lead to the release of Ca2+ from the mitochondria. 
Consequently, the effects of bisphosphonium compounds on intracellular calcium 
levels were examined. Intracellular Ca2+ was measured using the Screen QuestTM 
Fluo-8 Calcium Kit produced by ABD Bioquest. First of all, as mentioned in 
Chapter Two (Section 2.8), Ca2+ was determined during a 15 min exposure of the 
cells to 20 µM of different of bisphosphonium compounds. However, there was 
no calcium response over this period, although the positive control, 10 µM of the 
calcium ionophore A23187, caused a sharp and immediate increase in Ca2+ (data 
not shown). Therefore, a time course was used to determine Ca2+ level over a 
much longer period, i.e. at 0, 4, 8, and 12 h. During this time, the trypanosomes 
were grown in HMI-9 medium + 10% FCS in vented flasks with and without test 
compounds, as mentioned in the materials and methods section in Chapter 2 
(section 2.8). 
Figure 6.5 shows the effects of the bisphosphonium compounds CD38, CDIV48, 
EFpI7, and AHI9 (at 0.7, 0.5, 0.5, and 0.7 µM, respectively) on intracellular 
calcium levels; cells that were not exposed to any drug, but treated exactly the 
same with 1% DMSO instead, were used as a negative control. The results were 
expressed as a percentage of fluorescence for the non-treated control, the zero 
time point was taken immediately after the addition of the test compound. None 
of the compounds displayed a clear effect on Ca2+ levels at 4 h. However, Ca2+ 
levels were raised after 8 h for all compounds and this was still evident at 12 h. 
Abdulsalam Alkhaldi, 2012                                                                                      Chapter 6       166 
0 4 8 12
0
25
50
75
100
125
150
175
CD38- 0.7 M
CDIV48 - 0.5 M
EFpI 7 - 0.5 M
AHI 9 - 0.7 M
Time (h)
C
a
2
+
-a
s
s
o
c
ia
te
d
 f
lu
re
c
e
n
c
e
 (
%
 0
f 
c
o
n
tr
o
l)
* *
*
* **
* *
*
 
Figure 6.5. Effect of Bisphosphonium compounds on intracellular calcium levels of WT s427 
bloodstream-form T. brucei brucei at 0, 4, 8, and 12 h. Parasites were loaded with Fluo-8 
ﬂuorescent indicator after 0, 4, 8, or 12 h of incubation with Bisphosphonium compounds. 
Data are presented as percentages of the non-treated control, for which calcium-associated 
ﬂuorescence was measured in parallel cultures at the same time points. Results are the 
average of three independent determinations, and error bars are standard errors. *P<0.05, 
**P<0.01 (Paired Student’s t-test). 
 
Interestingly, these results perfectly mirror the effects of the same compounds 
on Ψm, but they are delayed by several hours. Apparently, the slow rise in 
intracellular calcium is preceded by damage to the mitochondria. While it is not 
possible to prove cause and effect at this point, the data are suggestive of a 
leakage of calcium from dysfunctional mitochondria and are consistent with the 
mitochondria being the primary target of the cationic bisphosphonium 
compounds. 
6.6 Cell cycle analysis in bisphosphonium-exposed cells 
In order to establish whether bisphosphonium compounds have any effect on the 
cell cycle of trypanosomes, the DNA content was measured over 36 h. Flow 
cytometry was used as described (Hammarton et al., 2003). The cell density was 
adjusted to 1×106 cells/ml with and without test compounds for the duration of 
the experiment. As described in Section 2.7, each sample was fixed in 1 ml of 
70% methanol and 30% PBS and left at 4 C overnight. After storage, the samples 
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were washed twice with 1 ml of PBS and subsequently resuspended in 1 ml of 
PBS containing propidium iodide and RNase A (both at 10 µg/ml) and incubated 
at 37 ºC for 45 minutes while being protected from light. Samples were analysed 
by Becton Dickinson FACSCalibur using the FL2-Area detector and CellQuest 
software. 
The results appeared to indicate that there was no effect on the T. b. brucei 
cell cycle by any of the bisphosphonium salts tested, as shown in Figure 6.6. 
There was no immediately obvious difference between the drug-free control and 
the test compounds, although the growth curve was reduced over the incubation 
time. Consequently, the ModFit programme was used to analyse the flow 
cytometry.   
 
Figure 6.6. An example for flow cytometry analysis of the DNA content of bloodstream-form 
wild type T. b. b., which was incubated for 8 and 24 h. (A) Drug free, 8h (B) CD38 (0.7 µM), 8h 
(C) CD38 (0.7 µM), 24h. 
 
 
ModFit LT software (Verity Software House) helps to analyse the flow cytometry 
data by modelling the histogram peaks in order to find the percentages of the 
population at each cell cycle phase (G1: all cells have one kinetoplast and one 
nucleus; G2: all cells have two kinetoplast and two nucleus; S: DNA synthesis). 
Four bisphosphonium compounds (CD38, CDIV48, EFpI7, and AHI9 at 0.7, 0.5, 
0.5, and 0.7 µM, respectively), including a drug-free control,  were tested in 
order to study their effect on the cell cycle of wild type Tb427 over 36 h.  
The results obtained from the analysis of the cell cycle by using ModFit software 
are presented in Appendix and the summary results are presented in Figure 6.8. 
It can be seen from the data in Figure 6.7 that there was a clear reduction of the 
cells in the S phase. This was observed for all compounds tested after 8 h of 
incubation, whereas as expected, there was no change in the S phase for the 
drug-free control when it maintained a normal growth rate. The percentages of 
A B C 
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S phase decreased by more than 50% at 12 h for all compounds, except CDIV48, 
which displayed a 30% decrease of S phase at 12 h. This decrease continued over 
the incubation period, and S phase was decreased by about 80% of its original 
rate over 24 h of incubation for all test compounds. In contrast the percentage 
of cells in the G1 rate was increased by more than 10% at 12 h for all 
compounds. 
The most striking result to emerge from the data is the strong relationship 
between the S phase and the growth curve, as is shown in Figure 6.8. The 
reduced S phase coincides with an inhibition of growth. Apparently the observed 
inhibition of DNA synthesis led to a cessation of growth and finally to the 
complete inhibition of the growth of the cells.  
 
Figure 6.7. An example of flow cytometry analysis of DNA content by Modfit LT software for 
two samples, drug-free and CD38 (0.7 µM), which were incubated for 16 hrs. 
 
 
 
 
Abdulsalam Alkhaldi, 2012                                                                                      Chapter 6       169 
0 4 8 12 16 20 24 28 32 36 40
0
20
40
60
80
100
G1
G2
S
Drug free
Time (h)
%
 C
el
ls
     
0 4 8 12 16 20 24 28 32 36 40 44 48 52
0
10
20
30
40
50
60
70
80
90
100
Drug free control
CD38 - 0.7 M
Time(h)
1
x
1
0
5
 c
e
ll
s
/m
l
                                                                                              
0 4 8 12 16 20 24 28 32 36 40
0
20
40
60
80
100 G1
G2
S
CD38 (0.7 M)
Time (h)
%
 C
el
ls
   
0 4 8 12 16 20 24 28 32 36 40 44 48 52
0
10
20
30
40
50
60
70
80
90
100
Drug free control
CD38 - 0.7 M
Time(h)
1
x
1
0
5
 c
e
ll
s
/m
l
            
0 4 8 12 16 20 24 28 32 36 40
0
20
40
60
80
100
G1
G2
S
CDIV48 (0.5 M)
Time (h)
%
 C
el
ls
0 4 8 12 16 20 24 28 32 36 40 44 48 52
0
10
20
30
40
50
60
70
80
90
100
Drug free control
CDIV48 - 0.5uM
Time(h)
1
x
1
0
5
 c
e
ll
s
/m
l
0 4 8 12 16 20 24 28 32 36 40
0
20
40
60
80
100 G1
G2
S
EFpI7 (0.5 M
Time (h)
%
 C
el
ls
  
0 4 8 12 16 20 24 28 32 36 40 44 48 52
0
10
20
30
40
50
60
70
80
90
100 Drug free control
EFpI7 - 0.5 M
Time(h)
1
x
1
0
5
 c
e
ll
s
/m
l
 
0 4 8 12 16 20 24 28 32 36 40
0
20
40
60
80
100
G1
G2
S
AHI9 (0.7 M)
Time (h)
%
 C
el
ls
0 4 8 12 16 20 24 28 32 36 40 44 48 52
0
10
20
30
40
50
60
70
80
90
100 Drug free control
AHI9 - 0.7uM
Time(h)
1
x
1
0
5
 c
e
ll
s
/m
l
 
Figure 6.8. FACS analysis of DNA content of BSF T. b. b. for untreated and treated cells with 
bisphosphonium compounds. The percentages of cells in the G1, G2 and S phases were 
determined by using ModFit LT software and plotted on the left-hand side of each panel. In 
addition, the growth curve for each test compound was presented on the right-hand side of 
each panel, which was measured by using microscopic cell counts performed in triplicate 
using a haemocytometer. The results shown are the average of three independent 
determinations; error bars depict standard errors. 
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6.7 Analysis of the effect of bisphosphonium compounds 
on DNA configuration using fluorescence microscopy 
 
The previous section showed that DNA synthesis was inhibited after 12 h of 
incubation, which was led to a clear reduction in S phase cells, and a block of 
cell division at that time. However, the flow cytometry gives no information as 
to whether both nuclear and kinetoplast division is affected.  In order to 
examine cell cycle progression in detail and confirm that cell division will be 
inhibited by exposure to those compounds, fluorescent microscopy (DAPI stain) 
was carried out. 
DNA configuration from nuclei and kinetoplasts were assessed using the dye 4,6-
diamidino-2-phenylindole (DAPI), which fluoresces when bound with DNA. Five 
hundred cells were recorded for each sample, scoring for the presence of DNA in 
nuclei and kinetoplasts. Cells were scored into the following these groups: 1N1K 
(one nucleus and one kinetoplast), 1N2K (one nucleus and two kinetoplasts, 
2N2K-E (two nuclei and two kinetoplasts, but no clear furrow towards cell 
division), and 2N2K-L (two nuclei and two kinetoplasts and the cells were almost 
completely divided into two daughter cells). Two samples were used in this 
experiment, a drug free control and CD38 (0.7 µM). The initial cell density for 
both the treated and untreated samples was 5 × 105 cell/ml. Once again a time 
course was used in this experiment, and the treated and untreated cells were 
examined at 0, 8, 16, and 24 h, and the percentage of population was 
determined by observing the improvement of the cell cycle.      
The results are shown in Figure 6.9. As was expected, there was no difference 
between the drug free controls and cells treated with CD38 at 0 h of incubation 
for all cell cycle stages. However, the percentages of cells in 1N2K that were 
incubated with CD38 was significant decreased from 10% to 4% (P<0.001) after 8 
h of incubation and continued to decrease to 2% after 16 h of incubation. In 
addition, after 24 h of incubation with CD38, no cells in 1N2K were measured. 
This clearly shows that the block was effective at the earliest part of cell 
division, i.e. the division of the kinetoplast, as well as inhibiting nuclear DNA 
synthesis (section 6.6). The percentages of cells in 2N2K-E decreased gradually 
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over the time incubation for the treated cells. It went from 7.7% at 0 h to 3% at 
8h and continued to decrease to 1% at 16 h, which was significantly different 
from the drug free control (P<0.01). Furthermore, the percentages of the 
population in 2N2K-L was slightly increased at 8 h of incubation for treated cells, 
but it had reduced at 16 h, and at 24 h, there was a significant difference as 
compared with control cells (P<0.001). Apparently, those cells that had entered 
cell division were able to complete this cycle. This conclusion is consistent with 
the observation that the percentage of cells in 1N1K was maintained at its 
original level for both the untreated and treated cells until 8 h of incubation but 
increased slightly at 16 h and significantly at 24 h, with 96% of cells in this cell 
cycle stage as compared with 82% for untreated cells (P<0.05). It is very clear 
that cells treated with CD38 cannot re=enter the cell cycle, due to inhibited DNA 
synthesis, explaining that after 24 h of incubation the majority of the population 
was in stage 1N1K, whereas at the same time there was dramatic decline in the 
other stages of the cell cycle. 
This result confirms the results of previous experiments (DNA content) that 
found that bisphosphonium compounds led to the inhibition the growth because 
DNA synthesis was inhibited. 
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Figure 6.9. Percentage of wild type Tb427 populations in each stage of the cell cycle, with 
and without incubation with CD38 (0.7 µM) over 24 h. For each culture, about 500 cells were 
counted and scored in terms of nuclei and kinetoplasts. N = nuclei, K = kinetoplasts, E = 
early stage of division, L= late stage of division. (* P<0.05, ** P<0.01, ***P<0.001) which 
indicate a significant difference from the drug free control. P-values were calculated by 
using the Chi-squared statistical test. 
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6.8 Microscopical investigation of cellular morphology 
after treatment with selected bisphosphonium 
analogues 
The previous results indicated that bisphosphonium compounds had a strong 
effect on bloodstream-form T. b. brucei, so it is important to study the 
trypanosomes‘ exterior morphology after exposure to these compounds. Giemsa 
staining and life cell microscopic images were produced to study the cellular 
morphology 
6.8.1 Using Giemsa staining    
When cultures of T. b. brucei that were treated with bisphosphonium compound, 
followed by Giemsa staining, were observed under a light microscope some 
atypical cells were observed. Some of the cells were swollen, in a characteristic 
manner i.e. they had posterior swelling and some had swelling in the middle of 
the cells. Many other cells appeared to be completely broken up (Figure 6.10). 
The drug concentration was increased to 1 µM, as initially imaging was done at  
0.7 µM CD38, 0.5 µM CDIV48, 0.5 µM EFpI7 and 0.7 µM AHI9 treated cells and the 
results showed that very few cells were affected by the presence of drug and 
showed the effects. So to observe a more noticeable swelling in the cell the drug 
stress on the cells was increased so that they may give a higher response to the 
drug and obvious swelling could be noted by increasing the concentration of the 
drug. 
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6.8.2 Life cells images 
Using the above method, images were taken of unstained cells. The images thus 
captured can show the swelling present in the cells. Cells incubated with test 
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Figure 6.10. shows the cells under bright field light microscopy with the visualisation of BSF 
T. b. b. stained with Giemsa stain. Cells were incubated with 1 µM CD38, CDIV48, EFpI7, and 
AHI9, in addition to a drug free culture, at 0, 12, and 24 h. It can be seen that the samples 
from 12 and 24 hours of incubation showed swelling at the posterior–central parts, 
indicated with an arrow in the figure (scale bar = 50 µM).   
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compound for 12 or 24 h showed swelling of the posterior and central regions as 
shown with the help of arrow s (Figure 6.11). 
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Figure 6.11. shows the images of live WT-s427 trypanosome cell samples. Samples were 
taken at 0, 12 and 24 h of incubation and were treated with 1 µM CD38, CDIV48, EFpI7, and 
AHI9, in addition to a drug free control, and were observed under DIC microscopy. Arrows 
indicate swelling and abnormal cells. Scale bar = 25 µM. 
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6.9 Electron microscopy of trypanosomes exposed to 
bisphosphonium compounds (TEM and SEM) 
 
According to the results that were obtained from the microscopic investigation 
of cellular morphology after treatment with selected bisphosphonium analogues, 
there is clear proof that these compounds had an effect on the morphology of 
the treated cells. Consequently, Transmission Electron Microscopy (TEM) and 
Scanning Electron Microscopy (SEM) were used to study the effects of these 
compounds on the cellular structure of the cells.    
   
 
6.9.1 Transmission electron microscopy (TEM) 
The study focused on the organelles that are considered as to be the major ones 
affected by trypanocides: the mitochondria, glycosomes, microtubule 
distribution, the nucleus, the flagellum, and the flagellar pocket. These were 
studied in detail under transmission electron microscopy (TEM). Parasites were 
treated with 1 µM of CD38 over 20 h or left untreated (control). 
 
Figure 6.12. Transmission electron micrograph of an untreated bloodstream-form Tb427 
wild type trypanosome. Control images taken at 0 h. (F.P.) = the flagellar pocket, (N) = the 
nucleus, and (M) = the mitochondrion. Magnification of 5000x. 
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Figure 6.13. Transmission electron micrograph of a wild type bloodstream-form Tb427 
trypanosome. Control images taken at 0 h . (F) = the flagellum, (P) = the paraflagellar rod, 
and (G) = glycosome. Magnification of 5000x. 
 
Samples taken at 0, 12, 16, and 20 h showed the effect of the drug, and they 
were observed to be more bloated and rounded than those in the 0-hour 
incubation control sample (Figure 6.12 and 6.13). Those that were drug treated 
had thin cytoplasm; the cell was seen to be patchy and had an irregular 
appearance under the microscope. 
The mitochondrion is one of the organelles that show the earliest signs that 
pathology has taken place. Abnormality in the mitochondrion can be observed at 
the 12 h and 16 h time points. The contents of the mitochondrion become very 
electron dense as they start to condense, whereas kinetoplasts appear to be 
unaffected at even this stage (Figure 6.14). 
When the culture at is observed after 12 hours, pathology can be noticed around 
the flagellar pocket, but is not that obvious (Figure 6.15). 
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Figure 6.14. Transmission electron micrograph of a wild type bloodstream-form Tb427 
Trypanosome. Cells treated with 1 µM CD38 and incubated for 12 hrs (image A) and 16 hrs 
(image B and C). (M) = the mitochondrion, (K) = the kinetoplast, and (dcm) = distinct 
condensation of material. It can be shown that the matrix is patchy and uneven for M at 12 h 
with dcm, but there is no change in K. Images B and C are of different areas of the same 
cell. dcm is present in image B, whereas in image C, it has just started to form, and K is still 
not changed. Magnification of 8000x for image A and 5000x for images B and C.    
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Figure 6.15. Transmission electron micrograph of an untreated bloodstream-form Tb427 
Trypanosome. Cells were treated with 1 µM CD38 and incubated for 12 h. (F) = the flagellum 
, which is swelling. Magnification of 5000x.   
 
It was observed that microtubules grew in the cytoplasm of the affected cell and 
that they were not seen in the region where they normally occur. This was noted 
in the treated cells taken after 16 h, as shown in (Figure 6.16). 
 
Figure 6.16. Transmission electron micrograph of a wild type bloodstream-form Tb427 
trypanosome. Cells were treated with 1 µM CD38 and incubated for 16 h. (Mic) = the 
microtubules, which are abnormal. Magnification of 5000x. 
  
 
Another organelle that is affected is the glycosome. Glycosomes from the 
control and treatment group were compared and it was seen that the 
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glycosomes from the treatment group had their content distributed and 
appeared irregular after 12 and 16 h (Figure 6.17). 
 
Figure 6.17. Transmission electron micrograph of a wild type bloodstream-form Tb427 
trypanosome. Cells were treated with 1 µM of CD38 and incubated for 16 h (image A) and 20 
h (image B). (G) = glycosome. In both images, all glycosomes are disrupted, and more 
incubation time led to the reduced density of glycosomes and increased patchiness, as 
shown in image B. Magnification of 5000x. 
 
It was observed in the cells taken at 20 h that the drug can also affect the 
nucleus of the cell. Under the microscope, it was seen that in the control group, 
the nucleus had round, visible boundary with a nucleolus present in it, whereas 
in the affected cell, the boundary of the nucleus appeared irregular, no 
nucleolus was visible, and the chromatin material of the nucleus was seen to be 
dispersed in the nucleus (Figure 6.18). 
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Figure 6.18. Transmission electron micrograph of a wild type bloodstream-form Tb427 
trypanosome. Cells were treated with 1 µM CD38 and incubated for 16 h (image A) and 20 h 
(image B). (N) = the nucleus, (Mic) = the microtubules. The nucleus became flaccid and the 
nucleolus is absent at 16 h, whereas at 20 h, the genetic material is dispersed and the 
nucleolus is as well. Magnification of 10000x for image A and 5000x for image B.   
 
 
 
6.9.2 Scanning electron microscopy (SEM) 
Bloodstream-form T. b. brucei was incubated with 1 µM CD38 and its morphology 
was studied by using scanning electron microscopy (SEM) to observe the changes 
in the shapes of the cells. Trypanosomes were incubated with or without the 
test compound for 20 h. 
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Figure 6.19. Scanning electron microscopy of bloodstream-form T. b. brucei that were 
incubated for 20 h. A: Drug free; B, C and D incubated for 20 h with 1 µM CD38. 
 
Figure (6.19 A) shows the control SEM of the normal structure of the 
trypanosomes that were incubated without the test compound for 20 h. Figure 
(6.19 B) shows that exposure of parasites with 1 µM of CD38 for 20 h resulted in 
clear distortions in general structure. In addition, Figure (6.19 C) demonstrates 
that there was a disorganisation of the structure of the cell surface, which led to 
the swelling of the cells. Figure (6.19 D) shows that the posterior of the 
trypanosome was concave as compared with normal cells.    
 
6.10  Bisphosphonium-induced cell death in 
trypanosomes does not require protein synthesis 
It is confirmed by the results presented in this thesis that bisphosphonium 
compounds have a strong effect on trypanosomes and can kill them at even sub-
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micromolar amounts. Apoptosis or Programmed Cell Death (PCD) is reported to 
occur in African trypanosomes, and this is a process that requires protein 
synthesis (Duszenko et al., 2006). Therefore, to examine whether 
bisphosphonium compounds-induced cell death depends on protein synthesis or 
not, cells were pretreated with cycloheximide (CHX), an inhibition of protein 
synthesis, and then treated with different concentrations of bisphosphonium 
compounds to observe cell growth over 24 h.  Control cultures were left 
untreated.  
The cell density of bloodstream-form T. b. brucei was adjusted to 5  105 cells/ 
ml, and the cells were divided into two groups. One of them was treated with 10 
µg/ml of CHX, and the second was left without CHX, but with the same 
concentration of DMSO (less than 1%). Then, the cells were incubated in normal 
culture conditions for 1 h. Both cultures were subsequently aliquoted into 
different flasks and treated with bisphosphonium compounds (CD38 and EFpI7) at 
0, 1, and 3 µM. The cell count was performed by using light microscopy  and a 
haemocytometer at 0, 4, 8, 12, and 24 h. 
Treatment of trypanosomes with CHX displayed growth arrest even in the 
absence of bisphosphonium compounds, due to their inability to produce the 
required proteins; this shows that the CHX treatment was effective. More 
interestingly, the results in Figure 6.20 show that after treatment with different 
concentrations of CD38 and EFpI7 the growth curves with and without CHX 
pretreatment were identical over 24 h. This appears to confirm that 
bisphosphonium-induced cell death in trypanosomes does not require protein 
synthesis and does not support the hypothesis that bisphosphonium compounds 
lead to programmed cell death for trypanosomes.  
Abdulsalam Alkhaldi, 2012                                                                                      Chapter 6       184 
 
0 4 8 12 16 20 24
0
10
20
30
40
50
CD38- 1M (+CHX)
CD38- 1M (-CHX)
Drug free (-CHX)
Drug free (+CHX)
 A
Time(h)
1
x
1
0
5
 c
e
ll
s
/m
l
0 4 8 12 16 20 24
0
10
20
30
40
50
EFpI7- 1M (+CHX)
EFpI7- 1M (-CHX)
Drug free (-CHX)
Drug free (+CHX)
C
Time(h)
1
x
1
0
5
 c
e
ll
s
/m
l
0 4 8 12 16 20 24
0
10
20
30
40
50
Drug free (+CHX)
Drug free (-CHX)
CD38- 3 M (+CHX)
CD38- 3 M (-CHX)
B
Time(h)
1
x
1
0
5
 c
e
ll
s
/m
l
0 4 8 12 16 20 24
0
10
20
30
40
50
Drug free (+CHX)
Drug free (-CHX)
EFpI7- 3 M (+CHX)
EFpI7- 3 M (-CHX)
D
Time(h)
1
x
1
0
5
 c
e
ll
s
/m
l
 
Figure 6.20. Effect of different concentrations of bisphosphonium compounds on the 
growth curve of bloodstream-form T. brucei brucei WT over 24 hrs. Cells were seeded at 5 x 
10
5
 cells/ml and treated with and 10 µg/ml of cycloheximide or not (+CHX, -CHX) for one 
hour and then treated with different concentrations of chemicals as follows: A: drug free 
and 1 µM of CD38, B: drug free and 3 µM of CD38, C: drug free and 1 µM of EFpI7, D: drug 
free and 3 µM of EFpI7. Microscopic cell counts were performed in triplicate using a 
haemocytometer. The results shown are the average of triplicate determinations, each 
triplicate taken from a separate sample but within the same experiment; error bars depict 
standard errors. 
 
To confirm that CHX led to the inhibition of protein synthesis, the concentration 
of CHX used in this experiment was identical to the one used in the experiments 
involving cell counting (above). First we performed a cell culturing step up to a 
density of 5 × 106 cells/ml and the culture was dispensed into two separate 
flasks, followed by the addition of cycloheximide (10 µg/ml) into one of them. In 
the other flask, no CHX was added, but 1% DMSO was added instead (CHX 
solvent) and served as the control. Both flasks were kept in incubators at 37oC 
Abdulsalam Alkhaldi, 2012                                                                                      Chapter 6       185 
and 5% CO2 for 1 h. The addition of a radioactive isotope was performed in each 
flask, employing 25 µCi of [3H] lysine, and they were kept in incubation for 3 h. 
As mentioned in Chapter Two (Section 2.16.1), the labelling of the protein pool 
in T. b. brucei was determined by measuring the amount of incorporation of [3H] 
lysine in the trypanosome populations in both flasks. 
 
Figure 6.21. The graph shows the radioactivity count of a 10 ml culture of bloodstream-form 
T. b. b. at 5 × 10
6
 cells/ml, which were incubated with (+CHX) and without (-CHX) 10 µg/ml 
cycloheximide for 1 h, following incubation with 25 µCi of [
3
H] lysine for 3 hrs. As mentioned 
before, the measurement of the radioactivity was performed at different stages. 1- Culture 
medium after first spin (100 µl), 2- pellet of cells after added 1% SDS for lysing the cells, 3- 
trichloro acetic acid (TCA) supernatant, 4- the second TCA supernatant for washing, 5- 
protein pellet. 
 
 
From Figure 6.21, the radioactivity count for both samples, with and without 
CHX, in different stages can be seen. However, the main result in this graph is 
that the amount of [3H] lysine in the protein pellet for the culture that was 
treated with CHX is six-fold less than that of the sample which was untreated 
with CHX , which confirmed the fact that the CHX led to the inhibition of protein 
synthesis. 
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6.11 TUNEL assay 
Programmed cell death or apoptosis is also associated with DNA fragmentation. 
Therefore, a TUNEL assay was used to detect DNA fragmentation after exposure 
to different compounds. Two bisphosphonium compounds, CD38 (0.7 µM) and 
EFpI7 (0.5 µM), were used in this experiment, and a positive control was used, 
which was phleomycin (2 µg/ml) (Sleigh, 1976). In addition, a negative control 
was drug free. The cells were treated for 24 h, and the results show that there 
was significant different between the drug free cultures and the cells treated 
with CD38 or EFpI7 (Figure 6.22). Phleomycin also displayed a strong effect on 
the cell population but, at the concentrations used, the bisphosphonium 
compounds appeared to induce an even more pronounced DNA fragmentation 
after 24 h (Figure 6.23).  
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Figure 6.22. TUNEL assay of apoptotic cells of bloodstream-form T. b. b. that were treated 
with different compounds or left untreated and incubated for 24 h. Cellular DNA was stained 
with PI while DNA strand breaks were labelled with Br-dUTP followed by FITC-conjugated 
Br-dU antibody. 
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Figure 6.23. . TUNEL assay of DNA fragmantation cells of bloodstream-form T. b. b. that 
were treated with different compounds or left untreated and incubated for 24 h. Cellular DNA 
was stained with PI while DNA strand breaks were labelled with Br-dUTP followed by FITC-
conjugated Br-dU antibody. Results are the average of three independent determinations 
and error bars are Standard errors for Dot plot figures. The data are expressed as % 
difference of cells with significant DNA fragmentation. P-values calculated using the 
unpaired Student’s t-test (* P<0.05, ** P<0.01) compared with drug free control. 
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6.12 Discussion  
A study of the mode of action of bisphosphonium compounds in wild type 
bloodstream-form T. b. brucei was performed in this chapter. As mentioned 
before, bisphosphonium compounds have a strong effect on the mitochondria of 
Leishmania (Luque-Ortega et al., 2010), which led to the inhibition of complex II 
of the respiratory chain, leading in turn to several other changes, such as 
decreased levels of ATP and reduced mitochondrial membrane potential. 
Therefore, our hypothesis here is that the target of the bisphosphonium 
compounds in bloodstream-form T. b. brucei could be the mitochondria. 
A number of techniques were used and developed to assess the effects of these 
compounds on trypanosome growth, mitochondria membrane potential, 
intracellular calcium level, ATP level, DNA content, DNA configuration and cell 
morphology after treatment with test the compounds. In addition, that these 
compounds induce apoptosis in trypanosomes was investigated.  
An assessment of trypanosome growth shows that bisphosphonium compounds 
have a slow effect at concentrations close to EC50, whereas the effect was 
increasingly rapid at higher concentrations. For example, at concentrations 
≤EC50 of CD38, there was little effect on growth, while at 5 x EC50 (1 µM), all 
cells were killed after 24 h. The slow effect of bisphosphonium compounds has 
already been confirmed by various experiments, such as real-time viability 
monitoring (Taladriz et al., 2012). On the other hand, these results assisted us in 
choosing the best concentrations and incubation time combinations for studying 
the mode of action. Indeed, the concentration that has a strong inhibitory effect 
on cells, but does not yet kill the cells is preferred because it helps in tracking 
the early changes in the cells over the period of the test. 
Monitoring the mitochondrial membrane potential (Ψm) with TMRE flow 
cytometry shows that cells treated with bisphosphonium compounds led to the 
depolarisation of Ψm. With the exception of AHI9, all compounds decreased Ψm 
after 1 h of incubation time, and at 4 h all compounds showed a depolarisation 
of Ψm, which continued until the end of the time course at 12 h. In addition, 
there was the inhibition of intracellular ATP levels when cells were treated with 
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these compounds after 1 h as well, which may be good evidence that the effect 
on Ψm led to inhibited ATP levels because the loss of MMP caused the 
dysfunction of the mitochondria, which led to inhibition of ATP synthesis. The 
mitochondria were unable to recover as Ψm and ATP levels remained reduced 
throughout the 12 hours of the experiment. 
It is difficult to decide which one of these actions happens first, ATP inhibition 
or Ψm depolarisation. However, both actions depend on one another. Due to 
bisphosphonium compounds‘ effect on Ψm, which led to the dysfunction of the 
mitochondria, Ca2+ was released (or leaked) from the mitochondria into the 
cytosol, and intracellular calcium levels started to increase after 8 h of 
incubation. This result is similar to the effect choline-derived compounds 
displayed on Ψm and Ca
2+ level when the depolarisation of MMP led to increased 
Ca2+ level (Ibrahim et al., 2011). 
The initial findings from this study show that treated cells experienced stress, 
expressed clearly in reduced Ψm and ATP levels. Another effect of 
bisphosphonium compounds was on cell cycle, and their cell cycle arrest of 
trypanosomes, apparently preventing entry into S phase. In other words, DNA 
synthesis was inhibited and the cell cycle could not be completed. As a result 
cells accumulated in the G1 phase, which was significantly increased after 8 h, 
showing that cells in cell division were able to complete this and re-enter G1. 
This was confirmed by fluorescence microscopy. Staining trypanosomes exposed 
to CD38 (0.7 µM) with DAPI and scoring the DNA configuration appears to show 
that after 8 h of incubation with CD38 DNA synthesis was inhibited even before 
kinetoplast division and that, consequently, the number of cells that had 1N2K 
decreased gradually with increasing treatment cells. At the same time, the 
number of cells that had 1N1K gradually increased, and the cell cycle 
progression blocked.  
The microscopic investigation of the morphology of cells that were treated with 
selected bisphosphonium compounds was applied. Giemsa staining and life cell 
images were used first, and the results show that these compounds have a slow 
effect on cell morphology, which was very clear after 12 h of exposure. For all 
the compounds that were used, the cells had damage and swelling, but light 
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microscopy did not provide the resolution necessary to determine which 
organelles caused these, so transmission electron microscopy (TEM) and scanning 
electron microscopy (SEM) were used to observe changes in the cells. When seen 
under TEM, it was observed that the material in the cell was condensed. This 
condensation of the contents of the cell may be due to the destruction of the 
organelles or due to the accumulation of the drug compound within the 
organelles, which is a significant mode of action for diamidines (Mathis et al., 
2006).  
One explanation for the swelling observed in the light microscopy pictures would 
be an effect on the flagellar pocket. We know that the flagellar pocket plays an 
important role in protein trafficking (Field & Carrington, 2009). When 
endocytosis or exocytosis is inhibited this area becomes affected first, usually 
appearing grossly enlarged as a result. There are two possible reasons for this, 
one being that it is the only site at which all the endocytosis takes place, so it is 
the nearest region to become affected. The other reason is that because this 
area of the cell is important in protein trafficking, an inhibition of vesicular 
traffic results in a damaging accumulation of material at that site, and a dearth 
of essential proteins in some organelles. However, the TEM images do not 
support this explanation, as flagellar pockets appeared normal after treatment 
and there was no gross build-up of vesicular matter in its vicinity, nor were any 
abnormalities of the flagellum itself observed. 
Instead the bisphosphonium compounds appeared to affect other organelles, 
such as the mitochondria, nucleus, glycosomes, and microtubules. It was not 
possible to determine with certainty the sequence by which these organelles 
were affected, but at 12 h the most striking observation was probably the 
appearance of condensed, electron-dense material in the mitochondria. This is 
consistent with the decrease of Ψm and ATP levels as early events after 
exposure, as well as the known mitochondrial targeting of phosphonium 
compounds in Leishmania (Luque-Ortega et al., 2010) and human cells (Jiang et 
al., 2009). In addition to the mitochondrial effects, bisphosphonium compounds 
clearly affected the nuclei, showing loss of shape and nucleolus; this is probably 
the cause for the specific cell cycle arrest in G1 phase. After 24 h the TUNEL 
assay indicated the presence of double strand breaks in DNA, although the DNA 
content assays showed that after 24 h the total content of nuclear DNA was not 
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strongly affected, i.e. the evidence suggests the presence of breaks rather than 
wholesale degradation of DNA.  
The TUNEL result and mitochondrial damage could be taken as evidence for 
apoptosis or programmed cell death (PCD). Certainly, DNA fractionation is 
commonly taken to be part of the apoptotic process in mammalian cells and has 
equally been proposed to be a PCD indicator in protozoa; the slow release of 
mitochondrial calcium stores after mitochondrial damage also fits this model 
(van Zandbergen et al., 2010). However, PCD is also believed to have an 
absolute requirement for protein synthesis and the prediction would be that 
inhibition of protein synthesis by pre-incubation with CHX would prevent 
bisphosphonium-induced lysis. In fact, this was not observed and we 
provisionally conclude that the cell death observed is not the result of apoptosis, 
at least not in the classical sense, where proteases are expressed in order to 
digest the cellular content, leading to cell death. 
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Despite the strenuous efforts of some organisation including as Medecins-sans-
Frontiers, DNDi, the Bill & Melinda Gates Foundation and the Consortium for 
Parasitic Drug Development, as well as the efforts generated by the Millennium 
Goals, the burden of human and veterinary parasitic disease is still unacceptably 
high, especially in less developed countries. Among the most neglected tropical 
parasitic diseases, Human African trypanosomiasis (HAT) and leishmaniasis are 
infections that are caused by species of protozoa called Trypanosoma and 
Leishmania species, respectively. Many efforts are being made to control these 
diseases, including the use of chemotherapy. However, there are many problems 
associated with the few available drugs, including drug toxicity, resistance, a 
lack of guaranteed supply and high cost. Toxicity of some antiparasitic drugs has 
become a concern and has led doctors to urge precautions before use. For 
example, melarsoprol, which was used for treatment of the second stage of 
African trypanosomiasis, is toxic and causes a 5% death rate for patients who use 
it (Burri, 2010). In addition, side effects consist of nausea, vomiting and 
encephalopathy (Garcia, 2007;Jannin & Cattand, 2004;Legros et al., 2002). The 
other issue is resistance to current antiparasitic agents. For instance, resistance 
to eflornitine (Vincent et al., 2010) and melarsoprol (Delespaux & de Koning, 
2007;Legros et al., 1999) for late stage HAT, and pentavalent antimonials for 
leishmaniasis (Sundar et al., 2008) have been reported, further limiting 
treatment options. A further serious problem is the cost of the drugs, which has 
led to increased problems with therapy, especially in the poor countries where 
the diseases are concentrated. For example, the average cost to treat a second-
stage T. b. gambiense HAT patient rose from €28 to €336 (Simarro et al., 2012) 
from 2002 to 2010. As a result, for the reasons above and because of the 
limitations of existing drugs, development of new drugs is urgently needed for 
the most neglected diseases, such as trypanosomiasis and leishmaniasis.  
Development of new anti-trypanosomiasis/leishmaniasis drugs should aim at an 
affordable cost, which would lead to an overall reduction in treatment costs. 
Solutions with an appropriate cost/benefit balance could well include natural 
products, but the search for new antiparasitics should by no means be limited to 
this strategy alone. However, the impetus to make new compounds from natural 
products is considerable (Newman & Cragg, 2007). Our study examined two types 
of compounds, which are curcumin and phosphonium-based, as potential 
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therapeutic lead compounds against Trypanosoma and Leishmania parasites. 
Curcumin, a polyphenolic compound obtained from the nutritional spice 
turmeric, is derived from the rhizome and roots of the plant Curcuma longa 
(Ammon & Wahl, 1991). Curcumin is used as an herb for adding spice, colour and 
flavour to food and is used as a traditional medicine in India and as such has 
little or no toxicity, and is cheap. Phosphonium compounds also include natural 
products (Taladriz et al., 2012). 
Methods that are generally used to evaluate drug activity were used in this study 
to examine the effectiveness of curcumin and phosphonium compounds against 
trypanosomes and leishmania parasites. A total of 158 curcumin analogues were 
tested against Leishmania species, and many of the analogues appeared to be 
effective against these parasites. In some cases, they were more active, 
measured by in vitro EC50, than clinical drugs like pentamidine. Similarly, a 
majority of phosphonium analogues that were tested in this study (83) displayed 
strong activity against bloodstream form Trypanosoma brucei brucei, and more 
than 20% of these compounds have EC50 values < 100 nM. Resistant strains were 
also applied in this study as a model to examine cross-resistance between 
existing treatments and potential new trypanocides, a key issue for any new 
antiparasitic agent. Two T. brucei strains of increasing levels of multi-drug 
resistance were used and the results with both strains was compared with the 
activities observed against the sensitive parental strain, obtained in parallel. 
None of the analogues of curcumin and phosphonium displayed cross-resistance 
with the diamidine and melaminophenyl arsenical classes, i.e. there were no 
significant differences in EC50 values between the three strains for any of the 
compounds tested. As resistance to these important trypanocides has been 
linked to the loss of the P2 and HAPT drug transporters (Bridges et al., 
2007;Matovu et al., 2003) it follows that these are not involved in the 
internalisation of curcuminoid and phosphonium compounds. 
As mentioned above, it is very important for the development of new 
antiparasitic drugs that the new compounds must not be toxic to human cells; 
thus, their effectiveness against parasites should be optimised while toxicity is 
reduced, leading to increasing selectivity index (SI). Therefore, the toxicity 
levels for curcumin and phosphonium analogues were determined by testing 
these compounds on Human Embryonic Kidney (HEK) cells in vitro using an 
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Alamar Blue test. The results show that all of curcumin compounds were lower 
in toxicity to HEK cells than to bloodstream form T. b. brucei and L. mexicana 
amastigotes, consistent with our previously published results (Changtam et al., 
2010a). In addition, all phosphonium analogues appeared to have lower toxicity 
for human cells than to bloodstream form T. b. brucei: 60 out of 83 
phosphonium compounds displayed an SI >200-fold.(Taladriz et al., 2012).   
A Structure Activity Relationship (SAR) is the relationship between the biological 
activity of a molecule and its structure. Using SAR analysis on a library of 
compounds will help determine the most important functional groups of the 
pharmacophore and is an essential tool in the further optimisation of the 
scaffold. SAR analysis was used in this study and depended on the EC50 that was 
established by Alamar Blue tests for curcumin and phosphonium analogues. For 
curcumin compounds, 158 were tested on Leishmania spp and T. b. brucei and 
the results of SAR indicated the activity was improved in the following cases. 
First, mono-O-demethylated analogues increased activity against these 
parasites. Second, the addition of one or two pentyl pyridinium (C10H15N) groups 
leads to an increase of activity. Third, analogues that have an isoxazole ring 
show more activity against parasites, which is identical with other literature that 
has indicated that isoxazole analogues also have activity against Mycobacterium 
tuberculosis (Changtam et al., 2010b). Fourth, pentyl bromide (OC5H10Br) 
substitutions at positions R3 led to the improvement of activity. Finally, the 
trienone analogues showed increased activity against all parasites tested. For 
phosphonium analogues, 83 of these compounds also were tested against T. b. 
brucei. SAR studies indicated that the EC50 for some compounds were at 
nanomolar levels due to the bulky substituents around the bisphosphonium 
cations, while the linkers have less power to determine the activity. In addition, 
some monophosphonium analogues, such as AT31 and AT33, registered the 
lowest value of EC50 of all the phosphonium compounds. The fact that 
phosphonium analogues displayed SAR against T. b. brucei and Leishmania 
(Luque-Ortega et al., 2010) and in some cases displayed promising selectivity 
over human cells, gives hope that they might have broad anti-kinetoplastid 
activity. The essential next step is a thorough investigation of their in vivo 
efficacy. 
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To investigate the mode of action for curcumin compounds, various methods 
were employed. A preliminary investigation into the cellular actions of some 
curcumoids was performed by my colleague Hasan Ibrahim, and he employed 
several tests including cell cycle progression, mitochondrial membrane 
potential, DNA fragmentation and production of reactive oxygen species. 
Although curcuminoids did not affect any of these parameters there was one 
experiment that could open new doors for understanding their mode of action. 
AS-HK014 compounds showed a strong and fast depletion of glutathione content 
in the hepatocytes of rats.  
As part of the mode-of-action investigation we determined whether 
curcuminoids affect the plasma membrane or second messenger systems of 
trypanosomes, but there was no effect on cellular cAMP levels, plasma 
membrane potential, or any rapid effect on the intracellular free calcium 
concentration in bloodstream form T. b. brucei. However, addition of different 
concentrations of L-glutathione to trypanosome cultures led to a dose-
dependent decrease of AS-HK014 activity. Evidently, glutathione reacted with 
the active compound and this appeared to confirm the observation with primary 
hepatocytes cultures.  
A common method to study the mode of action is through an induction of 
resistance for the drug. So, a new line, resistant for AS-HK014, was generated 
for that reason. Metabolomic assessment of ASHK014 action on T. b. brucei was 
employed on both sensitive cells (WT) and the resistance line of AS-HK014 
(TA014). The results show that for WT, AS-HK014 led to depletion of glutathione 
and trypanothione during 30 minutes of incubation, relative to the control 
(untreated cells). Results also showed reduced trypanothione disulfide. 
However, there was no evidence for an inhibition of trypanothione synthesis, as 
there was no change to levels of glutamate, ornithine and spermidine, which 
means that the effect is probably not metabolic but chemical, i.e. a direct 
chemical reaction between AS-HK014 and certain thiols. Strong evidence for this 
was also provided by the laboratory of Prof. Apichart Suksamrarn, which 
synthesised the curcuminoid library, and showed that AS-HK014 indeed forms a 
covalent adduct with glutathione (section 4.8).  
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On the other hand, it does not explain the resistance mechanism of TA014 cells. 
First, the protein expression levels of the two key enzymes of trypanothione 
biosytnthesis, γ-GCS and GS, were analysed by western blot, but the result 
showed no difference in protein level between the cell lines, or for untreated 
and treated cells. Second, sequence analysis of two genes (γ-GCS and GS) was 
used to look for any mutation in the resistance line that led to resistance; 
however, no mutations were found in the γ-GCS and GS open-reading frames. 
To gain an insight into the possible resistance mechanism, cross-resistance 
between T. b. brucei-WT and TA014 cell lines for some curcumin analogues and 
current clinical trypanocides was assessed. Although there was no cross-
resistance between WT and TA014 for some curcumin compounds and clinical 
trypanocides, a clear cross-resistance was detected for curcumin compounds 
with a mono-enone linker, which confirms that this linker has some responsibility 
for the drug‘s activity and the resistance is to the mono-enone moiety and the 
chemical reaction it makes with thiols. The resistance may be linked to an 
increased efflux of the curcumin analogue or, more likely, the trypanothione 
adduct. 
The effect of some bisphosphonium analogues on bloodstream form 
Trypanosoma brucei brucei was investigated to identify the target of these 
compounds. The compounds have been reported as leishmanicidal compounds, 
by causing mitochondrial dysfunction (Luque-Ortega et al., 2010) and indeed 
these lipophilic cations accumulate in organelles, specifically mitochondria (Ross 
et al., 2006). We found that all bisphosphonium analogues tested in this study 
led to a rapid reduction of T. b. brucei Ψm after as little as 1 hour of incubation 
and decreased the intracellular ATP level within the same incubation period. 
These observations are consistent with the mitochondria being the target these 
compounds. It was also observed that levels of intracellular calcium increased 
gradually after 8 hrs of incubation with these compounds and we interpret this 
as possible evidence that the damaged mitochondria are unable to retain the 
stored Ca2+ as their membrane potential dissipates. 
Although bisphosphonium analogues act slowly on trypanosomes‘ viability 
(Taladriz et al., 2012), their effect on mitochondria and ATP levels was 
relatively fast; this encouraged us to study their effect on the cell cycle, 
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reasoning that their effect could be trypanostatic, through deprivation of ATP, 
long before the treatment killed the trypanosome population outright. This was 
also visualised using growth curves in the presence of various concentrations of 
selected bisphosphonium salts. After 8 h of incubation with different compounds 
the cell cycle defects were becoming apparent because DNA synthesis could not 
be initiated, leading to a dramatic reduction of cells in S phase. Definitively, 
some actions, such as reduction in Ψm and ATP level, happened well before 8 h, 
suggesting, but not proving, a causal relationship between the mitochondrial 
damage and cell cycle arrest. A final observation adding weight to the 
mitochondrial target hypothesis is the mitochondrial damage observed in TEM 
images taken after 12 h of exposure to selected bisphosphonium salts. 
In a further investigation of the mechanism of action for bisphosphonium 
analogues, we tested whether these compounds can induce programmed cell 
death (PCD or apoptosis) in trypanosomes. TUNEL assay was employed for 
detecting DNA fragmentation, and the results showed an increase in DNA 
fragmentation after 24 h of incubation with CD38 and EFpI7 compounds. This 
result, along with the results of Ψm, could be taken as evidence that PCD occurs 
in treated cells. However, the evidence for PCD was inconclusive and would 
need far more stringent investigation, especially as bisphosphonium-induced cell 
death appeared to not depend on protein synthesis. 
Overall, it can be concluded that curcumin and phosphonium analogues have 
promising antiparasitic qualities. Unfortunately, initial in vivo results for these 
compounds, determined by Hasan Ibrahim at the University of Glasgow 
(curcuminoids) and Marcel Kaiser at the Swiss Tropical and Public Health 
Institute (phosphonium salts), were not encouraging. However, these initial tests 
were performed with only a few compounds and doses, and with a more 
systematic approach as well as optimisation of protocols and lead compounds it 
may yet be possible to develop genuine pre-clinical drugs from these series. For 
instance, for the curcuminoid scaffold the in vivo and mode of action work has 
so far focussed mostly on the very interesting enone series, but we must 
conclude that in their present chemical form the enones are too reactive with 
(host) thiols to have genuine drug-like qualities, despite their undoubted in vitro 
activity. Several other curcuminoids, that were not thiol-reactive, also displayed 
promising in vitro activity and further investigation should now focus on those 
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analogues. On the other hand, using ADME (Administration, Distribution, 
Metabolism and Excretion) analysis in order to discover new drug before in vivo 
studies is very useful to shorten the time, reduce the cost and avoid false 
negatives, i.e. failure of the compound in the in vivo model due to inappropriate 
administration protocols etc. Therefore, a proper investigation of ADME issues 
before testing a lead compound in an animal model can much improve the value 
of the test. 
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Appendix A: general buffers and solution  
 
 
1-Assay buffer (pH 7.3) 
Components                                         Quantity per liter 
D-Glucose     2.53 g 
HEPES               8 g 
MOPS      5 g 
NaHCO3     2 g 
KCl      347.5 mg    
MgCl.6H2O     62.5 mg 
NaH2PO4.2H2O    913.5 mg 
CaCl2. 2H2O                                 40.7 mg 
MgSO4. 7H2O     19.9 mg 
NaCl       5.7 g 
Store at 4 °C. 
 
2- 10% SDS 
 
Sodium Dodecyl Sulfate   10 g 
ddH2O                                                   500 ml 
 
3- LB medium -Luria Bertani broth- (pH 7) 
LB powder (Sigma-Aldrich)                                25 g 
dH2O                                                                 1 L 
 
4- LB agar  
Luria Agar (Sigma-Aldrich)               35 g 
dH2O                  1 L 
Autoclaved and agar is liquefied before making agar plates. 
 
5- 1× TE 
1 M Tris.HCl                                                       10 ml 
0.5 M EDTA at pH 8.0                                         2 ml 
dd H2O                                                              1 litre 
 
6- NTE buffer 
Tris-HCl, pH 8.0                10 mM 
NaCl                                                                100 mM 
EDTA                                                                5 mM 
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7- SOC medium 
Tryptone                           20 g 
Yeast extract                   5 g 
NaCl                              0.5 g 
250 mM KCl                           10 ml 
2 M MgCl2                                                           5 ml 
dd H2O                                                                 1 litre  
Adjust pH at 7.0 with 5 M NaOH. Autoclave and when cooled down 1 M of sterile 
glucose 20 ml was added. 
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Appendix B: Structurs of Curcumin analogues 
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Appendix C: Mitochondrial membrane potential determinations 
 
Mitochondrial membrane potential (%Ψm), untreated cells (drug free) 
Time First repeat Second repeat Third repeat 
 
 
 
1h 
   
 
 
 
 
4h 
   
 
 
 
8h 
   
 
 
 
 
12h 
   
Mitochondrial membrane potential (%Ψm), treated cells with 
Valinomycine (100 nM) 
Time First repeat Second repeat Third repeat 
 
 
 
1h 
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Mitochondrial membrane potential (%Ψm), treated cells with 
Troglitozone (10 µM) 
Time First repeat Second repeat Third repeat 
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4h 
   
 
 
 
8h 
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12h 
   
Mitochondrial membrane potential (%Ψm), treated cells with CD38 
 (0.7 µM) 
Time First repeat Second repeat Third repeat 
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4h 
   
 
 
 
8h 
   
 
 
 
 
12h 
   
Mitochondrial membrane potential (%Ψm), treated cells with CDIV48 
 (0.5 µM) 
Time First repeat Second repeat Third repeat 
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Mitochondrial membrane potential (%Ψm), treated cells with EFpI7 
 (0.5 µM) 
Time First repeat Second repeat Third repeat 
 
 
 
1h 
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Mitochondrial membrane potential (%Ψm), treated cells with AHI9 
 (0.7 µM) 
Time First repeat Second repeat Third repeat 
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Appendix D: DNA content 
 
DNA content, untreated cells (drug free) 
Time First repeat Second repeat Third repeat 
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16h 
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DNA content, treated cells with CD38 (0.7 µM) 
Time First repeat Second repeat Third repeat 
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DNA content, treated cells with CDIV48 (0.5 µM) 
Time First repeat Second repeat Third repeat 
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DNA content, treated cells with EFpI7 (0.5 µM) 
Time First repeat Second repeat Third repeat 
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DNA content, treated cells with AHI9 (0.7 µM) 
Time First repeat Second repeat Third repeat 
 
 
 
0h 
   
217 
 
 
 
 
8h 
   
 
 
 
12h 
   
 
 
 
 
16h 
   
 
 
 
 
24h 
   
 
 
 
36h 
   
 
 
 
 
218 
Appendix E: TUNEL assay 
 
% Fragmantation by TUNEL assay, Dot Plot figures. 
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% Fragmantation by TUNEL assay, Histogram figures. 
Time First repeat Second repeat Third repeat 
  
D
ru
g
 f
re
e
 
D
r 
fr
e
e
  
   
  
P
h
le
o
m
y
c
in
 (
2
 µ
g
/m
l)
 
 
P
h
 
   
  
C
D
3
8
 (
0
.7
 µ
M
) 
1
2
h
 
   
  
E
F
p
I7
 (
0
.5
 µ
M
) 
 
1
6
h
 
   
 
 
 
 
 
 
 
220 
 
Appendix F: The nucleotide and amino acid sequences of gamma-
glutamylcysteine synthetase (γ-GCS) (G1) from all the cloned sequences taken 
from AS-HK014 resistant TA014 strain and parental wildtype.  
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Appendix E: The nucleotide and amino acid sequences of glutathione 
synthetase (GS) (G1) from all the cloned sequences taken from AS-HK014 
resistant TA014 strain and parental wildtype. 
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